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Abstract.
The CCND1 gene codes for a recently discovered member of the 
cyclin D family of proteins and is thought to function during the G1 phase of 
the cell cycle. Amplification and transcript over-expression of CCND1 have in 
the past two years been reported in several types of human tumours, 
providing the initial evidence for the contribution of its product in the 
development of cancer. This investigation was aimed at clarifying the 
involvement of the CCND1 gene in transformation.
The CCND1 gene dosage, transcript and protein levels were 
characterised in a panel of newly derivedjSCC cell lines, revealing the same 
frequency of amplification as reported in tumour biopsies. The frequency 
differed from the previous analyses of established cell lines and may reflect 
the methods used to derive the cell lines. In all cases amplification resulted in 
upregulated levels of the CCND1 mRNA and protein (p34cYcD1), although 
amplification was not necessary for over-expression of CCND1. These 
findings further emphasise the status of this gene as the target of 11 q13 
amplification. Interestingly, the cell lines that exhibited CCND1 amplifications 
had also increased expression of the tumour suppressor protein pRb, a 
potential regulator or substrate of p34cYcD1.
SCC derived cell lines, original tumour biopsies and xenografts 
revealed an exclusively nuclear localisation of p34cYcD11 as previously 
determined for fibroblast cell lines. Serum stimulation of GO arrested 
fibroblasts induced an increase of p34°ycD1 levels four hours from exposure, 
which reached a maximum between 8-12 hours and declined thereafter. The 
same oscillation pattern was observed in EGF stimulated keratinocytes where 
cell cycle delay was achievable through serum deprivation.
To analyse the stage during transformation at which a cell might find it 
beneficial to over-express p34cYcD1, two types of transfection analyses were 
carried out. An established, poorly tumourigenic SCC cell line (SCC12) that 
originated from a skin SCC, was lipofected with sense or antisense Cyl-1 
cDNA expression vectors and the derived clones examined for their ability to 
form tumours in immunodeficient mice. No alterations in growth patterns or 
tumourigenicity of the transfected cells were observed. Alternatively, human 
foreskin primary keratinocytes transfected with Cyl-1 cDNA expression 
vectors alone or in combination with HPV-16 E6 or E 7expression constructs 
exhibited the ability to overcome the M1 restrictive stage and therefore 
achieve an extended life span. It remains speculative if in vivo, over­
expression of CCND1 may contribute to immortalisation of epithelial cells. 
Examination of rodent fibroblast cell lines and their fos over-expressing 
clones revealed the lack of correlation between p34cyc^ 1 levels and fos 
induced transformation.
In conclusion, these studies may suggest a significant contribution of 
CCND1 over-expression in the initial stages of epithelial transformation. 
Increased levels of p34cycD1 could permit escape of epithelial cells from 
growth control and therefore differentiation, resulting in their indefinite lifespan 
which allows the occurrence and fixation of other genetic alterations.
However, these results do not contradict the potential involvement of CCND1 
in later stages of tumour development.
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INTRODUCTION
CHAPTER 1 : Introduction.
1.1 The plasticity of chromosomes in cancer.
The human genome consists of approximately 7.1 x109 base pairs, the 
entire length of which is packed into 23 pairs of chromosomes. In these 
structures lies most of the information a cell needs to live and proliferate and it 
is here that accumulative changes may bring about disordered cellular growth 
resulting in transformation and cancer.
The abnormalities most commonly seen in chromosomes have been 
classified into structural (translocations, insertions, inversions, deletions and 
amplifications) and numerical (changes in chromosome number). In the past 
decade great progress has been made to link consistent chromosomal 
aberrations with certain types of cancer, leading to the discovery and isolation 
of many new genes.
1.1.1 Changes In chromosome number.
Polyploidy is not commonly seen in cancer and is a term used to 
characterise an increase in the number of haploid sets of chromosomes. A 
more common phenomenon in transformation is aneuploidy, the loss of a 
single chromosome and the gain of one or more (Yang-Feng 1991). These 
changes cause alterations in huge blocks of DNA making it hard to identify 
specific genes involved in the phenotype of the cancer cell. In several 
instances a link between aneuploidy and poor prognosis has been suggested 
although this is still under debate (von Rosen 1989, Suchy et a /1992, Johan et 
al 1992).
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Restriction fragment length polymorphism (RFLP) analysis has revealed 
the deletion of chromosome 11 in a significant number of neuroblastomas 
(Strivatsan et al 1993). The loss of this chromosome is also seen in rare cases 
of parathyroid adenomatosis (Arnold and Kim 1989). Trisomy, hyperploidy to 
near tetraploidy and even rare cases of polyploidy were observed in a study of 
59 ovarian carcinomas (Pejovic et a /1992). The most frequent chromosome 
gain was +20. Specific loss of chromosomes 8, X, 13,14,17 and 22 were also 
reported (Pejovic et a /1992).
What causes aneuploidy ? In a study of colorectal neoplasms point 
mutations in the Kirsten-ras proto-oncogene (K-ras) were proposed to 
contribute to the development of aneuploidy (Suchy eta ! 1992). Loss of 
functional tumour suppressor protein p53 is a frequent event in most cancers 
and may indirectly lead to gross mutations and rearrangements of the genome 
(Weinberg 1991, Lane 1992). p53 is a sequence specific DNA binding protein 
proposed to act as the "guardian of the genome", protecting cells from DNA 
damage (Lane eta ! 1993). Several reports have implicated p53 in the G1 
check point (Lane 1992) and it may also be involved in apoptosis (Yonish- 
Rouach et al 1993). The removal of this "guardian" is predicted to lead to 
genome instability and accumulation of many genetic alterations, of which 
aneuploidy may be one.
A majority of cell lines that have been derived from tumour tissues show 
aneuploidy, although alterations caused by adaptation to tissue culture 
conditions must be taken into account (Edington et al submitted). For example 
aneuploidy has been observed during later stages of rodent and human 
fibroblast or keratinocyte immortalisation (Hawley-Nelson et a /1989, Rice e ta l 
1993, Edington et al submitted). One of the potential causes of several types of
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chromosomal abnormalities such as rearrangements, deletions and aneuploidy 
in these cells is thought to be telomere shortening, due to the absence of 
functional telomerase, a ribonucleoprotein containing the ability to compensate 
for sequence loss during replication (Harley 1991, Counter ef a/1992).
1.1.2 Deletions.
In 1971 Knudson (Knudson 1971) proposed a mechanism by which 
tumours arose from specific DNA deletions. Today the theory is widely 
accepted and chromosomal losses in human tumours are regarded as 
evidence that the affected regions contain tumour suppressor genes. The 
malignancies are thought to arise from two distinct genetic events, one 
inherited from a parent or taking place during gametogenesis and the other 
occurring somatically. Conversely, both events may be somatic.
The del (13)(q14;q14) is associated with retinoblastomas, a rare type of 
childhood tumour and results in the loss of the tumour suppressor gene, Rb 
(Knudson 1971, Friend ef a/1986, Varmus 1989, Sikora et a /1990, Solomon et 
al 1991). The fact that the protein pRb is a target for inactivation by viral 
oncogenes such as the SV40 T antigen, human papilloma virus (HPV-)16 E7 
and adenovirus 5 E1 a suggests its importance as a negative regulator of 
cellular proliferation (Weinberg 1991).
The WT1 gene is a potential transcription factor and tumour suppressor 
gene (Hastie 1993). Deletions of chromosome 11 p13 result in the loss of one 
WT1 allele predisposing the individuals to a disease known as Wilms' tumour 
that results from the absence of functional WT1 products (Sikora et al 1990; 
Solomon et a /1991).
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Work on colorectal carcinomas has revealed the existence of several 
potential negative regulators of cell growth. The loss of 17q proved to remove a 
now well known tumour suppressor gene, p53 (Baker et al 1989, Finlay et al 
1989) and occurs in more than 70% of cases. The absence of functional p53 
releases the cell from an important G1 check point and will allow for the 
accumulation of DNA mutations (Lane 1992, Prives 1993). Deletion of 18q 
takes place at a similar frequency (-70%) resulting in the loss of the DCC 
gene, the product of which is related to NCAM, a neural cell adhesion molecule 
(Bishop 1991, Srivatsan eta! 1993, Porfiri ef a/1993). A dominantly inherited 
disorder, familial adenomatous polyposis (FAP) is closely linked to the loss of 
chromosome 5q in -20% of studied cases (Solomon eta ! 1987, Miki eta ! 1992, 
Sen-Gupta 1993). Heterozygous individuals develop multiple benign polyps 
that frequently progress to malignant adenocarcinomas (Solomon et al 1987, 
Sikora 1990) following a mutational event that inactivates the other FAP allele.
1.1.3 Chromosomal amplification.
In some organisms at specific points during development a requirement 
for copious amounts of certain gene products must be reached. Transcription 
from single genes would not be sufficiently rapid to reach the requirements and 
in these instances DNA amplification takes place. The best known examples of 
developmentally regulated amplification are the accumulation of rDNA in 
Xenopus laevis germ cells and of the chorion genes in Drosophila egg 
chambers. In these instances gene dosage may increase a 1000-fold or up to 
60-fold, respectively (Stark and Wahl 1984). In mammals no examples of 
developmentally regulated amplification have been found, however it has been 
well documented as an abnormal process in cancer (Stark 1986, Stark e ta l
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1989). Specific regions of the human genome have proved to be common 
targets for amplification in certain types of cancer and this is linked to poor 
prognosis for the patient (Tsuda et al 1989a, Kitagawa et a /1991, Schuuring et 
al 1992b).
The gene dosage of N-myc is increased in a high proportion (-50%) of 
neuroblastomas, some retinoblastomas and Wilms' tumours (Schwab and 
Amler 1990, Solomon et a /1991). The extent of amplification may vary from 3- 
300 fold
in different tumours and strongly correlates with more advanced stages of 
neuroblastomas. The high frequency of these events suggests that it is 
advantageous to have increased levels of N-myc. N-myc\s located on 
chromosome 2p23-p24, however copies of the gene may be found at several 
other chromosomal homologous staining regions (HSRs) in tumours where 
amplification has taken place (Schwab et a /1984). The other two members of 
the myc-box family, c-myc and L-myc, have increased gene dosage in several 
types of lung carcinoma, c-myc is also amplified in breast carcinomas and 
Burkitt's lymphoma (Stark 1986).
The epidermal growth factor receptor (EGFr) is an important component 
of the signal transduction pathway, the gene of which (c-erbB) is located on 
chromosome 7q22 and is amplified in -10-20% of squamous cell carcinomas 
(SCC), 1% of breast cancers, 80-90% of late stage glioblastomas and 
occasional meningiomas (Libermann eta ! 1985, Wong et a /1987, Haley e ta l 
1987, Ro e ta l 1987, Malden e ta l 1988, Harris and Nicholson 1988, Ishitoya et 
al 1989). A related gene c-erbB2, also known as HER-2/neu, commonly has 
increased gene dosage in human mammary carcinomas and derived cell lines 
(Schwab and Amler 1990, Stanton eta l, submitted).
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The size of the amplified DNA fragment is generally much greater than 
one gene and can involve up to 10,000kb, suggesting that many sequences 
are co-amplified with a key gene, the increased expression of which is selected 
for (Stark e ta l 1989). A good example is the commonly amplified 11q13 region 
reported in -50% of head and neck squamous cell carcinomas (HNSCC),
-15% mammary tumours and oesophageal carcinomas (Zhou e ta l 1988, 
Berenson e ta l 1989, Tsuda et al 1989b, Somers e ta l 1990, Kitagawa e ta l 
1991). The identity of the key gene in this amplicon still remains debatable. 
This region will be described in greater detail in section 1.2.
The location of amplified DNA in mammalian cells can be:
(i) chromosomal - a stable form and more common in cancer. It is often found 
integrated into chromosomes as HSRs or extended chromosomal regions 
(ECR) (Stark e ta l 1989), or
(ii) extrachromosomal - DNA found free of chromosomes usually in double 
minutes (DMs), a transient type of amplification frequently seen in clinical 
resistance to drug treatment and tissue culture conditions (Stark et al 1989).
In cancer, amplified DNA is often found near to or at the site of the original 
gene from which it was derived, although this is not always the case (Roelofs 
e ta l 1993).
The exact mechanisms of amplification are thought to be specific for 
each event. Likely models include unequal sister chromatid exchange during 
mitosis, unscheduled replication and chromosomal rearrangements see Figure 
1. Commonly, other gross abnormalities of the genome such as chromosome 
deletions, rearrangements, translocations and even loss have been coupled 
with amplification.
7
Figure 1. Two mechanisms of DNA amplification.
Schematic diagram representing a) DNA amplification due to unscheduled 
replication and subsequent recombination; b) DNA amplification due to 
chromatid misalignment during mitosis (Stark and Wahl 1984).
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1.1.4 Translocations, insertions and inversions.
Chromosomal rearrangements affect genes in the proximity of the 
translocation breakpoint resulting in their deregulation, or the formation of 
oncogenic fusion genes. Although this type of chromosomal abnormality is 
most common in cancer the mechanism by which the events take place are not 
known, probably due to their diversity.
The consequences of chromosomal rearrangements have been 
separated into two categories:
(i) Rearrangements that result in the formation of a new chimeric product which 
contains coding sequences and transforming potential from both partners.
A well known example is the Philadelphia chromosome in chronic 
myelogenous leukaemia (CML), present in over 90% of patients with this 
disease (Bishop 1989, Solomon efa/1991, Seeker-Walker and Craig 1993). It 
results from a reciprocal translocation between 9p34 and 22q11 causing the 
formation of the bcr-ablfusion mRNA and protein. The breakpoint cluster 
region (bci) encodes a guanosine triphosphatase (GTP-ase) binding protein 
(GAP) for p21rac. c-abl is a specific protein tyrosine kinase, the activity of 
which is unmasked by the fusion to bcr, this is attributed to the replacement of 
the normal N-terminal domain of c-abl by the domain derived from bcr (Bishop
1989).
(ii) Rearrangements that place a cellular proto-oncogene under the control of a 
strong promoter causing over-expression of the gene.
The immunoglobulin heavy (IgH) chain locus on 14q32 is frequently 
involved in rearrangements with several regions: 8q24,11 q13 and 18q21. The 
t(8;14)(q24;q32) translocation is a characteristic feature of Burkitt's lymphoma 
(BL), a malignancy of immature B cells evident in -80% of patients suffering
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from the disease (Bishop 1989, Hiyama et a /1991). The consequence of the 
rearrangement is upregulation of the c-myc transcripts and protein (Petroni et 
al 1992). Other less common events in Burkitt's lymphoma, involving 8q24 and 
2p11 or 22q11 have a similar effect on c-myc expression and may encompass 
the PVT gene located 260kb downstream of c-myc (Shtivelman and Bishop
1990).
The t(11 ;14)(q13;q32) and t(14;18)(q32;q21) rearrangements are 
proposed to link the IgH chain promoter and genes located in these two 
regions. The former will be described in greater detail in section 1.2.1 .b.
1.2 CCND1, the gene coding for human cyclin D1.
1.2.1 The 11 q13 region.
The q13 band on chromosome 11 is a dynamic area commonly 
amplified or rearranged in human tumours (Lammie and Peters 1991, Gaudray 
e ta l 1992). 11 q13 is suggested to be ~15 million base pairs (mb) long and may 
be divided into five sub-regions by the use of cytogenetic analysis of extended 
pro-metaphase spreads (Lammie and Peters 1991, Brookes e ta l 1993). Most 
of the genes expected to reside in this area remain unknown, although rapid 
progress is under way leading to their elucidation.
1.2.1 .a FGF-3 and FGF-4.
The mouse mammary tumour virus (MMTV) is capable of inducing 
mammary carcinomas in susceptible mice after a long latency period. This was 
proposed to be by activating host genes in the vicinity of the viral DNA 
integration site and was used for the isolation of new proto-oncogenes (Nusse 
and Varmus 1982, Peters e ta l 1983, Dickson e ta l 1984, Dickson and Peters
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1987). Following this strategy, MMTV integration into murine chromosome 7 
led to the identification of the activated int-2gene (Peters et al 1983, Dickson 
e ta l 1984). The human homologue of int-2 \Nas mapped to chromosome 
11 q13 (Casey et al 1986).
In 1986 Sakamoto caused transformation of a mouse fibroblast cell line, 
NIH3T3, by transfection with specific DNA sequences obtained from patients 
with stomach cancer (Sakamoto e ta l 1986). The transforming sequences were 
isolated, cloned and the new gene initially named hst, was later termed hstf-1 
for Jieparin binding secretory transforming factor (Yoshida et al 1988). hstf-1 
mapped to chromosome 11 q13.3 and the vicinity of int-2 (Yoshida et al 1988). 
These were the first candidates for the key genes of 11 q13. Following the new 
nomenclature, the int-2 and hstf-1 genes will be referred to in subsequent 
sections as FGF-3 and FGF-4, respectively.
1.2.1.b Rearrangements involving 11q13.
One of the first observed rearrangements of 11q13 were made in small 
or large cell diffuse lymphoma and B-cell chronic lymphocytic leukaemia 
patients and involved chromosome 14q32 (Erikson e ta l 1984). The events 
were postulated to activate a proto-oncogene near to or at the breakpoint 
region on 11q13, by placing it under the control of the strong IgH chain locus 
(Erikson e ta l 1984). The breakpoint region was named bcl-1 for B-cell 
leukaemia/lymphoma. It was initially cloned from a case of chronic lymphocytic 
leukaemia (CLL) and successfully used as a probe to detect translocations of 
the same DNA sequences in other types of B-cell malignancies (Tsujimoto e ta l
1984). In 1988 and 1989 it became clear that the chromosomal break can 
occur at 1 kb, 2kb, 36kb or even 63kb away from the major translocation
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cluster, examples of which were observed in different types of B-cell 
malignancies (Rabbits et al 1988, Koduru et al 1989, Meeker et al 1989, 
Lammie and Peters 1991).
Since its discovery, the t(11 ;14)(q13;q32) rearrangement has been 
reported in several B-neoplasms, including non-Hodgkin's lymphoma 
(Vanderberghe et al 1992), centrocytic lymphoma (Williams et al 1991, 
Rosenberg et al 1991 a) and myeloma (Seto e ta l 1992). In rare cases of 
benign parathyroid adenomatosis 11q13 is rearranged with the parathyroid 
hormone gene on 11 p15 (Arnold et al 1989, Rosenberg et al 1991 b). A 
t(8;11)(p21 ;q13) translocation was reported in one case of B-cell non- 
Hodgkin's lymphoma (Vanderberghe e ta l 1992).
1.2.1 .c Amplification of 11 q13.
Initially, reports of chromosome 11q13 amplification were made in 
primary breast carcinoma (Varley e ta l 1988, Zhou e ta l 1988), HNSCC (Zhou 
et al 1988) and patients with lymph node metastasis of stomach cancer 
(Yoshida e ta l 1988). This stimulated the interest in FGF-3and FGF-4, 
revealing increased gene dosage in oesophageal carcinomas (Tsuda e ta l 
1989b, Kitagawa e ta l 1991), transitional cell carcinomas of the bladder 
(Theillet et a /1989, Proctor e ta l 1991), lung carcinomas (Berenson e ta l 1990), 
melanomas (Theillet e ta l 1989) and many new cases of breast carcinoma and 
HNSCC (Linderau e ta l 1988, Liscia e ta l 1989, Berenson e ta l 1989, Theillet et 
al 1989, Berenson e ta l 1990, Theillet e ta l 1990, Saint-Ruf e/a/1991). Even 
though FGF-3 and FGF-4 were not normally expressed in adult murine or 
human tissue, their homology to fibroblast growth factors and apparent
12
transforming potential made them good candidates for the targeted 
gene/genes of chromosome 11 q13 (Lammie and Peters 1991).
It is widely believed that the key transforming gene of an amplicon must 
fulfil the following criteria: (i) the amplification unit contains the essential 
gene(s) in all examined cases, (ii) the essential gene(s) is amplified to the 
greatest level when compared to other genes in the amplicon, (iii) the essential 
gene(s) is expressed to the highest extent when compared with the other 
members of the amplicon, (iv) the structure and function of the gene(s) is 
consistent with the implied role in oncogenesis and (v) no other marker should 
fulfil the same criteria (Schuuring et al 1992a).
Expression of FGF-3 and FGF-4 were shown to rarely accompany 
amplification of chromosome 11q13, eliminating both genes as potential key 
targets of this genomic region (Liscia et al 1989, Theillet et al 1989, Faust and 
Meeker 1992).
The mechanisms by which a cell may increase the dosage of a specific 
gene(s) was described briefly in sections 1.1.1 and 1.1.3. Analysis of the 11 q13 
region and FGF-3 in a panel of human cell lines that have amplified these 
sequences, was carried out using the method of fluorescence in situ 
hybridisation (FISH) (Roelofs e ta l 1993). Low levels of amplified sequences 
were detected only at the original gene location, suggesting that formation of 
extrachromosomal structures was not the mechanism by which increased gene 
dosage had taken place in the majority of examined tumours. This was based 
on the proposal that DMs and similar extrachromosomal particles often 
integrate at non-native genome locations (Roelofs e ta l 1993). Amplification of 
11 q13 was suggested to take place by an in situ process and was coupled with
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specific translocations, duplications and inversions detected in the examined 
cell lines (Roelofs e ta l 1993).
1.2.2 The identification of D11S287.
In a survey of 297 mammary tumours, amplification of bcl-1 alone was 
seen in 6 patients (Theillet et al 1990). Two other studies showed amplification 
of FGF-3 but not of FGF-4 in breast and oesophageal carcinomas, a surprising 
observation considering the small distance separating the genes (Ali e ta l 
1989, Tsuda e ta l 1989b). These data, coupled with the frequent involvement 
of bcl-1 in B-cell chromosomal rearrangements suggested the presence of a 
gene located between the FGF tandem and bcl-1 that may be the key gene of 
the amplicon (Theillet e ta l 1990).
The first indications of the identity of this putative gene came from rare 
cases of parathyroid adenomatosis (Arnold e ta l 1989). Examination of the high 
molecular weight DNA isolated from a parathyroid adenoma obtained from a 68 
year old patient, revealed an abnormal BamH1 restriction fragment that 
hybridised to a parathyroid hormone (PTH) specific probe. The abnormality 
was clonal and resulted in a 50% loss of the normal PTH gene in all the tumour 
cells. Digestion of the DNA with combinations of several restriction enzymes 
suggested that a break had separated non-coding exon-1 from the 
downstream sequences of the gene.
Further characterisation of the involved DNA was carried out with the 
use of probes specific to the sequences immediately 5' (A) or 3' (B and C) of 
the PTH gene breakpoint. The non-PTH gene sequences were mapped to 
chromosome 11q13.3-11q13.5 by in situ hybridisation studies and Southern 
blot analysis of human/mouse hybrids. In accordance with the Human Gene
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Mapping Library system the new locus was termed D11S287. All three probes 
detected single copy sequences in normal human DNA, with A and C also 
hybridising to mouse sequences at conditions of high stringency. The 
sequences specific to this locus were completely unrelated to bcl-1, FGF-3 and 
FGF-4. This suggested that the D11S287 locus was a well conserved, new 
gene, the expression of which had been influenced by the translocated, highly 
active 5’ PTH gene region.
Probe B was used to confirm the proposal. It detected D11S287 
transcripts (D11S287E) in parathyroid adenomas with or without the 
t(11 ;11)(p15;q13) rearrangement and normal placenta (Rosenberg e ta l 
1991 b). However, in adenomas carrying the t(11 ;11 )(p15;q13) rearrangement, 
dramatic over-expression was evident, suggesting upregulation of D11S287E 
by the displaced PTH regulatory elements. The full length transcript of 
D11S287E (4242bp) was isolated from a human placental cDNA library and a 
new name proposed for the gene, PRAD-1 for parathyroid adenomatosis 
(Motokura e ta l 1991). The longest reading frame starting from the first ATG 
codon was estimated to encode a protein of 295 amino acids and 33,729D in 
size. Screening the Genbank peptide database with the identified sequence, 
revealed extensive homology only with members of cyclin families (Motokura et 
al 1991).
Cyclins were initially discovered in marine invertebrates and proved to 
be essential regulatory compartments of the cell cycle (Rosenthal e ta l 1980, 
Evans e ta l 1983) It is easy to imagine how increased expression of cell cycle 
promoting proteins may contribute to deregulated cellular proliferation.
However, until the discovery of PRAD1 (later referred to as cyclin D1 or 
CCND1) very little evidence existed for the involvement of cyclins in cancer.
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1.3 Cyclins.
1.3.1 The Maturation promoting factor.
Unfertilised, fully grown frog oocytes are arrested at the G2/M boundary 
of meiosis I. In vivo, this arrest is broken by the action of progesterone, 
secreted by the surrounding follicle cells, causing oocyte passage through 
meiosis I and arrest at metaphase of meiosis il. The second arrest point is 
overcome by insemination (Smith and Ecker 1971, Minshull 1993). In 1971 it 
was postulated that exposure to progesterone activated an intracellular factor 
termed maturation promoting factor (MPF), causing nuclear envelope 
breakdown, chromosome condensation and passage of fully grown oocytes 
through meiosis I (Masui and Market 1971). Injection of mature progesterone- 
induced Rana pipiens oocyte extracts into immature oocytes of the same 
species, caused the latter to mature without the presence of progesterone, 
consistent with the above proposal (Masui and Market 1971, Smith and Ecker 
1971). In 1970 a phenomenon resembling initiation of mitosis, termed 
premature chromosome condensation (PCC), was observed in non-mitotic 
human HeLa cells, upon fusion with mitotic cells of the same line (Johnson and 
Rao 1970). PCC was also achieved in unstimulated mosquito cells, Xenopus 
laevis kidney cells, embryonic chick fibroblasts and erythrocytes, Chinese 
hamster ovary cells, bovine spermatozoa and horse lymphocytes by fusion to 
mitotic HeLa cells (Johnson and Rao 1970). The discovery that almost all 
meiotic and mitotic cells contained interchangeable MPF activity led to the idea 
that the factor was conserved in all eukaryotes (Reynhout and Smith 1974, 
Sunkara e ta l 1979, Kishimoto e ta l 1982, Kishimoto e ta l 1984, Sorensen e ta l
1985).
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Eukaryotes depend on de novo protein synthesis for cell cycle 
progression, a requirement which is bypassed by injection of MPF (Wasserman 
and Masui 1975, Minshull 1993). In vivo, MPF activity is specific only to late G2 
and M-phase cells, a characteristic convincingly shown by induction of 
Xenopus laevis oocyte maturation with extracts from HeLa cells synchronised 
to late G2 or M phases, whereas G1 and S phase HeLa cell extracts had no 
effect on the oocytes (Sunkara et a /1979). Partial purification of MPF revealed 
it to be a protein complex of approximately 100kD, which was subsequently 
shown to consist of a 34kD protein homologous to the Schizosaccharomyces 
pombe cdc2 (this will be further described in section 1.3.3.a) and a cyclin 
(Dunphy et al 1988, Gautier et al 1988, Draetta et al 1989).
1.3.2 The discovery of cyclins.
Mitotic cyclins were initially recognised in marine invertebrates due to 
their oscillation patterns at specific stages of the cell cycle and ability to induce 
mitosis. Tim Hunt and his students were the first to identify cyclins A and B, in 
embryos of two sea urchin species Arbacia punctulata and Lytechinus pictus 
and surf clam, Spisula solidissima oocytes (Evans e ta l 1983). The initial 
experiments on 35S-methionine labelled Arbacia punctulata eggs, revealed that 
upon fertilisation or treatment with parthenogenic reagents NH4CI or A23187, 
the levels of one protein significantly increased. In cells that had been fertilised, 
the protein, termed cyclin A, was destroyed more or less completely every time 
the embryos divided, as opposed to weak base and Ca++ ionophore treated 
eggs that were unable to pass through mitosis. Similar analysis of Lytechinus 
pictus and Spisula solidissima revealed the presence of two cyclin proteins A 
and B that oscillated in different phases (Evans e ta l 1983). The two cyclins,
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known as proteins A and B, had been previously identified in Spisula 
solidissima. Following fertilisation the surf clam embryos were exposed to 35S- 
methionine or 3H-leucine and the labelled proteins analysed on one 
dimensional acrylamide gels (Rosenthal e ta l 1980). This revealed a 
substantial increase of proteins A and B, while proteins termed X, Y and Z 
decreased in amount, however in 1980 the role of proteins A and B in cell cycle 
regulation had not been realised (Rosenthal e ta l 1980).
MPF activity coincided with entrance of cells into mitosis (Gerhart and 
Kirshner 1984, Sunkara et al 1979) a characteristic described in section 1.3.1 
of this chapter. The requirement for de novo protein synthesis in each cell 
division, even in amphibian oocytes despite the great abundance of mitotic 
proteins present in these cells, suggested that a component of the MPF may 
be a protein synthesised prior to each round of cell division. Cyclins proved to 
be the best candidates for the MPF regulatory component, however until 1989 
there was no evidence to confirm these speculations. The first in vitro cell 
cycle, carried out using cytoplasmic preparations of Rana pipiens oocytes and 
demembranated Xenopus laevis sperm nuclei, was the key to the analysis of 
this phenomenon. A crude cytoplasmic extract obtained by centrifugation of 
activated oocytes, termed "the heavy ooplastic fraction", caused morphological 
changes of the sperm nuclei that resembled those seen during pronuclear 
formation in intact cells (Lohka and Masui 1984). The results of the 
experiments confirmed previous reports of MPF activity, while the 
reconstruction of the cell cycle by using cell-free extracts from amphibian eggs 
allowed a whole new approach to the analysis of protein interactions that lead 
to cell division. Thus, in 1989, Murray and Kirshner were able to demonstrate 
that cyclin B was a component of the MPF (Murray and Kirshner 1989).
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Treatment of activated Xenopus laevis oocytes with pancreatic RNase caused 
destruction of the endogenous mRNA and prevented the cells from entering 
mitosis. However, the addition of in vitro transcribed sea urchin cyclin B mRNA 
completely restored the morphological and biochemical events characteristic of 
mitosis, a phenomenon which was not achieved by the use of tobacco mosaic 
virus RNA.
1.3.3. Cyclin B and mitosis, the mechanism of action.
Since 1983 and the discovery of cyclins, our knowledge of the cell cycle 
has increased dramatically. Today, seven cyclin families have been isolated, 
which have the potential to interact with over 11 identified catalytic subunits at 
different points of the cell cycle. Due to the structural similarities of the involved 
proteins, the catalytic and regulatory subunit interaction and kinase activation 
are thought to follow a similar pathway. Currently, most is known about the 
associations of the two cyclin B proteins (B1 and B2) with p34cc*c2i the 
mechanisms of which are described in the following sections and are used as 
an example of the interactions that may take place between the other known 
cell cycle regulators.
1.3.3.a The association of p34cc*c2 ancj cyclin.
The 34kD protein cdc2 was initially identified in Schizosaccharomyces 
pombe as a critical regulator of the M phase (Nurse and Thuriaux 1980), six 
years later it was shown to function as a protein kinase (Simians and Nurse
1986). The human homologue of cdc2 was cloned with the use of yeast 
genetics. Rescue of the non-viable S. pombe cdc2-33 leu1-32 mutants was 
attempted by the introduction of a LEU2 selectable marker and a full-length
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human fibroblast cDNA library made in an Subexpression vector (Okayama 
and Berg 1983, Lee and Nurse 1987). Cell cycle restoration was achieved by 
the presence of a cDNA that upon examination showed extensive homology to 
the S.pombe cdc2 and related S. cerevisiae CDC28 genes.
Work carried out by two research groups independently showed the 
presence of the Xenopus laevis cdc2 homologue in the MPF. In one study, the 
specific association of cdc2 and a 13 kD protein suc1, previously described in 
yeast, was used to isolate cdc2 from Xenopus cell extracts (Brizuela et al 1987; 
Dunphy e ta l 1988). When crude MPF was chromatographed on a suc1 
agarose column, the activity of MPF was quantitatively depleted, suggesting 
that cdc2 was a component of the maturation factor (Dunphy et al 1988).
These results were confirmed by detection of cdc2 in purified Xenopus oocyte 
MPF, with the use of antibodies to S.pombe cdc2 in immunoblot and 
immunoprecipitation analyses (Gautier e ta l 1988). The proof that cyclins A or 
B complex with cdc2 to form the MPF, yet again came from experiments on 
amphibian cell free lysates (Draetta e ta l 1989). Isolation of cyclins A and B 
was achieved by incubation of M phase surf clam embryo extracts with sucl- 
Sepharose beads already known to precipitate cdc2. The identity of the two 
cyclins was proved by treatment with N-chlorosuccinimide, a reagent that 
specifically cleaves at tryptophan residues creating an array of short peptides 
specific to individual proteins. Both cdc2-cyclin A and cdc2-cyclin B complexes 
exhibited H1 kinase activity (Draetta e ta l 1989).
1.3.3.b The current model of mitosis.
Cyclin B is now recognised as an essential positive regulator of the cell 
cycle that functions by associating with cdc2, thus enabling the onset of mitosis
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(Westendorf e ta l 1989). Unlike cyclin B, the cdc2 protein does not oscillate 
with the cell cycle, however its activity is tightly regulated by specific 
phosphorylations that are dependent on the association with cyclin B (Solomon 
e ta l 1990, Krek and Nigg 1991). In middle to late G2, newly synthesised cyclin 
B binds to inactive, monomeric cdc2 triggering phosphorylation of cdc2 on 
residues Thr-14 and Tyr-15, maintaining the inactive state of this kinase 
(Solomon e ta l 1992). The reaction is thought to be catalysed by two 
homologues of S.pombe kinases weel and mik1, the activity of which is also 
regulated by phosphorylation (Lundgren e ta l 1991, Parker and Piwnica-Worms 
1992, Parker et al 1993, Wu and Russell 1993, Tang et al 1993). The Tyr-15 
residue is located within a consensus sequence (GXGXXG) of the cdc2 protein 
which represents a putative nucleotide binding site, suggesting that 
phosphorylation of Tyr-15 inhibits the kinase activity of cdc2 by preventing the 
binding of ATP (Gould and Nurse 1989). However, a recently derived three 
dimensional model of cdc2 based on the crystal structure of cAPK (the catalytic 
subunit of cyclic AMP-dependent protein kinase), suggested that 
phosphorylation of |Tyr15 displaces a highly conserved cdc2 domain necessary 
for cyclin binding away from the cdc2 substrate recognition site, preventing 
interaction between the two domains and peptide recognition (Marcote e ta l 
1993). These results confirmed preceding observations determined by FSBA 
(the nuclear analogue 5'-p-fluorosulphonyl-benzoyladenosine) labelling 
experiments that|Tyr15 phosphorylation does not
prevent ATP binding (Atherson-Fessler e ta l 1993).The cdc2/cyclin B complex 
will remain in this inactive state until the end of G2 when DNA synthesis, repair 
and other essential processes have been completed (Dasso and Newport 
1990, Enoch and Nurse 1990). Activation of cdc2 involves removal of the
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phosphates on Thr-14 and Tyr-15, a reaction catalysed by a family of specific 
phosphatases termed cdc25 (Gautier et al 1991, Izumi et al 1992, Lee et al 
1992). In humans three related cdc25 proteins have been identified and termed 
cdc25A, cdc25B and cdc25C of which all three are able to rescue yeast cdc25 
deficient mutants (Sadhu e ta l 1990, Galaktionov and Beach 1991). The 
catalytic activity of the cdc25 proteins is considerably weaker than other known 
PTPases which is possibly due to the absence of a potential activating domain 
shared by other known PTPases. However, cyclin B has been shown to contain 
the PTPase specific activating domain which is thought to contribute to cdc25 
activation "in trans" by intermolecular interactions (Galaktionov and Beach 
1991, Zheng and Ruderman 1993). Interestingly, recent reports have 
suggested that the phosphatase activity of cdc25C is also enhanced by Ser/Thr 
phosphorylation catalysed by the functional cyclin B/cdc2 complex, thus 
generating a positive feedback loop (Hoffmann et al 1993). Activation of the 
cyclin B/cdc2 complex at the G2/M transition will not take place in the absence 
of a positive phosphorylation of cdc2 at residue Thr-161. There is evidence that 
the CAK (£dc2 activating Kinase) protein also known as the Xenopus p40MO15 
cdc2-related kinase, catalyses this reaction (Solomon efa/1992, Solomon e ta l 
1993, Poon eta l 1993). The activated cyclin B/cdc2 complex proceeds to 
function as a Ser/Thr kinase phosphorylating specific nuclear substrates and 
allowing mitosis to take place. Two major components of the nuclear envelope, 
the lamin intermediate filament proteins A and C are specifically 
phosphorylated by the cyclin B/cdc2 kinase (Ward and Kirshner 1990, Heald 
and McKeon 1990). Phosphorylation of these proteins causes their 
disassembly and solubilisation, resulting in the nuclear envelope breakdown. 
The cyclin B/cdc2 complex is also thought to be responsible for other mitotic
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events such as spindle assembly and chromosome condensation (Janssen et 
al 1991, Verde et al 1992, Leiss et al 1992). Potential substrates of this kinase 
include tumour suppressor protein p53, pp60c-src and numatrin - a nuclear 
matrix phosphoprotein (Bischoff e ta l 1990, Feuerstein 1991, Shenoy e ta l
1992). Dephosphorylation of Thr-161 and inactivation of the cyclin B/cdc2 
complex is necessary for the cell to enter anaphase (Lorca e ta l 1992,
Holloway et al 1993). This is followed by the dissociation of cdc2 and cyclin B 
of which the former remains in the cell in the inactive monomeric form, while 
the latter is rapidly degraded by the ubiquitin pathway (Draetta and Beach 
1988, Krek and Nigg 1991, Glotzer et al 1991, Hunt 1991).
1.3.4 The cell cycle.
"The cell cycle is the period during which events required for successful 
cell reproduction are completed" (Nurse 1990). The two major phases S and M 
characterised by chromosome replication and segregation respectively, are 
separated by the G1 and G2 gap phases. Proteins active during G1 and G2 
tightly regulate the two major phases. In terms of duration G1 is the most 
variable in length. It may last several hours or longer, when it is frequently 
referred to as GO, or be completely absent as in rapidly dividing cells during 
development (Wintersberger 1991).
The importance of cyclin B for the onset and passage through mitosis 
was described in detail in the preceding sections. In the recent years 
increasing attention has also been focused on the G1 phase of the cell cycle 
where several cyclin families are proposed to function. However, the protein 
interactions that take place in this phase of the cell cycle have proved to be far 
more complicated than in mitosis, a major cause being the many growth
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stimulators and repressors that act in the G1 phase by binding to specific cell 
surface receptors and activating a cascade of events that regulate proliferation. 
In view of the multitude of interactions that take place in this phase, it is clear 
that it may also be the most common source of mutations that could lead to 
transformation and cancer, a topic that will be discussed in later sections.
1.3.4.a Mammalian G1 cyclins.
The G1 cyclins were initially discovered in budding yeast 
Saccharomyces cerevisiae (Hadwiger et al 1989, Richardson et al 1989).
Today at least four families of mammalian cyclins (C, D, E and G) are 
proposed to regulate G1.
The Saccharomyces cerevisiae CLN family of cyclins consists of 
members CLN1, CLN2 and CLN3, initially proposed to be partially redundant, 
although contradicting evidence now exists (Richardson e ta l 1989, Cross and 
Tinkelenberg 1991, Tyers et al 1993). S. cerevisiae haploid cells have three 
possible fates: when nutrients are limiting they may enter the resting phase GO; 
if exposed to mating factors the cells differentiate into gametes, capable of 
conjugating with neighbouring cells of an opposite mating type; the last option 
available is to continue cycling and divide when sufficient nutrients are present 
(Nasmyth 1990). During the G1 phase of the cell cycle there is a decision point 
termed START where the haploid cell must decide whether to proceed with the 
cell cycle or not. The decision is determined by cell size and the presence of 
nutrients or secreted mating factors (Lew et al 1991, Xiong et al 1991). Just 
one functional CLN protein is sufficient to allow passage through START, upon 
which the cell is committed to division (Richardson e ta l 1989). This potential 
redundancy created an excellent system for the isolation of novel mammalian
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genes and led to the discovery of several G1 cyclins (Xiong et al 1991, Lew et 
al 1991).
In one study a yeast strain was constructed in which CLN3 was altered 
to allow conditional expression from a galactose-inducible, glucose-repressible 
GAL1 promoter (Xiong e ta l 1991). CLN2ar\6 CZJV3 were rendered inactive by 
insertional mutagenesis. When grown on 1% galactose, the yeast strain had a 
doubling time indistinguishable from the CLN parental wild type strain, although 
differed in size. Removal of galactose or addition of glucose caused 
accumulation of cells in the G1 phase and cell division ceased. Introduction of 
a human glioblastoma cDNA library into the yeast was attempted with the aim 
to prevent the G1 block using a human functional equivalent. The expression 
vector that carried the cDNA library contained a LEU2 selectable marker which 
enabled detection of spontaneous revertants. From the ~3x106 transformants 
screened, only two revertants contained the LEU2 marker. Restriction enzyme 
digestion and partial DNA sequencing were able to show that in both cases the 
same human gene was involved. A full length cDNA was subsequently isolated 
from a HeLa cell line cDNA library (1325bp) and was calculated to correspond 
to a 33,670D protein. The new protein (cyclin D1) was identical to the 
previously described PRAD-1 (Motokura e ta l 1991).
An independent, but very similar study also led to the isolation and 
cloning of cyclin D1 (Lew e ta l 1991). Two strains of S.cerevisiae (DL1 and 
YCS1) were constructed where all three CLN genes were disrupted by 
insertional mutagenesis. Survival of DL1 and YCS1 was enabled in the 
presence of galactose due to an integrated chimeric gene containing the 
coding region of CLN2 expressed from the regulatable GAL1 promoter. Under 
growth repressible conditions the DL1 strain was rescued by introduction of two
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human cDNA libraries derived from either HepG2 or HeLa cells. A human 
glioblastoma cDNA library was introduced into the YCS1 strain. Transformed 
S.cerevisiae were selected for either in the absence of uracil, as HepG2 and 
HeLa libraries contained the URA3 gene, or due to the presence of the LEU2 
marker in the glioblastoma cDNA library. Eighteen colonies from the HepG2 
transformants, 23 from the HeLa and 3 colonies containing glioblastoma cDNA 
were dependent on library plasmids for growth. The majority of cDNAs were 
derived from cyclins B1, B2 and A, however three novel genes were identified 
and named cyclin C (HepG2 library), cyclin D (glioblastoma library) and cyclin 
E (HeLa library) and were predicted to code for proteins of 303, 295 and 396 
amino acids, respectively. Cyclin D was identical to the previously described 
PRAD-1 gene (Motokura et al 1991, Xiong et al 1991).
The simultaneous discovery of the D-type cyclins in mouse 
macrophages provided further evidence for their importance as G1 phase 
regulators. The dependency of bone-marrow macrophages on colony 
stimulating factor-1 (CSF-1) for growth, was used for the isolation of the PRAD- 
1/cyclin D1 mouse homologue (Matsushime et a/1991). CSF-1, also known as 
the macrophage growth factor, belongs to a family of glycoprotein regulators 
that control proliferation and differentiation of granulocytes, macrophages and 
certain haematopoietic cells by binding to a specific receptor at the cell surface. 
In doing so the receptor intrinsic tyrosine kinase is triggered and will 
subsequently phosphorylate specific protein substrates activating the signal 
transduction pathway (Metcalf 1990). The CSF-1 receptor (CSF-1 R) is coded 
for by the c-fms proto-oncogene and is specific to macrophages (Sherr eta l
1985).
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In the absence of CSF-1, bone-marrow macrophages arrest in the G1 
phase of the cell cycle. This invariably results in cell death if the growth factor 
is withdrawn for longer periods (Tushinski and Stanley 1985). However, cell 
cycle synchronisation of mouse macrophages can be achieved by transient 
starvation followed by stimulation with CSF-1. Cells treated in such a way will 
move synchronously through G1 and into the S phase (Matsushime e ta l 
1991). This allows the identification of specific genes that respond to CSF-1, 
and was used in the following experiments (Matsushime e ta l 1991):
The mouse macrophage cell line BAC1.2F5A was not viable following 
growth in the absence of CSF-1 for over 36 hours. When deprived of growth 
factor for 18 hours and then stimulated with CSF-1 for 3 hours, the cell line 
responded by synchronised entry into the S phase 10-12 hours following 
exposure to CSF-1. A cDNA library was constructed from the messenger RNA 
isolated from stimulated cells which was in turn screened with a subtracted 
cDNA probe enriched for sequences expressed in induced cells. Due to its 
homology to known cyclins, the newly identified gene was named Cyl-1 for 
cyclin-]ike 1 gene and represented the mouse homologue of the human cyclin 
D1 gene. During the screening, phage plaques that weakly hybridised to 
probes derived from the most highly conserved regions of Cyl-1 were also 
identified. To further investigate this phenomenon, cDNA libraries from mouse 
thymus cells and a fibroblast cell line (NIH3T3) were screened with a probe 
derived from nucleotide sequences of one such phage and the previously used 
Cyl-1 cDNA probe. This led to the isolation of two related but distinct genes 
Cyl-2 and Cyl-3 that were 63% and 49% identical to Cyl-1, respectively and 
61% homologous to one another in regions of the proteins termed the "cyclin 
box" known to be evolutionarily conserved in all cyclins.
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The existence of three mouse Cyl genes and the extensive homology 
between human (proposed new nomenclature CCND1) and mouse (Cyl-1) 
cyclin D1 equivalents suggested the presence of two additional human D-type 
cyclins. Cyclins D2 and D3 (new nomenclature CCND2 and CCND3) were 
according to predictions independently isolated in several laboratories, also 
leading to the identification of two pseudogenes proposed to originate from 
them (Xiong e ta l 1992a, Inaba e ta l 1992, Motokura e ta l 1992a, Kiyokawa et 
al 1992). Interestingly comparison of CCND1, CCND2 and CC/VD3 with Cyl-1, 
Cyl-2 and Cyl-3 revealed a greater degree of identity of the human and mouse 
counterparts than between the D-family members of one species, implying a 
high degree of evolutionary conservation and distinct functions of the three 
genes (Xiong e ta l 1992a, Inaba ef a/1992).
Complementation analysis of S. cerevisiae triple CLN mutants was also 
used in an independent isolation of human cyclin E (Koff e ta l 1991). A yeast 
strain was derived that contained CLN3 expressed from the GAL1 regulatable 
promoter, all three endogenous CLN genes were mutated. Rescue at 
restrictive growth conditions (growth on glucose) was achieved by the 
introduction of a human glioblastoma cell line (U118) cDNA library. The 
isolated 1.7kb cDNA predicted to encode a 395 amino acid protein was 
designated cyclin E. Only human cyclin B1 was able to fully rescue the CLN 
deficient yeast strain, cyclin A proved to be lethal and cyclin E was much less 
efficient. This was attributed to the ability of the three cyclins to associate with 
CDC28, the S. cerevisiae homologue of the S.pombe cdc2 kinase. CDC28 is 
required in S.cerevisiae for the function of START and the entry into mitosis, 
cyclin E was postulated to only be effective in G1 therefore allowing DNA 
replication but not passage through the G2/M transition phase. The hypothesis
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was confirmed with the use of a cdc28-13 mutant strain that was nonfunctional 
at restrictive temperatures of 38°C, but allowed growth at 30°C. The strain was 
used as a host to screen the glioblastoma cell line cDNA library for human 
genes that associated with cyclin E to perform START. Five clones that 
depended on exogenous DNA sequences for survival were tested, four 
contained human homologues of cdc2 and one contained a new, related gene 
termed cdk2. cdk2 had previously been isolated in Xenopus laevis and will be 
further described in section 1.3.4.e of this chapter. In conjunction with cdc2 or 
cdk2, cyclin E was able to perform all the functions of START providing 
evidence for its function in the G1 phase of the cell cycle (Koff et al 1991).
The existence of at least one more potential G1 cyclin has recently been 
reported. Cyclin G was isolated in an effort to identify new rat homologues of 
the c-src kinase family (Tamura et al 1993). A rat fibroblast cell line (NRK) 
cDNA library was screened with a mixture of probes containing the domains of 
rat c-src, c-fyn or c-yes cDNAs. The predominant cDNA isolated was 3.17kb in 
size and showed homologies to known cyclins especially Cig1, a B-type cyclin 
found in Schizosaccharomyces pombe and thought to function at the G1/S 
boundary (Tamura e ta l 1993). The discovery of cyclin F, was reported by 
Simon Elledge at "The Cell Cycle Meeting" in Cold Spring Harbor, 1991. The 
protein consists of 786 amino acids making it the largest known cyclin. It is not 
yet clear at what stage of the cell cycle cyclin F might function, however within 
the cyclin box region it displayed greatest homology to cyclin A (39%) 
suggesting a functional relatedness of these two proteins.
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1.3.4.b The oscillation patterns of G1 cyclins.
The first indications for the oscillation behaviour of the cyclin D proteins 
came from the analysis of mouse macrophage cell lines (Matsushime et al
1991). Advantage was made of the ability of these cells to arrest in G1 when 
deprived of CSF-1. The time of entry into the S phase was determined by flow 
cytometric analysis of propidium iodide stained cells. Synchronous DNA 
replication was observed 10 hours after stimulation with a maximum 
percentage of cells in S phase at 13-16 hours. Cyl-1 mRNA species of 3.8 and 
4.5kb were detected with the use of Cyl-1 cDNA probes in northern blot 
analysis 1 hour after release from the G1 arrest. The maximum levels were 
reached 4-6 hours post stimulation and the mRNA species remained elevated 
at 23 hours which was the duration of the experiment. A 6kb Cyl-2 mRNA 
specie appeared several hours after Cyl-1 and peaked at the G1/S transition 
phase. The oscillation pattern of Cyl-3 was not determined. A polyvalent 
antibody raised against bacterially produced Cyl-1 was used to analyse the cell 
cycle pattern of protein expression. CSF-1 starved cells had low amounts of 
the Cyl-1 protein which rose 2 hours after stimulation and the highest levels 
were seen at 10-12.5 hours. The protein levels declined during the S and G2 
phases reaching the lowest point in mitosis (~22.5 hours post stimulation).
These observations were subsequently confirmed in several 
independent studies of human fibroblasts synchronised to GO by serum 
starvation (Surmacz e ta l 1992, Won e ta l 1992, Baldin e ta l 1993). In 
quiescence cyclin D1 mRNA and protein levels were found to be low. Upon 
stimulation with serum, the BB form of platelet derived growth factor (PDGF- 
BB), epidermal growth factor (EGF), fibroblast growth factor (FGF) or TPA, 
expression of cyclin D1 and cyclin D3 transcripts was upregulated. In all
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instances except after TPA treatment the cells entered S phase, indicating that 
cyclin D1 or D3 expression alone was not sufficient for cell cycle progression 
(Won e ta l 1992). Exposure of quiescent cells to insulin-like growth factor 1 
(IGF-1), insulin, the AA form of PDGF or transforming growth factor beta (TGF- 
(3) had no effect on the mRNA levels of these two cyclins (Surmacz et a l 1992, 
Won e ta l 1992). However, IBMX an inhibitor of cyclic nucleotide 
phosphodiesterases and forskolin an activator of adenylate cyclase, caused a 
decrease of cyclin D1 and D3 mRNA levels and [3H]thymidine incorporation, 
suggesting that the activated cAMP pathway may have negatively regulated 
cyclin D expression (Won eta l 1992). In serum or growth factor treated 
fibroblasts where a rise in expression was seen, levels of cyclin D1 or D3 
mRNA increased gradually reaching a plateaux at -12 hours from stimulation 
and declining over the next 26 hours. At 20 hours from stimulation, most of the 
cells had entered the S phase, which was determined by the degree of 
[3H]thymidine incorporation.
The cell cycle regulated expression of cyclin D1 protein was also 
confirmed in quiescent human fibroblasts (Baldin e ta l 1993). The duration of 
the G1 phase in the examined cells was determined by 5-bromodeoxyuridine 
(BrdU) incorporation and flow cytometry. Exposure to serum induced 
proliferation and by 24 hours post stimulation -80% of the cells had entered 
the S phase. Cyclin D1 levels were analysed by immunoblotting and 
immunoprecipitation techniques, revealing low levels in quiescence that rapidly 
increased at 8-10 hours, reaching a plateaux 20 hours after exposure to 
serum. At -24 hours a decrease was observed that lasted until the 32 hour 
time point, when accumulation of the cyclin D1 protein began again, however 
further analysis was hindered by the loss of cell synchrony.
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Immunofluorescence analysis was able to reveal an exclusively nuclear 
localisation of the protein during the G1 phase. Quiescent cells or those where 
DNA synthesis was taking place had undetectable cyclin D1 protein levels, as 
determined by this technique.
It is becoming increasingly evident that cyclin D1 may function in cells 
during the central part of the G1 phase. However, an exception to the rule 
arose from the analysis of human HeLa cells synchronised to G1/S by 
sequential thymidine-amphidicolin treatment. After release, cyclin D1 mRNA 
levels peaked in the G2/M transition phase as well as in G1, the synchrony of 
the cells was monitored by determining [3H]thymidine incorporation and 
expression of histone H4 transcripts (Motokura e ta l 1991). The altered 
oscillation pattern of cyclin D1 transcripts was attributed to accumulated 
abnormalities over the long period HeLa cells have resided in culture. Currently 
these are the only reported cells where cyclin D1 levels do not follow the 
previously described oscillation pattern.
In a separate study, G1/S arrested HeLa cells were used to determine 
the periodicity of cyclin C and cyclin E expression (Lew et al 1991). The mRNA 
levels of cyclin C did not vary more that 2-3 fold during the cell cycle, a modest 
peak was evident in G1/S arrested cells followed by a slow decline during the 
S, G2 and M phases. Cyclin E transcripts also predominated in arrested cells, 
although in this case the levels oscillated more dramatically and a sharp 
decrease was observed as they entered the S phase. In both cases the 
detected transcripts were 2-2.5 kb in size. The oscillation patterns of the cyclin 
G protein were determined in NRK rat fibroblasts synchronised to G1 by serum 
starvation and contact inhibition. Upon release, transcription from the cyclin G
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gene was induced 3 hours after stimulation, however, the levels did not change 
thereafter (Tamura et al 1993).
1.3.4.c Structural comparison of cyclins.
A major feature of all cyclins is a highly conserved region termed the 
"cyclin box", initially identified by amino acid sequence comparison of the 
budding yeast cyclins with their surf clam and frog counterparts (Minshull eta! 
1989, Draetta 1990). The "cyclin box" is defined by ~100-200 amino acids of 
which only five well spaced residues Arg-Asp-Leu-Lys-Phe (single letter code - 
RDLKF) show complete conservation from yeast to man, with the exception of 
human cyclin C in which Arg and Asp residues are altered (Draetta 1990, 
Kobayashi et al 1992, Tamura et al 1993). The position of the cyclin box within 
the proteins varies between G1 and G2/M cyclins where the location may be N- 
terminal (rat cyclin G is the most extreme example) or central, respectively. In 
general, reported identities between different cyclins are largely confined to 
comparisons of amino acid sequences within the "cyclin box". However, a 
number of homologous islands have been identified outside this region, of 
which the most significant are the PEST, destruction and P boxes (Rogers e ta l 
1986, Nugent et al 1991, Hunt 1991, Glotzer et al 1991, Zheng and Ruderman
1993).
The destruction box is specific to the N-terminal domain of A and B 
cyclins, it is identifiable by a partially conserved Arg-X-X-Leu-X-X-lle-X-Asn 
sequence (RXXLXXIXN) followed by a Lys-rich stretch (Hunt 1991, Nugent et 
al 1991). This motif was shown to be recognised by the highly conserved 
ubiquitin protein, resulting in rapid cyclin degradation (Glotzer e ta l 1991, 
Hershko et al 1991). Mutational analysis of both cyclins A and B revealed the
33
importance of this region for the specific destruction of the two proteins, 
allowing anaphase initiation and the completion of mitosis in Spisula 
solidissiama and Xenopus laevis egg extracts (Luca et al 1991, Kobayashi et al 
1992, Holloway e ta l 1993) and HeLa cells (Gallant and Nigg 1992).
The PEST hypothesis was based on the sequence analysis of forty five 
distinct proteins with different intracellular half-lives (Rogers e ta l 1986). 
Proteins with half-lives less than two hours, such as c-myc, p53, c-fos 
adenovirus 5 E1A and ornithine decarboxilase (ODC), contained one or more 
regions rich in Pro, Glu, Ser and Thr (termed PEST regions) which were absent 
from the majority of more stable proteins. The presence of these sequences 
correlated much better with rapid degradation than with compartmentalisation, 
function or common ancestry. To date PEST sequences have been identified 
at the C-termini of all the mammalian G1 cyclins, S.pombe Cig1 and 
S.cerevisiae CLN1, CLN2 and CLN3, an exception to the rule is rat cyclin D1, 
while cyclin F has not been examined (Hadwiger e ta l 1989, Lew efa/1991, 
Tamura e ta l 1993).
A small conserved region of Xenopus cyclin B termed the P-box, was 
recently proposed to contribute part of a phosphatase-activating domain to 
cdc25 (Galaktionov and Beach 1991, Zheng and Ruderman 1993). Three 
highly conserved residues Arg202, Glu221 and Asp231 within this 33 amino 
acid stretch, were shown to be essential for the functioning of the domain. 
Mutation of the P-box had no effect on cdc2 binding and subsequent inhibitory 
Thr14 and|Tyr15 phosphorylations, however the mutated cyclin B/cdc2 
complex arrested in its inactive state and cdc25 remained in the low activity 
form preventing progression through mitosis (Zheng and Ruderman 1993).
Two of the functional P box residues, Arg202 and Asp231 were found in
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equivalent positions in all cyclins except cyclin C and HCS26 (an S.cerevisiae 
mitotic cyclin) while cyclins F and G have not been examined. HCS26, cyclin C 
and the CLNs also lack the third, Glu221 residue which is conserved in the A,
B, D and E-type families (Zheng and Ruderman 1993). This suggests that the 
P box may represent the second functional domain common to most cyclin 
proteins.
Several mutation studies have been carried out in the effort to determine 
the specific regions of cyclins required for binding to their catalytic subunits 
(Luca e ta l 1991, Kobayashi e ta l 1992). Removal of the first 161 N-terminal 
amino acids from Xenopus or bovine cyclin A had no effect on the ability to 
associate with cdc2 or cdk2 in frog cell-free extracts, although deletions 
beyond the highly conserved Tyr169 abolished binding (Luca et al 1991, 
Kobayashi e ta l 1992). Alterations of any amino acids within the "cyclin box" or 
small C-terminal deletions also prevented formation of the protein complex. 
Kinase functional assays revealed the loss of the ability to phosphorylate 
histone H1 in all the mutants that were unable to associate with subunits cdc2 
orcdk2 (Kobayashi e ta l 1992). Similar results were observed in the analysis of 
cyclin B (Luca et al 1991, Zhang et al 1993).
1.3.4.d The phosphorylation of cyclins.
The discovery that cyclins are also kinase substrates was initially shown 
for cyclin B (Lohka e ta l 1988). Tryptic peptide mapping of 
[32P]orthophophosphate-labelled cyclin B of human or Xenopus origin, 
revealed specific Ser residues as sites of phosphorylation (Pines and Hunter 
1989, Izumi and Mailer 1991). In extracts derived from fertilised sea urchin 
oocytes, histone H1 kinase activity correlated well with the appearance of
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phosphorylated forms of cyclin B (Meijer e ta l 1989). Suggestions that cdc2 
may have catalysed this reaction were confirmed by the in vitro ability of 
purified MPF to phosphorylate cyclin B, although significant phosphorylation 
was also demonstrated in resting oocytes prior to maturation and the activation 
of cdc2 (Gautier et al 1990, Gautier and Mailer 1991). Cyclin B may also be 
phosphorylated by c-mos and microtubule associated protein (MAP) kinase at 
sites indistinguishable from those targeted by MPF (Roy e ta l 1990, Izumi and 
Mailer 1991). The c-mos proto-oncogene codes for a Ser/Thr kinase, the 
function of which is essential for germinal vesicle breakdown during the 
maturation of frog eggs, it is normally expressed only in germ cells and 
undetectable in most sommaticcells (Sagata e ta l 1988, Sagata e ta l 1989, 
Freeman e ta l 1989). MAP kinase is a proposed major component of the ras 
signalling pathway and a member of a larger family of related proteins. Meiotic 
activation of frog and clam oocytes leads to a one-time activation of MAP 
kinase that will function as a Ser/Thr kinase for many hours until the 
metaphase II arrested egg is fertilised (Ruderman 1993). This kinase was able 
to phosphorylate Xenopus cyclin B1 in vitro, however, it was largely inactive 
towards cyclin B2 (Izumi and Mailer 1991).
Recent reports have questioned the importance of cyclin B 
phosphorylation in mitosis. Mutations of amino acids Ser90 in cyclin B1 and 
Ser94 or Ser96 in cyclin B2 did not alter the activation or efficiency of the cdc2 
histone H1 kinase, nuclear envelope breakdown and chromosome 
condensation. The rate of cyclin degradation was also unaltered and the only 
observed difference was a decreased translation efficiency of the mutant forms 
in Xenopus oocyte extracts (Izumi and Mailer 1991).
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Several independent studies have reported Tyr phosphorylation of 
cyclins A, B and D (Tamura et al 1990, Matsushime et al 1991, Hall et al 1993). 
Cyclin A phosphorylation was observed as a response to mitogen treatment of 
a human vulvar SCC cell line A431, and the same was catalysed in vitro and in 
vivo by purified c-src, a Tyr-specific protein kinase (Hall et al 1991). The 
homologue of c-fms found in the McDonough strain of feline sarcoma virus 
(SM-FeSV) also induced the in vitro phosphorylation of cyclins A and B 
(Tamura e ta l 1990). Immunoprecipitation of cyclin D1 from 
[32P]orthophosphate labelled mouse macrophages revealed two phosphate 
containing forms of the protein, the labelling index of which was highest during 
the G1 phase (Matsushime e ta l 1991). These observations were confirmed by 
the detection of cyclin D1 with anti-phosphotyrosine antibodies in western blot 
analysis of extracts derived from foetal and adult rat alveolar epithelial cells, a 
human lung carcinoma cell line and Ewing’s sarcoma cells (Hall e ta l 1993). 
Purified recombinant c-src was able to phosphorylate bacterially produced 
cyclins A and D in vitro and the same was true for the cyclin A/cdc2 kinase 
although it exhibited an apparent preference for cyclin A (Hall e ta l 1993).
1.3.4.e The current model of the mammalian cell cycle.
The turning point in the study of the cell cycle was the discovery that 
cyclins function as regulators of specific Ser/Thr kinases, the activation of 
which depends on direct interactions between the two types of proteins. Cyclin 
B activation of cdc2 was the first to be identified and currently the best 
understood (see section 1.3.3.b). In yeast a single 34kD protein (CDC28 in S. 
cerevisiae and cdc2 in S. pombe) interacts with both G1 and mitotic cyclins to 
regulate the G1/S and G2/M transitions, respectively (Reed 1991, Solomon
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1993, Nasmyth 1993). The discovery of the cdk2 kinase in Xenopus /aewsand 
mammalian cells suggested that cell cycle regulation in higher eukaryotes was 
far more complex than in yeast. Human cdk2 was able to rescue budding yeast 
that lacked functional CDC28, a characteristic that led to its isolation (see 
section 1.3.4.a) (Koff efa/1991, Elledge and Spottswood 1991, Ninomiya-Tsuji 
e ta l 1991). In Xenopus laevis, cdk2 (initially known as Eg1) was identified as a 
maternal protein by the differential screening of an unfertilised oocyte cDNA 
library (Paris e ta l 1991). In the most extensive study, degenerate 
oligonucleotides synthesised from highly conserved regions of cdc2 were used 
in the search for new genes by screening human HeLa and Nalm-6 (a pre-B 
leukaemia) cell lines, leading to the isolation of eight genes of which five were 
novel (Meyerson e ta l 1992, Tsai efa/1991). Following a proposed convention, 
the cdc2-like kinases shown to associate with cyclins were given the synonym 
cdk for cyclin dependent kinase. The remaining proteins were named after their 
amino acid sequences within the highly conserved region of the cdc2 PSTAIRE 
motif (Lee and Nurse 1987). Comparison of the predicted amino acid 
sequences allowed grouping of the proteins into subfamilies, represented in 
Table 1 (Lee and Nurse 1987, Meyerson e ta l 1992, Hanks 1987, Bunnell e ta l 
1990, Solomon 1993, Lew efa/1992).
The activity but not the levels of cdk2 were shown to oscillate with the 
cell cycle in a distinct pattern to that of cdc2 (Draetta and Beach 1988). In 
synchronised HeLa cells cdk2 activity increased to a peak at the time of DNA 
synthesis, four hours after release from the G1/S arrest, fell slightly and 
increased again two hours prior to the peak of mitotic cdc2 activity 
(Rosenblatt et al 1992). This was shown to be due to the formation of active 
complexes with cyclin E in late G1 and the G1/S transition, followed by cyclin A
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Table 1. Cyclin dependent kinase families.
Currently known cyclin dependent kinases can be subgrouped into five families 
based on their sequence homologies (Meyerson e ta l 1992, Solomon 1993).
Table 1
kinase
subfamilies
Thr14 & Tyr15 
aa. residues
Thr161 
aa. residue
cdc2
cdk2
conserved
all kinases
cdk3 have
cdk5 a Ser or Thr
PCTAIRE-1
PCTAIRE-2
PCTAIRE-3
conserved
amino acid 
residue
cdk4 Thr14
as an
cdk6
replaced by 
Ala
equivalent
of Thr161
KKIALRE Thr14 
replaced by
p58-GTA
Ser
in S and G2 phases (Dulic et al 1992, Koff et al 1992, Rosenblatt et al 1992, 
Tsai et al 1993, Pagano et al 1993). A high degree of diversity in the choice of 
subunits is characteristic of the D-type cyclins, which have been shown to 
complex with cdc2, cdk2, cdk4, cdk5 or cdk6, although contradicting evidence 
exists for most of these associations with exception of cdk4 (Motokura e ta l
1991, Elledge and Spottswood 1991, Xiong et al 1992b, Matsushime e ta l
1992, Kato e ta l 1993, Sherr 1993, Hall e ta l 1993). Substrate specificity of the 
D-family of cyclins may vary in dependence of the catalytic subunit present in 
the complex, a proposal recently supported by the predominance of cyclin D1 
associated with cdk5 or cdk6 in breast tumour cells as opposed to the majority 
of cyclin D1 bound to cdk2 or cdk4 in normal cells (Peters e ta l1993). The 
identities of the kinases regulated by cyclin C, cyclin F or cyclin G are 
unknown. Figure 2 represents the currently accepted model of the mammalian 
cell cycle, depicting the coordinate oscillation patterns of the known protein 
kinase complexes.
1.3.4.f What are the substrates of G1 and G1/S cyclins?
Currently the substrates of only the mitotic cyclin B/cdc2 kinases are 
known (see section 1.3.3.b), while the function of other cyclin families are 
under constant debate, the most puzzling of which are the D-type cyclins. 
Association of D cyclins with the proliferating cell nuclear antigen (PCNA), a 
well characterised DNA replication and repair factor, was recently described in 
a human diploid fibroblast cell line (WI38) (Xiong et al 1992b). Antibodies 
raised against cyclins D1 or D3 selectively co-precipitated the two cyclins with 
PCNA, cdk2, cdk4, cdk5 and an unrelated 21 kD protein that did not correspond 
to human max or ras. In vitro kinase assays did not reveal phosphorylation of
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Figure 2. The mammalian cell cycle.
Schematic representation of most of the known cyclins, specific catalytic 
subunits and other cellular proteins they associate with at different points of the 
cell cycle (Pines 1993).
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PCNA or p21 by various combinations of cyclin D/cdk subunits, suggesting that 
these two proteins were not primary cyclin D substrates and could function as 
members of larger complexes. Subsequent immunoprecipitation analyses have 
suggested that PCNA and p21 are universal components of cyclin A, B or D 
dependent kinases in all normal human diploid fibroblasts. However, upon 
transformation with the SV40 T antigen, the p21 protein was replaced by two 
unrelated proteins : |p19 associated with cyclins A or B1 andjp16 bound to cdk4 
(Xiong and Beach 1993).
The retinoblastoma protein pRb is a potential substrate of cyclins A, E 
and D. pRb was identified as a nuclear target of three distinct viral oncogenes 
and a common site of inactivating mutations in several types of cancer (Whyte 
e ta l 1988, DeCaprio e ta l 1988, Dyson e ta l 1989, Weinberg 1991). Human 
papillomavirus-16 (HPV-16) oncoprotein E7, adenovirus-5 (Ad-5) oncoprotein 
E1a and simian virus-40 (SV40) T antigen share two conserved regions (CR-I 
and CR-II) both of which are essential for transformation (Ruley 1983, Phelps 
et al 1988, DeCaprio et al 1988, Jones et al 1990, Raychaudhuri et al 1991). 
CR-II contains a highly conserved core motif Leu-X-Cys-X-Glu (LXCXE) 
preceded by an acidic amino acid. Mutations of any amino acid residues in this 
motif will reduce or abolish binding to pRb (Jones e ta l 1990, Heck e ta l 1992). 
The products of three viral oncogenes, E7, E1a and T antigen, recognise 
specific sequences of the pRb protein termed the "pocket" (Livingston et al 
1993). The region was mapped with the use of in vitro translation systems and 
mutational analysis and divided into two subdomains A (amino acids 373-579) 
and B (amino acids 640-771). The subdomains are separated by a spacer 
sequence the length but not the amino acid content of which is important for 
protein binding (Huang e ta l 1990, Ewen et al 1993a). Substitution or deletion
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of any residues located in subdomains A or B abolished oncoprotein-pRb 
complex formation in vitro, these were also the sites of pRb mutations detected 
in human tumours (Huang e ta l 1990).
The function of pRb in the suppression of transformation was shown in 
several studies by the introduction of wild type sequences into established 
tumour cell lines where the endogenous pRb was mutated. In all cases this 
resulted in a significant decrease of transformation and tumourigenicity (Huang 
e ta l 1988, Banerjee e ta l 1992, Hinds e ta l 1992). During the cell cycle pRb 
switches between a Ser/Thr hyper-phosphorylated and a relatively under- 
phosphorylated state (DeCaprio e ta l 1989, Weinberg 1991). The hypo- 
phosphorylated form, present in the G1 phase was shown to be the exclusive 
target of viral oncogenes (Ludlow et al 1989, Ludlow et al 1990). Entry into the 
S phase was characterised by accumulation of hyper-phosphorylated pRb 
which remained in this state throughout G2 and was lost during the M phase, 
when the dephosphorylated protein reappeared (DeCaprio e ta l 1989, Ludlow 
e/a/1990, DeCaprio e ta l 1992). The observed oscillation patterns of pRb 
phosphorylation suggested that it may regulate the cell cycle and represent a 
substrate for cell cycle dependent kinases. Confirmation of the former proposal 
came from the observed effects of injected wild type pRb on synchronised 
human osteosarcoma cell lines Saos-2 (containing truncated pRb) and SR-40 
(Goodrich et al 1991). Cell cycle progression and 5-bromodeoxyuridine (BrdU) 
incorporation were blocked for up to four days in Saos2 and SR-40 cells, if the 
injections took place early in the G1 phase. However, pRb injected six to ten 
hours prior to the G1/S transition or during the S phase had little or no effect on 
cellular proliferation, suggesting that pRb functioned as a growth suppressor in 
GO and G1. A significant discovery supporting the second proposal was the
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identification of an intact LXCXE motif (LLCCE) preceded by the Glu residue at 
the N-termini of cyclins D1, D2 and D3 (Dowdy et a11993). Currently these are 
the only discovered cellular proteins that contain the conserved pRb binding 
motif characteristic of viral transforming genes. However, conflicting data has 
been generated in several laboratories, thus it is still unclear whether the D- 
cyclins bind to and/or cause pRb phosphorylation in vivo.
Several studies addressing this question made use of the distinct 
morphological changes and growth inhibition induced in Saos2 cells by the wild 
type form of pRb (Hinds et ai 1992, Ewen et al 1993a, Dowdy et al 1993). Co­
transfection of cyclin A or E cytomegalovirus (CMV) expression vectors with 
wild type pRb resulted in a 90%-100% reduction in the pRb mediated flat 
morphology as was the effect of the adenovirus-5 E1 a oncoprotein. Cyclin D1 
or D3 expression vectors had a reduced rescuing ability (~60%-80% and 52%, 
respectively) which was increased to 90% for cyclin D1 upon mutation of the 
LLCCE pRb binding domain, suggesting that in vivo pRb is a negative regulator 
of cyclin D1 (Hinds et al 1992, Dowdy et al 1993). The B-type cyclins were 
unable to revert the flat morphology of inhibited Saos2 cells (Hinds e ta l 1992).
Hypo-phosphorylated pRb exhibits tight nuclear association in 
comparison to the hyper-phosphorylated form of the protein. This can be 
detected by treating cells with weak non-ionic detergents which will cause the 
release of only the highly phosphorylated pRb protein. In Saos2 cells 
transfected with wild type pRb virtually all of the tumour suppressor protein was 
tightly tethered to the nucleus and remained so upon the introduction of cyclins 
B1, B2 or D1, however, expression of cyclins A or E reduced the degree of 
nuclear association by half (Hinds e ta i 1992). Immunoprecipitation analysis of 
[35S]methionine or [32P]orthophosphate labelled Saos2 cell extracts indicated
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that E1a, cyclin A, cyclin D2, cyclin E and to a lesser extent cyclin D3, induced 
the phosphorylation of pRb, while cyclins B1 and B2 did not. Some controversy 
existed with regards to the ability of cyclin D1 to phosphorylate pRb in Saos2 
cells, although even in the positive observations the levels of phosphorylation 
were small (Hinds et al 1992, Ewen et al 1993a, Dowdy et al 1993). The G1 
block normally induced by pRb was overcome in cells containing E1a, cyclin A 
or cyclin E and to a lesser extent by cyclin D2. Expression of cyclins D1 or D3 
was observed to have little or no effect on the arrested Saos2 cells, although 
mutation of cyclin D1 at the LLCCE domain increased the number of cells in S, 
G2 and M phases, suggesting the absence of pRb-mediated control (Hinds et 
al 1992, Ewen e ta l 1993a, Dowdy e ta l 1993). In summary, the results 
obtained from analysis of Saos2 cells suggested that cyclins A and E were the 
most effective in phosphorylating pRb and preventing its growth suppressive 
function, the B-type cyclins had no effect and the D family, especially cyclin D1, 
functioned through a different pathway.
In a separate set of experiments, cyclin D3 produced in insect cells from 
baculovirus expression vectors was able to bind cdk4 in vitro and function as 
an active pRb and p107 (a pRb related protein) kinase. Cyclin D1 also readily 
complexed with cdk4 while the affinity of cyclin D2 for the kinase subunit was 
reduced in comparison, both complexes lacked the ability to phosphorylate 
pRb or p107 (Matsushime e ta l 1992). However, a subsequent report from the 
same laboratory contradicted these results. Lysates of insect Sf9 cells 
coinfected with baculovirus vectors encoding all three D-type cyclins and cdk4, 
exhibited a protein kinase activity that was able to phosphorylate a 
glutathionine S-transferase (GST)-pRb fusion protein in vitro (Kato e ta l 1993). 
Mutational analysis of pRb revealed the Ser807 residue as a major
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phosphorylation site. Cyclins A or B1 could activate cdc2 pRb kinase activity 
while cyclin E was a potent activator of cdk2, all three cyclins were unable to 
cause pRb phosphorylation in the presence of cdk4 (Kato et al 1993, Ewen et 
al 1993a).
To address the possibility of direct interactions between pRb and cyclin 
D1, bacterially produced recombinant cyclin D1 was used to make an affinity 
matrix and a number of binding proteins were identified in extracts from 
Ewing's sarcoma (EW-1) cells of which pRb was one. The pRb suppressor 
protein was also able to bind cyclin A affinity columns of a similar type (Hall et 
al 1993). Confirmation for the in vivo pRb-cyclin D1 association came from 
immunoprecipitation experiments and site directed mutagenesis of the cyclin 
D1 LLCCE motif which were carried out in human diploid fibroblasts and Saos2 
cells (Dowdy e ta l 1993). A separate set of experiments revealed the ability of 
cyclins D2 and D3 to associate with pRb in vitro with much greater affinity than 
cyclin D1 (Ewen e ta l 1993a, Kato efa/1993).
A major target of pRb during the G1 phase of the cell cycle is the E2F 
transcription factor, originally encountered through its ability to transcribe the 
adenovirus-5 E2gene by recognising two S'-TTTCGCGC-S' motifs in the 
promoter region (Kovesdi e ta l 1986, Kovesdi e ta l 1987, Bagchi e ta l 1990, 
Raychaudhuri e ta l 1991, Chellappan e ta l 1991). E2F binding sites have been 
mapped in the promoters of several cellular genes which include c-myc, N- 
myc, c-myb (Lipp et al 1987, Thalmeier et al 1989, Mudryj et al 1990), 
dihydrofolate reductase (DHFR) (Blake and Azaizkhan 1989, Mudryj e ta l
1990), thymidine kinase (Kim and Lee 1991) DNA polymerase a (Pearson e ta l
1991), EGFr (Mudryj e ta l 1990) cyclin A (Brechot 1993) and CCND1 
(Motokura and Arnold 1993). Recent reports have suggested a dual role for
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E2F, the activity of which may alternate between a positive and negative 
transcriptional factor during the progression of the cell cycle depending on its 
association with other cellular proteins (Weintraub efa/1992). Free E2F, of 
which three different forms have recently been identified, is believed to function 
as a positive transcription factor (Mudryj e ta l 1991, Nevins 1992, Chittenden et 
al 1993). However, expression from the E1a oncogene was shown to be 
negatively regulated by E2F in the presence of hypo-phosphorylated pRb, 
suggesting that this complex actively functions as a repressor of transcription 
(Chellappan eta l 1991, Weintraub e ta l 1993). Inhibitory activity of E2F-pRb 
was confirmed on a simple promoter consisting of a TATA box and an ATF 
transcription factor site or the more complex SV40 early gene promoter, both of 
which contained 5'-TTTCGCGC-3' binding sequences (Weintraub e ta l 1992). 
Co-transfection of Saos-2 cells with pRb and cyclin D1 or D3 expression 
vectors considerably reduced the abundance of detectable pRb-E2F in 
comparison to cells that were transfected with pRb alone, while full inhibition 
was achieved in the presence of cyclin D2 (Ewen et al 1993a). Therefore, 
inhibition of E2F and pRb association was achieved in the presence of cyclins 
that potentially phosphorylate the tumour suppressor protein. In the same type 
of analysis carried out in Sf9 cells, only cyclin D1 prevented association 
between the transcription factor and suppressor protein, while cyclins D2 and 
D3 effectively abolished E2F-pRb complex formation only in the presence of 
cdk4 expression vectors (Kato e ta l 1993). One proposed mechanism for the 
cyclin action is the conversion of pRb to the hyper-phosphorylated state, 
however since there is wide controversy on the ability of different D-family 
members to phosphorylate and/or bind to pRb, the mechanisms may involve 
structural alterations of E2F.
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pRb is not the only cellular protein that interacts with E2F. Extracts from 
synchronised NIH3T3 murine fibroblasts revealed the presence of two E2F 
protein complexes one of which contained cyclin A and was present exclusively 
during the S phase, while the other was G1 specific (Mudryj e ta l 1991). The 
E2F-cyclin A complex was later shown to contain cdk2 and the pRb related 
protein p107 (Cao e ta l 1992, Devoto e ta l 1992, Shirodkar e ta l 1992, Pagano 
et al 1992c), while in G1 E2F was found in association with cyclin E, cdk2 and 
p107 or with p107 alone (Lees ef a/1992, Nevins 1992). Recently, p107 was 
shown to suppress gene expression in the G1 and S phases acting by cell-type 
and cell-cycle dependent mechanisms distinct from those of pRb (Schwarz et 
al 1993, Zhu et al 1993, Zamanian and La Thangue 1993). Transfection of 
p107 into Saos2 cells caused them to arrest in G1, although the distinct flat 
morphology induced by wild type pRb was not evident in this case. Interestingly 
co-transfections with cyclin A or cyclin E expression vectors did not overcome 
the growth inhibitions as was seen in the case of pRb, confirming the above 
proposal (Zhu e ta l 1993). p107/cyclin A/cdk2/E2F complexes isolated from S- 
phase synchronised NIH3T3 fibroblasts were shown to posses both DNA 
binding and histone H1 kinase activities, suggesting the involvement of cyclins 
in a negative control of proliferation (Devoto e ta l 1992). Cyclin A/cdk2 and 
cyclin E/cdk2 kinases were also able to phosphorylate p107 in vitro at most of 
the Ser/Thr sites phosphorylated in human cells in vivo (Lees et al 1992, 
Peeper ef a/1993). In summary, association of E2F with cyclin/cdk kinases and 
the potential E2F dependent transcription from the cyclin A and cyclin D1 
genes, has suggested a new, important component of the cell cycle machinery. 
E2F is proposed to direct cyclin dependent kinases to specific promoter 
regions where phosphorylation of other DNA-binding proteins might take place.
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This activity may in turn be negatively regulated by the association of E2F or 
cyclins with suppressor proteins such as pRb or p107.
1.3.5 The cell cycle machinery is linked to the signal transduction 
pathway.
Signal transduction from the cell surface to targets inside the nucleus 
plays an important role in many cellular and developmental processes. There is 
no doubt that a link must exist between the rapid, cytoplasmic response and 
the nuclear cell cycle machinery, although, due to the complexity of 
mammalian systems analysis of these pathways has proved difficult. However, 
the mating pheromone signal transduction pathway in yeast is an easily 
manipulated, genetically tractable model system that has recently revealed the 
missing link.
1.3.5.a FAR-1.
Haploid S.cerevisiae cells have three possible fates, they may enter a 
GO arrested state, divide, or in the presence of secreted pheromones arrest in 
G1 and differentiate into gametes that are capable of conjugating with cells of 
opposite mating type. Cells exposed to pheromones were shown to arrest at 
the same point as yeast mutants defective in the function of all three CLN 
cyclins or CDC28, suggesting that the mating factors operated by inhibiting the 
function of G1 cyclin/CDC28 kinases (Reed 1980, Richardson e ta l 1989,
Cross 1990). Pheromone response in yeast starts with the binding of 
extracellular mating factors to specific cell surface receptors (Nasmyth 1990, 
Marsh et al 1991). Two types of conjugating S.cerevisiae exist, those of a 
mating type that secrete the a-factor and have a-factor receptors, or those of a
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Imating type that produce the a-factor and a-factor receptors. Therefore a 
mating type S.cerevisiae will respond to the presence of a-factor and the 
opposite is true for the a mating type cells (Marsh et al 1991). Both a- and a- 
factors are short polypeptides that act by binding complex cell surface 
receptors linked to an apyheterotrimeric G protein (guanine nucleotide binding 
protein). Ligand/receptor association triggers release of the G^y subunit which 
will propagate the signal by activating specific cytoplasmic Ser/Thr kinases 
(Cairns e ta l 1992). Two components of this pathway FUS3 and KSS1 are 
related to mammalian MAP kinases, however only FUS3 is able to mediate the 
pheromone induced G1 arrest (Elion e ta l 1991). Initially FUS3 was thought to 
transcriptionally repress CLN1 and CLN2 while its effect on CLN3 was 
unknown and hypothesised to be post-transcriptional 
(Elion e ta l 1991). Recently a more general role for FUS3 was proposed, in 
vitro kinase assays revealed the ability of FUS3 to phosphorylate FAR1, a 
protein that is rapidly phosphorylated in haploid S.cerevisiae upon exposure to 
mating factors (Chang and Herskowitz 1992). Immunoprecipitation analysis 
revealed specific association of activated FAR1 with the CLN1/CDC28, 
CLN2/CDC28 and CLN3/CDC28 complexes and the importance of these 
interactions for cell cycle arrest was shown by mutational analysis (Peter e ta l 
1993, Tyres and Futcher 1993). The three CLN/CDC28 complexes were also 
able to function as FAR1 kinases, the consequences of which remain unknown 
(Peter e ta l 1993, Tyres and Futcher 1993). The current model of pheromone 
induced Saccharomyces
cerevisiae cell cycle arrest based on the recent discoveries is depicted in 
Figure 3, this pathway may be analogous to that of negative growth factors that
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Figure 3. Pheromone induced signal transduction in 
S.cerevisiae.
Schematic representation reflecting the proteins shown to be involved in the 
mating factor induced cytoplasmic signal transduction pathway in S. cerevisiae, 
leading to cell cycle arrest, apy represents the heterotrimeric G protein, while 
STE5, STE20, STE11 and STE7 are some of the cytoplasmic proteins that lead 
to the activation of FUS3 and KSS1 (two human MAP kinase homologues). 
FUS3 contains the ability to activate FAR1 by phosphorylation, which will 
subsequently associate with CLN/CDC28 complexes resulting in cell cycle 
arrest (Marsh et al 1991, Peter et al 1993).
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control differentiative responses in higher eukaryotes.
1.3.5.b In mammalian cells TGFp acts to uncouple cyclin E/cdk2 
complexes.
Transforming growth factor-p (TGFp) is a paracrine polypeptide that 
regulates the production of extracellular matrix, cell proliferation and 
differentiation (Massague 1990, Moses et al 1990). TGFp is prototypic of a 
larger family of proteins : three isoforms are known in man (TGFps 1, 2 and 3) 
and five closely related proteins have been found in vertebrates (TGFps 1, 2, 3, 
4 and 5). The family also includes many structurally highly related proteins 
such as inhibins, activins, embryonic morphogens and Mullerian inhibiting 
substance (Sporn and Roberts 1992, Massague 1990). TGFp functions as a 
homo- or hetero-dimer composed of the same or different TGFp gene products 
that can bind to three receptors present on the surface of most cells, of which 
only types I and II are involved in signal transduction (Cheifetz e ta l 1987, 
Massague 1990, Massague 1992, Sporn and Roberts 1992).
Type II receptor codes for a transmembrane Ser/Thr kinase protein 
recently shown to require association with the type I receptor for the binding of 
TGFp. The two receptors are proposed to initiate diverse cellular responses, 
with type I accounting for the effects on the extracellular matrix and type II 
affecting nuclear proteins (Wrana e ta l 1992, Chen e ta l 1993). The proposed 
dual functioning of TGFp has been the subject of great interest. Currently the 
protein is viewed as a mesenchymal cell growth stimulatory factor and a growth 
inhibitor for epithelial cells (Moses et al 1985). Exposure of fibroblast cells to 
low concentrations of TGFp induces synthesis of the AA and BB forms of 
PDGF, confirming the stimulatory role of this factor, however, inhibition of the
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same cell type can be achieved by increasing the concentrations of TGFp and 
is thought to be due to the loss of PDGF receptor a subunit expression (Moses 
e ta l 1990). Equivalent observations have been made in several other 
instances and suggest that the mitogenic effects of TGFP seen in cells of 
mesenchymal origin may be secondary to other (inhibitory) processes 
(Massague 1990).
TGFp prevents proliferation of almost all non-neoplastic epithelial cells 
and is able to overcome the EGF-induced mitogenic effects (Moses e ta l 1990, 
Howe et al 1991, Abraham efa/1992). Recent studies have revealed rapid 
reduction of c-myc transcript levels and predominance of hypo-phosphorylated 
forms of pRb in cultured epithelial cells as a consequence of the exposure to 
TGFp, although in the case of pRb conflicting evidence now exists (Coffey e ta l 
1988, Moses e ta l 1990, Pietenpol et al 1990a, Pietenpol et al 1990b, Laiho et 
al 1990, Yan et al 1992).
The effects of TGFp mediated growth inhibition have been studied most 
extensively in a mink lung epithelial cell line (MvlLu). Exposure of MvlLu cells 
to TGFp for 24 hours was shown to cause reversible inhibition of DNA 
synthesis and proliferation, with ~90% of the cells accumulating in G0/G1 
phases, an observation that correlated well with the absence of pRb 
phosphorylation and most importantly with the loss of functional cyclin E/cdk2 
kinase (Laiho et al 1990, Koff et al 1993). Cells treated with TGFp did not 
exhibit altered expression levels of cyclin E or cdk2, however, a 
phosphorylated form of cdk2 (proposed to be the Thr160 phosphorylated 
species) that normally predominates in G1 disappeared if TGFp treatment was 
carried out at the start of, or up to six hours after the onset of G1. Once 
formed, the cyclin E/cdk2 complexes were resistant to subsequent effects of
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TGFp, suggesting that this factor acts to prevent recognition and stable 
association of the two subunits.
It would not be unreasonable to assume that TGFp may act on other 
cyclin-dependent kinases that form during G1 or even in later phases of the cell 
cycle, such a proposal has already gained support from the observed inability 
of exogenous cyclin A to activate cdc2 or cdk2 from extracts of TGFp treated 
MvlLu cells (Koff e ta l 1993). Loss of cdc2 kinase activity had been previously 
shown to result from a reduction in mRNA expression levels as well as the 
absence of post-translational modifications of the cdc2 protein, resulting in the 
absence of detectable histone H1 kinase activity (Howe et al 1991, Abraham et 
al 1992). TGFp mediated reduction of cdk4 expression in MvlLu cells, 
subsequently leading to the loss of cdk2 kinase and G1 arrest has also been 
reported (Ewen eta! 1993b).
The cellular growth advantage of some carcinomas, brain tumours, 
melanomas and some haematologic tumours is thought to derive at least 
partially from resistance to the inhibitory effects of TGFp (Massague 1990, 
Game et al 1992). Transfection of viral oncogenes E1a, T antigen or E7 
expression vectors (TGFp prevents transcription of the HPV-16 early genes) 
and cellular proto-oncogenes such as ras or mutant p53 into epithelial cells that 
respond to TGFp by arresting in G1, may result in the acquired resistance to 
this factor (Pietenpol et al 1990b, Woodworth et al 1990, Game et al 1992, 
Missero et al 1991 a, Missero et al 1991b, Abraham e ta l 1992, Reiss e ta l 
1993). Confirming observations were made following transfection of TGFp 
antisense expression vectors into a poorly tumourigenic human colorectal 
carcinoma cell line. Reduction of endogenous TGFp expression in the derived 
clones, resulted in their increased transformation and tumourigenicity potential,
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determined by growth in semisolid medium and the formation of xenografts in 
athymic mice (Wu and Russell 1992). Resistance to TGFp has been 
associated with the loss of cell surface receptors and/or a reduction of its 
autocrine production (Massague 1990).
1.4 Cyclins and cancer.
Cyclins and their dependent kinases are central to the regulation of the 
eukaryotic cell cycle, therefore they represent good targets for deregulation 
that may lead to neoplasia. Currently there is substantial evidence only for the 
involvement of cyclin D1 in transformation. This protein was identified in 
several independent studies as a cyclin and a potential proto-oncogene, the 
evidence being the different names it was initially known by : D11S287 (Arnold 
e ta l 1989, Rosenberg et al 1991b), PRAD-1 (Motokura e ta l 1991, Schuuring 
e ta l 1992a), Cyl-1 (Matsushime e ta l 1991), cyclin D1 (Lew efa/1991, Xiong 
et al 1991) and bcl-1 (Withers et al 1991). Loss of regulated expression of 
cyclins A and E have also been reported, although only in a small number of 
examined cases (Keyomarsi and Pardee 1993, Buckley e ta l 1993, Leach e ta l 
1993).
1.4.1 CCND1 is most likely the "bcl-1 linked oncogene".
The first indications that cyclin D1 may be a proto-oncogene came from 
its identification in chromosomal rearrangements specific to parathyroid 
adenomatosis (Bale e ta l 1990, Motokura efa/1991, Rosenberg et al 1991b). 
Further evidence supporting this proposal was obtained by mapping the exact 
chromosomal location of the gene to the proximity of the bcl-1 breakpoint 
marker on 11 q13, a common site of rearrangements with chromosome 14q32
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(Erikson et al 1984, Rosenberg et al 1991 b, Withers et al 1991, Seto et al
1992).
The majority (60-90%) of CpG nucleotide doublets found in eukaryotic 
genomes are methylated (Bird 1986). However, approximately 1% of 
vertebrate DNA, known as the HTF-fraction, is highly rich in unmethylated CpG 
sequences (Cooper e ta l 1983, Bird 1986, Lindsay and Bird 1987). The HTF- 
islands are found surrounding transcription start sites of the majority of known 
genes, although not exclusively. In a few examples, such as the glucose-6- 
phosphate dehydrogenase gene (G6PD) the islands are located elsewhere, in 
this case the 3' end of the gene (Bird 1986). Since HTF islands are most 
commonly found 5' of genomic coding sequences, one way of locating new 
genes would be to identify new islands. This hypothesis was used in the 
isolation of the gene targeted by the t(11 ;14)(q13;q32) translocation in B-cell 
lymphocytic malignancy and therefore in proximity of the breakpoint marker 
bcl-1. The first telomeric HTF-island was located 110kb downstream from the 
breakpoint marker by the technique of chromosome walking (Withers e ta l
1991). Subsequent Southern and northern blot analysis of the cloned region 
revealed it to be the new cyclin CCND1 gene, the expression of which had 
become deregulated by the t(11 ;14)(q13;q32) translocation. The absence of 
any other CpG islands between the bcl-1 major translocation cluster and 
CCND1, strongly suggested that the cyclin D1 gene was the "bcl-1 proto­
oncogene" (Bale ef a/1990, Lammie ef a/1991, Withers e ta l 1991, Brookes et 
al 1992).
Since its characterisation, the t(11 ;14)(q13;q32) translocation has been 
identified in a number of B-cell neoplasms of which most frequently (up to 70%) 
in centrocytic lymphoma (Williams e ta l 1991; Williams e ta l 1993). In all cases
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the coding regions of the cyclin D1 gene were left intact, although in some 
instances loss of the 3' non-translated regions was observed (Rosenberg e ta l 
1991a, Withers efa/1991, Seto et a l 1992). Furthermore, both 
t(11 ;14)(q13;q32) and t(11 ;11 )(p15;q13) rearrangements were uniformly 
associated with over-expression of CCND1 transcripts, postulated to be due to 
the juxtaposed strong promoter regions of the IgH chain locus or the 
parathyroid hormone promoter regions, respectively (Rosenberg e ta l 1991a, 
Withers et al 1991, Motokura et al 1991, Seto et al 1992). The levels of over­
expression varied in the different cases examined and could reach up to 37- 
fold more than in a range of control, non-neoplastic cell lines (Rosenberg e ta l 
1991 a, Rosenberg et al 1991 b, Withers et al 1991, Seto et al 1992).
D-type cyclins show a degree of tissue type specificity with cyclin D1 
and cyclin D3 transcripts predominating in epithelial and mesenchymal cells or 
in T- and B-lymphocytes, respectively, while cyclin D2 mRNA species have 
been reported in epithelial and lymphoid cell lines (Palmero e ta l 1993, 
Matsushime efa/1991, Inaba e ta l 1992). The proposed non-overlapping 
functions of D-type cyclins during the development of different cell lineages has 
suggested an even greater significance of CCND1 over-expression seen in 
transformed lymphoid cells (Palmero e ta l 1993).
1.4.2 Amplification of cyclin genes.
1.4.2a The incidence of cyclin amplification in human carcinoma and the 
effects on patient prognosis.
Currently the gene dosages and expression levels of cyclins A, B1, B2, 
D1, D2, D3 and E have been examined in a variety of human tumours, as 
previously mentioned, only the cyclin D1 gene is amplified and subsequently
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over-expressed in a significant number of cases (Jiang et al 1992, Schuuring et 
al 1992a, Buckley e ta l 1993). Independent clinical studies on breast, 
oesophageal and SCCs have implicated the amplification of chromosome 
11 q13 as an important prognostic factor. In breast carcinomas increased gene 
dosage of the 11 q13 markers was associated with lymph node metastasis, a 
short relapse free period following curative surgery and poor patient prognosis, 
while in most cases no correlations were found with patient age, tumour size, 
histological grade, or menstrual status (Linderau e ta l 1988, Tsuda e ta l 1989a, 
Adnane e ta l 1989, Fantl eta l 1990, Schuuring e ta l 1992b). Breast tumours 
with increased copy numbers of chromosome 11 q13 were in several studies 
also shown to have highly elevated oestrogen receptor (ER) levels (Adnane et 
al 1989, Fantl e ta l 1990, Borg e ta l 1991). Amplifications of chromosome 
11 q13 in oesophageal and HNSCC are more common than in breast 
carcinomas, in these tumours increased gene dosage was correlated with poor 
differentiation, a higher incidence of distant organ metastasis and low patient 
survival rates (Tsuda et al 1989a, Berenson e ta l 1989, Berenson efa/1990, 
Kitagawa e ta l 1991). The use of mouse skin carcinogenesis models allowed 
an experimental analysis of the role of cyclin D1 in tumour development. 
Following TPA treatment, modest amplifications of the murine CCND1 
homologue (Cyl-1) and highly elevated transcript levels were observed in the 
majority of late papillomas (38 to 39 weeks of promotion with TPA), suggesting 
that Cyl-1 played an important role in tumour progression and the acquisition of 
autonomous growth (Bianchi e ta l 1993).
The human cyclin D2 gene (CCND2) has been mapped to the short arm 
of chromosome 12 at 12p13 and cyclin D3 (CCND3) to 6p21 (Motokura e ta l 
1992a, Inaba e ta l 1992, Xiong e ta l 1992a, Motokura e ta l 1992b). To date,
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there is little evidence for the direct involvement of these genes in cancer, 
however, isochromosomes of 12p and 6p were observed in ~90% of germ cell 
tumours (GCTs) and 40-60% retinoblastomas, respectively (Samaniego e ta l 
1990). Increased copy numbers of the two regions were also observed in 
several cases of CLL, malignant lymphoma, hyperploid acute lymphocytic 
leukaemia and one colorectal carcinoma cell line, suggesting the potential 
involvement of CCND2and CCND3\n transformation (Han e ta l 1984, Leach et 
al 1993).
Increased gene dosage and/or over-expression of one or more of the 
cyclin A, B1 or E genes were observed in to independent studies of breast 
cancer cell lines and one case of colorectal carcinoma (Keyomarsi and Pardee 
1993, Buckley e ta l 1993, Leach e ta l 1993). The prognostic significance of 
these abnormalities have not yet been analysed.
1.4.2.b CCND1 and EMS1 are commonly co-amplified.
The incidence and levels of 11q13 amplification in breast, lung, 
oesophageal and SCCs were described in section 1.2.1.C. Increased gene 
dosage and most significantly up-regulated expression of the cyclin D1 gene 
were observed in all the tumours harbouring 11q13 amplifications, suggesting 
that CCND1 may represent the targeted ("key") gene of the amplicon (Lammie 
e ta l 1991, Faust and Meeker 1992). However, in a study of human breast 
carcinomas and HNSCCs, a new gene termed EMS1 (chromosome eleven, 
band q13, mammary tumour and squamous cell carcinoma-associated gene) 
was identified and shown to co-amplify and co-express with CCND1 in most 
tumours with an amplification of the 11 q13 region, despite the large distance 
between the two genes (Schuuring e ta l 1992a).
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EMS1 was cloned in an effort to isolate the putative oncogene of 
chromosome 11q13. A cDNA library derived from a SCC cell line (UMSCC2) 
harbouring 20 copies of the 11q13 region was differentially screened using 
[32P]dCTP - labelled cDNAs obtained from UMSCC2 or a low 11 q13 copy 
number cell line (UMSCC1), the two identified genes corresponded to CCND1 
and EMS1 (Schuuring et al 1992a). The predicted EMS1 protein sequences 
showed greatest identity (85%) with the chicken p80/85 proteins, previously 
described as substrates of the oncogenic src tyrosine kinase (Wu et al 1991, 
Schuuring e ta l 1993). The fact that EMS1 may represent the human 
homologue of chicken p80/85 was further supported by the detection of a 
p80/85 protein doublet in denaturing acrylamide gels with the use of affinity 
purified antibodies raised against EMS1 (Schuuring e ta l 1993).
In a study of 127 breast carcinomas, 41 HNSCCs and derived cell lines 
amplification of chromosome 11 q13 markers (FGF3, FGF4 and bcl-1) was 
detected in 40 tumours and nine cell lines, all of which had increased the 
CCND1 gene dosage (Schuuring e ta l 1992a). The absence of co-amplified 
EMS1 was evident in only three cases, although in four tumours the EMS1 
gene was amplified to a greater extent than CCND1. Northern blot analysis 
revealed over-expression of the two genes in all cell lines with corresponding 
amplifications, however increased copies of 11 q13 were not a prerequisite for 
transcriptional upregulation, as observed in two cell lines and one tumour, 
indicating that mechanisms other than increased gene dosage may activate 
these putative proto-oncogenes (Schuuring e ta l 1992a).
In normal chicken cells p80/85 proteins are phosphorylated on Ser and 
Thr residues and exhibit a predominantly cytoplasmic location. However, in 
cells expressing activated forms of the src protein, substantial Tyr
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phosphorylation is easily detectable and p80/85 co-localises with actin in 
rosette-like structures representative of membrane contact sites with the 
substratum (Wu et al 1991). This distribution of p80/85 is characteristic of cells 
transformed with tyrosine kinase oncogenes and the rosette structures termed 
podosomes also contain a variety of other cytoskeletal proteins such as a- 
actinin, vinculin, talin and fibrin (Burridge e ta l 1988). Immunocytochemical 
analysis of human SCC cell lines with or without amplifications of chromosome 
11 q13 revealed the same pattern of EMS1 protein subcellular localisations as 
seen in transformed and non-transformed chicken cells, respectively 
(Schuuring efa/1993).
Recently several lines of experimental evidence have suggested that 
over-expression of only EMS1 or CCND1 genes is not sufficient to induce 
transformation (Schuuring e ta l 1993, Dr Gordon Peters, ICRF, London, 
England, unpublished data; Vladimir Grigorijev, Beatson Institute, personal 
communication). However, the presence of numerous potential 
phosphorylation sites mapped to the EMS1 protein and the common co­
amplification of EMS1 and CCND1 genes observed in a significant number of 
carcinomas, has indicated that cyclin D1/cdk complexes might be one of the 
EMS1 protein kinases (Schuuring e ta l 1993). Therefore, the over­
representation of both proteins may have significant effects on cell cycle 
regulation, the organisation of the cytoskeleton and focal adhesion.
The EMS1 gene was mapped to a position 800-1 OOOkb telomeric from 
CCND1 with the use of pulsed field gel electrophoresis, chromosome walking 
and chromosome jumping techniques (Schuuring e ta l 1992a, Brookes e ta l
1993). Based on the presence of non-methylated CpG islands, the ~1 OOOkb 
region was postulated to contain at least five genes of which two are the
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fibroblast growth factors FGF3 and FGF4 (described in section 1.2.1 .a), while 
the other candidates remain unknown and also represent potential targets of 
the 11 q13 amplicon (Brookes e ta l 1992, Brookes e ta l 1993). In summary, the 
pathogenic significance of CCND1 involvement in tumours with 11q13 
amplifications is less certain than in parathyroid adenomas and centrocytic 
lymphomas with detectable clonal rearrangements.
1.4.3 Viral insertion causes elevated cyclin expression.
Epidemiological studies have revealed a significant correlation between 
chronic infection by the hepatitis B virus (HBV) and development of liver cancer 
(Brechot 1993). The observed frequent integration of HBV into the genome of 
primary liver cancer cells led to the proposal that this may result in the 
activation of a cellular proto-oncogene. In a comparative study, the region of 
HBV integration was cloned from a very early, well-differentiated primary 
hepatocellular carcinoma and its germline counterpart (Wang et al 1990). 
Analysis of the sequences revealed that the virus had disrupted the cyclin A 
gene by integrating into its second intron (Wang e ta l 1990, Wang e ta l 1992). 
In vitro translation of several hybrid cyclin A-HBVcDNAs isolated from the 
tumour, produced a 50kD protein. The N-terminal 152 amino acids of cyclin A 
that normally contain the destruction box, had been replaced with 150 amino 
acids corresponding to the viral PreS2 and S proteins, while the cyclin C- 
terminus of cyclin A (including the cyclin box) had remained intact. A frog 
oocyte in vitro degradation assay of the chimeric protein, confirmed the 
suspicions that the loss of the amino-terminal of the cyclin A protein had 
rendered it nondegradable by ubiqitination (Wang e ta l 1992). Analysis of the 
tumour tissue revealed a large quantity of the HBV-cyclin A mRNAs, however,
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for several proposed reasons no hybrid protein was detected in the examined 
samples (Wang e ta l 1992, Brechot 1993). The resulting implications for the 
effects of a undegradable cyclin A species that may exhibit altered subcellular 
localisation (the chimeric protein contains two hydrophobic helices necessary 
for membrane anchorage of the viral proteins) in developing liver cancer is 
considerable, although as yet no direct evidence has been found.
The murine Cyl-1 gene was mapped to mouse chromosome 7 in a 
region highly homologous to human chromosome 11 q13 and in the proximity of 
a Friend murine leukaemia virus (MuLV) integration site (Fis-1) (Lammie e ta l
1992). Normal lymphoid cells predominantly lack Cyl-1 transcripts, however, 
expression of the gene was induced in all the examined tumours that contained 
MuLV sequences integrated into Fis-1 of chromosome 7. Friend MuLV- induced 
erythroleukaemias and myelogenous leukaemias that were negative for 
insertion into the Fis-1 locus were also negative for Cyl-1 expression, 
suggesting that the presence of Cyl-1 mRNA was tightly linked to MuLV 
induced transcription (Lammie e ta l 1992).
Another common integration site of MuLV'm T-cell leukaemias was 
mapped to murine chromosome 12 and the proximity of the Vin-1 gene, which 
was subsequently identified by sequence analysis as the murine homologue of 
CCND2 (Cyl-2). Transcriptional activation of the Cyl-2 gene, as a consequence 
of viral insertion, was proposed to contribute to the growth disregulation of the 
malignant T cells (Hanna e ta l 1993). Therefore, as in the case of cyclin A, the 
over-expression of at least two members of the D-family of cyclins resulting 
from MuLV insertion proposes a mechanism by which this virus may act to 
transform cells, however many more studies will be necessary to elucidate the 
function of the cyclin proteins in these processes.
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1.4.4 The consequences of cyclin over-expression on the control of 
cellular proliferation.
Cell cycle events of most organisms are ordered into pathways in which 
the initiation of later events depends on the completion of early ones. To 
illustrate this, in eukaryotes entry into mitosis is dependent on the completion 
of DNA synthesis, which in turn is regulated by a number of DNA repair 
proteins that operate during G1 (Hartwell and Weinert 1989). The majority of 
decisions regarding proliferation of mammalian cells are made during the G1 
phase and depend on mitogenic stimulation (Pardee 1989). Analogous to 
START in budding yeast, a mammalian cell can switch between proliferation 
and arrest at a specific stage during the G1 phase, termed the restriction- (R-) 
point (Pardee 1974, Rossow e ta l 1979, Cross e ta l 1989). Once the R-point is 
passed the cell becomes committed to proliferation despite any extracellular 
signals, therefore it is temporarily growth factor independent. At least two 
stages in the cell cycle, the G1-S and G2-M transitions, are responsible for the 
detection and repair of DNA damage (Hartwell 1992, Murray 1992). Cells are 
able to delay cell cycle progression at these two checkpoints to allow repair 
before entering the S phase or mitosis, where DNA damage would cause the 
accumulation of mutations and the loss or gain of genomic material, 
respectively. Currently, the evidence for the involvement of the tumour 
suppressor protein p53 in the G1-S checkpoint is rapidly accumulating, there 
are also some indications that p53 is a substrate of cyclin dependent kinases 
(Bishoff e ta l 1990, Lane 1992, Hartwell 1992, Wang and Eckhart 1992).
G1 cyclins represent one of the best candidates for the regulators of 
progression through G1 and the timing of DNA synthesis, thus the major 
consequences of deregulated cyclin expression are suggested to be the
64
shortening of specific cell cycle phases causing the abolishment of check point 
controls (Dou e ta l 1993). This proposal has been analysed in two independent 
studies in which constitutive over-expression of cyclins D1, D2 or E were 
achieved in several fibroblast cell lines (Ohtsubo an Roberts 1993, Quelle e ta l
1993). Increased cyclin E expression was achieved in a rat fibroblast cell line 
and primary human foreskin fibroblasts by infection with a Moloney murine 
sarcoma virus expression vector, also containing the neomycin 
phosphotransferase gene as a selectable marker (Ohtsubo and Roberts 1993). 
At least two forms of the endogenous cyclin E protein were detectable in the 
examined fibroblasts, of which the smaller 50kD species predominated during 
G1 and exhibited increased expression in the transfected cells. In exponentially 
growing cells the over-expression of the cyclin E protein resulted in a three- to 
five-fold increase of cyclin E associated histone H1 kinase activity, which was 
relatively independent of the cell cycle. The duration of G1 was on average 
three hours shorter in infected cells when compared to the controls, although 
the overall length of the cell cycle was unchanged due to secondary delays in 
S and G2 . Upon forty eight hours of serum starvation, most of the control Rat-1 
and primary fibroblasts were in G1 (92% and 84%, respectively) the median 
length of which had increased from eleven to twenty three hours. However, the 
same experiment revealed a smaller number of cyclin E infected cells in G1 
(77% of Rat-1 and 64% of primary fibroblasts) which lasted only forteen hours, 
suggesting a reduction in serum requirement of these cells. Over-expression of 
cyclin E also resulted in up to a 30% decrease of fibroblast cell size, an 
analogous phenomenon to budding yeast that have increased levels of CLN 
cyclins (Hadwiger e ta l 1989).
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The effects of cyclin D1 and D2 over-expression in two rodent fibroblast 
cell lines (NIH3T3 and Rat-2) were similar to those previously observed for 
cyclin E, although transfections were hampered by apparent cyclin D toxicity 
(Quelle et al 1993). A shortening of the G1 and GO to S phase intervals by up 
to four hours was evident only in cells that had increased levels of cyclin D1, 
while the smaller effects of cyclin D2 were potentially less significant. 
Microscopic and Coulter counter analyses of cyclin D over-expressers revealed 
a reduction in cell size. NIH3T3 and Rat-2 cyclin D transfectants also exhibited 
a decreased serum requirement which was determined by the timing of DNA 
synthesis following serum stimulation of starved cells. Opposite to the 
previously described consequences of cyclin E over-representation, cyclin D 
transfected cells did not compensate for the shortening of G1 by extending 
subsequent phases and therefore exhibited a reduced generation time.
In 1974 Arthur Pardee proposed the G1 restriction point model which 
allowed distinction between "normal" cells that were able to arrest in G1 as a 
response to low serum, high cell density or partial inhibition of protein synthesis 
and tumourigenic cells that had lost this ability (Pardee 1974, Rossow e ta l 
1979). Subsequently the control of growth at the R point was suggested to 
depend on the accumulation of a specific "initiator" protein the expression of 
which would be deregulated in transformed cells (Rossow e ta l 1979, Campisi 
e ta l 1982). Currently it is becoming apparent that not one but a whole set of 
G1 specific proteins satisfy the criteria for the R factor (Dou et al 1993). The 
G1-S cyclins (A, C, D and E) accumulate throughout the G1 phase of the cell 
cycle, triggering the activation of a range of Ser/Thr kinases (Xiong and Beach 
1991, Pines 1993). Several reports have revealed associations of these 
proteins with tumour suppressor, DNA repair and transcription factors such as
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pRb, p53, PCNA or E2F (Xiong et al 1992b, Hinds efa/1992, Lees efa/1992, 
Zhang e ta l 1993, Hall ef a/1993). Constitutive over-expression of cyclins D 
and E induced by transfection experiments, causes premature DNA replication 
in cells and a reduced serum requirement (Quelle e ta l 1993, Ohtsubo and 
Roberts 1993). Taken together with the observed over-expression of cyclins in 
a variety of mammalian tumours, these data suggest that cyclins may form a 
new class of proto-oncogenes the function of which is important for the 
proliferation of "normal" and transformed cells.
1.5 Summary and aims.
Cyclins were initially given this name due to the periodic changes in 
expression during the cell cycle (Rosenthal e ta l 1980, Evans e ta l 1983). 
However, the classification is currently determined to a greater degree by the 
presence of specific evolutionarily conserved domains within these proteins, 
termed "the cyclin box". Furthermore, many newly discovered families, such as 
cyclins C and G, do not exhibit periodic oscillations in expression levels and 
depend on growth stimulation signals rather than the cell cycle itself (Tamura et 
al 1993)
Currently, cyclin D1 is the only cell cycle regulator revealing extensive 
involvement in human cancer. The gene (CCND1) is amplified and over­
expressed in HNSCCs, breast carcinomas, oesophageal carcinomas and 
transitional carcinomas of the lung (Zhou e ta l 1988, Berenson e ta l 1989, 
Tsuda et al 1989b, Berenson e ta l 1990, Somers e ta l 1990, Lammie and 
Peters 1991, Kitagawa e ta l 1991). Rearrangements involving the 
immunoglobulin heavy chain and the parathyroid hormone loci with 
chromosome 11 q13, result in CCND1 over-expression in B-cell leukaemias
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and lymphomas, therefore cell types that normally lack any expression of this 
gene.
Despite extensive studies, there has been a lack of published data 
investigating the expression levels and subcellular localisation of the CCND1 
protein product in original tumours or derived cell lines. Furthermore, the 
HNSCC cell lines examined revealed a higher frequency of CCND1 
amplification than that reported in tumour tissue samples, suggesting growth 
selection during cell line establishment (Lammie ef a/1991, Schuuring e ta l 
1992a, Edington et al submitted). In addition, the relevant studies failed to 
include normal epithelial cells during the gene dosage and mRNA expression 
analyses, potentially reducing the accuracy of the determined results (Lammie 
et al 1991, Schuuring et al 1992a).
This study was aimed at the characterisation of CCND1 gene dosage, 
transcript and protein expression levels in a panel of new SCC cell lines which 
had been derived under conditions that minimised selection of fitter variants. 
The obtained values were compared to those determined for human foreskin 
primary keratinocytes. The intent was to, by using the technique of lipofection, 
analyse the effects of increased CCND1 protein expression on the growth and 
transformation of human primary keratinocytes or established, non- 
tumourigenic epithelial cell lines.
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MATERIALS AND METHODS
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CHAPTER 2 : Materials and Methods.
2.1 Materials.
2.1.1 Chemicals.
The chemicals were of "AnalaR" grade, the majority of which were 
obtained from BDH Chemicals Ltd., Poole, Dorset, England or Sigma Chemical 
Co. Ltd., Poole, Dorset, England, except those obtained from the suppliers 
listed jbelow:
Supplier - Amersham International PLC, Amersham, Bucks, England.
Supplier - B.R.L. (UK), Gibco Ltd, Paisley, Scotland.
All restriction enzymes and buffer concentrates with the exception 
of where otherwise stated.
Select agar
Supplier - Biogenesis Ltd., Bournemouth, England.
RNAzol B
Supplier - Boehringer Mannheim UK Ltd., Lewes, East Sussex, England. 
Caesium chloride
DNA molecular weight markers IV and VI 
proteinase K 
primer p(dT)i5
RNase DNase free, from bovine pancreas 
Supplier - J.Burrough (FAD) Ltd., Witham Essex, England.
Ethanol
Supplier - Central Services, Beatson Institute.
a[32P] dCTP (3000Ci/mmol) 
[35S] dATP aS (600Ci/mmol)
Hybond-N+ 
p25|] EGF (50pCi/ml)
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CT buffer (6g NaCI, 2.96g trisodium citrate, 1.76g tricine,
5mg phenol red, 700ml water, pH7.8) Sterile distilled water 
L-broth Sterile PBS
PE buffer (0.04g KCI 0.04g, KH2P04,1.6g NaCI, 0.276g 
Na2HP04x2H20, 0.07g EDTA, 200ml water) 
Supplier - Difco Labs., Detroit, Michigan, USA.
Bacto-tryptone Bacto-yeast extract
Supplier - Gateway PLC, Glasgow, Scotland.
Marvel, dried non-fat milk powder 
Supplier - GIBCO Europe, Life Technologies Ltd., Paisley, Scotland. 
10xDMEM keratinocyte-SFM
foetal calf serum penicillin
200mM glutamine streptomycin
hydrocortisone 2.5% trypsin
7.5%sodium bicarbonate geneticin sulphate
protein molecular weight markers low and high range 
Supplier - ICN Biomedicals Ltd.,Irvine, Ayrshire, Scotland.
mycoplasma removal reagent 
Supplier - Oxoid Ltd., Basingstoke, England.
PBS tablets
Supplier - Pharmacia Ltd., Milton Keynes, England, 
ultrapure dNTP set
restriction enzymes Sail and Pst1 including appropriate buffer 
concentrates.
NICK™ columns, sephadex G50 
Supplier - Rathburn Chemicals Ltd., Walkeburn, Scotland.
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phenol (water saturated)
2.1.2 Kits.
Supplier - Amersham International PLC, Amersham, Bucks, England.
ECL Western Blotting analysis system 
Supplier - Bio 101 Inc., Stratech Scientific, Luton, England.
Geneclean kit
Supplier - Boehringer Mannheim UK Ltd., Lewes, East Sussex, England.
Transfection Reagent DOTAP 
Supplier - Cruachem Ltd., Glasgow, Scotland.
Cruachem oligonucleotide purification cartridges 
Supplier - Invitrogen corporation, Abingdon, Oxon, England.
TA Cloning™ kit
Supplier - Perkin Elmer Cetus Ltd., Beaconsfield, Bucks., England.
PCR Gene amplification kit RNA PCR kit
Suppler - Pharmacia Ltd., Milton Keynes, Bucks., England.
Oligo-labelling kit 
Supplier - Promega Ltd., Southampton, England.
Magic Minipreps DNA purification system 
Magic PCR* Preps DNA purification system 
Supplier - Sigma Chemical Co. Ltd., Poole, England.
Bicinchroninic acid protein concentration kit 
Supplier - Clonetics, TCS Biologicals Ltd., Buckingham, England.
KGM Bulletkit™
Supplier - United States Biochemical Corporation, Cleveland, USA. 
Sequenase version 2.0 DNA sequencing kit
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Supplier - Vector Laboratories, Bretton, Peterborough, England. 
ABC kit, peroxidase mouse IgG 
ABC kit, peroxidase rabbit IgG
2.1.3 Equipment.
In most cases the main pieces of equipment are referred to in the 
appropriate sections. The Beatson Institute stores provided the general 
plasticware, while the following companies supplied some of the most 
commonly used items:
Supplier - Becton Dickinson Labware, Plymouth, Devon, England, 
tissue culture dishes (35, 60 and 90mm) 
falcon tubes (15 and 50ml)
polystyrene round bottom tubes (12x75mm and 17x100mm) 
Supplier - Bibby-Sterilin Ltd., Stoney, Staffs., England.
bacteriological dishes (90mm)
Supplier - Chance Propper Ltd., Warley, England, 
gold star microslides (76x26mm) 
microscope glass cover slips (22x50mm)
Supplier - Costar, Cambridge, Massachusetts, USA.
6,24 and 96 well plates disposable cell scrapers
Supplier - Eastman Kodak Co., Rochester, New York, USA.
duplicating film X-ray film (XAR-5)
Supplier - Fuji Photo Co., Ltd., Japan.
X-ray film (RX)
Supplier - GIBCO Europe, Life Technologies Ltd., Paisley, Scotland. 
Nunc cryotubes (1 and 1.5ml)
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Nunc flasks (25, 80 and 175cm3) Nunc glass chamber slides 
Supplier - Griener Labortechnik Ltd., Dursley, England.
Eppendorf tubes 
Supplier - Labsystems, Basingstoke, England.
pipette tips (200 and 500pl)
Supplier - Millipore UK Ltd., Middlesex, England.
immobilon P transfer membrane 
Supplier - Sartorius Instruments Ltd., Surrey, England, 
collodion bags
Supplier - Whatman International Ltd., Maidstone, England.
3mm chromatography paper
2.1.4 Plasmids.
pA6
pAM91
pHR28-1
pHSG274
A 190bp cDNA fragment complementary to 7S RNA cloned 
into the pAT153 vector. A gift from Dr David Prowse, 
Beatson Institute (Balmain efa/1982).
A 1360bp Pst1 cDNA fragment from an actin mRNA 
expressed in adult skeletal muscle cloned into the Pst1 site 
of the plasmid pBR322. A gift from Dr Rob Nibbs, Beatson 
Institute (Minty e ta l 1982).
A 7kb fragment containing sequences homologous to 28S, 
the 3’ end of 18S and 5.8S rRNA cloned into the EcoR1 
site of the plasmid pAT153. A gift from Frances Fee, 
Beatson Institute.
A gift from Dr Kim Hawker, Beatson Institute (Brady e ta l 
1984).
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pJ5£2-D1
pJ4£216.E6
pJ4D16.E7
pMoE6
pMoE7
A 1290bp fragment containing the Cyl-1 cDNA was cloned 
into the EcoR1 site of the pJ5Q vector. A gift from Dr 
Gordon Peters, ICRF, London, England.
A 1.77kb fragment containing the HPV-16 E6 open reading 
frame was inserted into EcoR1/BamH1 restriction enzyme 
digested vector pJ4£X At the C-terminal of the E6 
fragment, amino acid Leu was replaced by His-Gly. A gift 
from Dr Lionel Crawford, ICRF, London, England (Storey 
et a /1988).
A 1.9kb fragment containing the HPV-16 E7 open reading 
frame and 1.6kb of 3' sequences beyond the E7 stop 
codon was cloned into the BamH1 site of plasmid pJ4£l A 
gift from Dr Lionel Crawford, ICRF, London, England 
(Storey et al 1988).
A 0.63kb fragment of HPV-16 DNA containing the intact E6 
open reading frame linked to the Molony murine leukaemia 
virus long terminal repeat, inserted into the pUC19 vector. 
A gift from Dr Karen Vousden, Ludwig Institute for Cancer 
Research, London, England (Vousden and Jat 1989, 
Hawley-Nelson e ta l 1989).
A 0.671 kb of HPV-16 DNA containing the intact E7 
open reading frame linked to the Molony murine leukaemia 
virus long terminal repeat, inserted into the pUC19 vector.
A gift from Dr Karen Vousden, Ludwig Institute for Cancer 
Research, London, England (Vousden and Jat 1989, 
Hawley-Nelson efa/1989).
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pSP64-ets1 Human c-ets1 cDNA cloned into the EcoR1 site of the
pSP64 vector. A gift from Dr Rob Nibbs, Beatson Institute. 
pJ7Q-D1 A 1290bp Cyl-1 cDNA fragment inserted in the correct 
orientation into the EcoR1 site of the pJ7£2 vector. A gift 
from Dr Gordon Peters, ICRF, London, England (Smith et 
al unpublished data). 
pJ7Q-antiD1 A 1290bp Cyl-1 cDNA fragment inserted in the incorrect 
orientation into the EcoR1 site of the pJ7Q vector. A gift 
from Dr Gordon Peters, ICRF, London, England (Smith et 
al unpublished data). 
pHR28-1 A 7kb fragment containing homologous sequences to 28S, 
the 3' end of 18S and 5.8S. A gift from Frances Fee, 
Beatson Institute.
2.1.5 DNA probes.
The probes for cyclin D1, ets-1, GAPDH, 7S, 18S and 28S ribosomal 
RNA, human skeletal actin and HPV-16 E7 are listed (below. The origin of most 
probes is schematically depicted in Figure 4.
cyclin D1 1.3kb EcoR1 fragment of mouse Cyl-1 cDNA.
ets1 4kb Pst1 fragment of human ets1 cDNA.
GAPDH 0.7kb PCR fragment of rat GAPDH.
7S 0.6kb EcoR1/Sal1 fragment containing a 190bp
stretch complementary to 7S RNA.
18S and 28S A 7kb fragment containing homologous sequences
to 28S, the 3’ end of 18S and 5.8S.
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actin 1.36kb Pst1 fragment of adult human skeletal
muscle specific actin cDNA.
HPV-16 E7 A 313bp region of the E7 open reading frame
isolated by BamH1 restriction of the vector 
pURHPV-16. A gift from Angeliki Malliri, Beatson 
Institute.
2.1.6 Immunological reagents.
Rabbit polyclonal anti-cyclin D1 (287-3). Used at dilutions 1:500 and 
1:3000.
A gift from Dr Gordon Peters, ICRF, London, England.
Rabbit polyclonal anti-cyclin D1. Used at a 1:500 dilution.
Pharmingen, AMS Biotechnology UK Ltd., Oxon, England.
Mouse monoclonal anti-cyclin D2 . Used at a 1:500 dilution.
Pharmingen, AMS Biotechnology UK Ltd., Oxon, England.
Mouse monoclonal anti-cyclin D3. Used at a 1:500 dilution.
Pharmingen, AMS Biotechnology UK Ltd., Oxon, England.
Rabbit polyclonal anti-cdk4 (10165). Used at a 1:1000 dilution.
A gift from Dr /Li Huei Tsai , Massachusetts General Hospital, Boston, 
USA.
Mouse monoclonal anti-pRb (XZ77). Used at a 1:10 dilution.
A gift from Dr j Li Huei Tsai, Massachusetts General Hospital, Boston, ’ 
USA.
Mouse monoclonal anti-PCNA. Used at a 1:1000 dilution.
Pharmingen, AMS Biotechnology UK Ltd., Oxon, England.
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Figure 4. Schematic representation of DNA fragments 
used as probes in Southern and northern blot analyses.
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Figure 4
a) cyclin D1 : 1.3kb fragment of Cyl-1 cDNA
5’ 3’
CMV
promoter cyM cdna Amp R
^ -----------1.3 kb------------
EcoR1 EcoR1
b) efs-f : 0.81 kb fragment of ets-1 cDNA
5’ 3’
sts-1 cDNA Amp R
0.81 kb ^
c) actin : 1.36kb fragment of actin
5’ 3’
human skeletal 
„ actttcDNA
^ --------- 1,36kb --------^
TcR
Pstl Pstl
d) 7S : 0.6kb fragment containing 7S cDNA
5’ 3’
Amp RMm
0.6kb >
EcoR1 EooRI
Mouse monoclonal anti-HPV16 E7. Used at a 1:10 dilution.
Triton diagnostics, Alameda, California, USA.
Mouse monoclonal anti-BrdU. Used at a 1:2000 dilution.
Sigma, Chemical Co. Ltd., Poole, Dorset, England
Donkey anti-mouse horseradish peroxidase-linked whole antibody 
(1:5000 dilution). Amersham International PLC, Amersham, Bucks, 
England.
Sheep anti-rabbit horseradish peroxidase-linked whole antibody (1:3000 
dilution). Amersham International PLC, Amersham, Bucks, England.
Anti-mouse IgG biotinylated antibody
Vector Laboratories, Bretton, Peterborough, England.
Anti-rabbit IgG biotinylated antibody
Vector Laboratories, Bretton, Peterborough, England.
2.1.7 Bacterial strains.
E.coli DH5a cells. Obtained from B.R.L.(UK), Gibco Ltd, Paisley, 
Scotland.
E.coli INVaF cells. Obtained from Invitrogen corporation, Oxon, 
England.
2.1.8 Cell lines.
BICR 3-22 Seven cell lines derived from human squamous cell
carcinomas of the head and neck by Kirsten Edington at 
the Beatson Institute. A gift from Kirsten Edington.
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MS-2
A431
SCC12-F
TFK104
HEKb
HEK34
HEK124
Saos-2
x3T3
Maintained in DMEM containing hydrocortisone in the 
presence of terminally irradiated fibroblasts.
A cervical squamous cell line derived by Margareta Nikolic 
at the Beatson Institute. Maintained in DMEM containing 
hydrocortisone in the presence of terminally irradiated 
fibroblasts.
A vulvar squamous cell carcinoma cell line obtained from 
Dr Brad Ozanne, Beatson Institute. Maintained in DMEM 
containing hydrocortisone.
A skin squamous cell carcinoma cell line obtained from Dr 
Ken Parkinson, Beatson Institute. Maintained in DMEM 
containing hydrocortisone.
HPV-16 E6/E7immortalised human foreskin primary 
keratinocytes. A gift from Dr Karen Vousden, Ludwig 
Institute for Cancer Research, London, England. 
Maintained in GIBCO SFM.
Human foreskin primary keratinocytes. A gift from Caroline 
Chapman, Beatson Institute. Maintained in Clonetics KGM. 
Human foreskin primary keratinocytes. A gift from Dr Ken 
Parkinson, Beatson Institute. Maintained in GIBCO SFM. 
Human foreskin primary keratinocytes. A gift from Dr Ken 
Parkinson, Beatson Institute. Maintained in GIBCO SFM.
A human osteosarcoma cell line. A gift from Dr Ken 
Parkinson, Beatson Institute. Maintained in DMEM. 
Terminally irradiated Swiss 3T3 fibroblasts used to provide 
optimal growth conditions for the BICR and MS-2 cell lines. 
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208F An immortalised rat fibroblast cell line. A gift from Dr Bob
Hennigan, Beatson Institute. Maintained in DMEM.
MMV c-fos transfected 208F fibroblasts. A gift from Dr Bob
Hennigan, Beatson Institute. Maintained in DMEM.
A1C FBJ infected 208F fibroblasts expressing v-fos. A gift from
Dr Bob Hennigan, Beatson Institute. Maintained in DMEM.
FBR FBR infected 208F fibroblasts expressing v-fos. A gift from
Dr Bob Hennigan, Beatson Institute. Maintained in DMEM.
Rati An immortal rat fibroblast cell line. A gift from Dr Bob
Hennigan, Beatson Institute. Maintained in DMEM.
1302 FBJ infected Rati fibroblasts. A gift from Dr Bob Hennigan,
Beatson Institute. Maintained in DMEM.
Swiss 3T3 An immortal murine fibroblast cell line. A gift from Dr Ken
Parkinson, Beatson Institute. Maintained in DMEM.
Balb 3T3 An immortal murine fibroblast cell line. A gift from Dr Brad
Ozanne, Beatson Institute. Maintained in DMEM.
NIH3T3 An immortal murine fibroblast cell line. A gift from Dr Brad
Ozanne, Beatson Institute. Maintained in DMEM.
T45 Swiss 3T3 murine fibroblasts exposed to high doses
(60Gy) of cobalt irradiation. A gift from Dr Garry Sibbet, 
Beatson Institute. Maintained in DMEM.
2.1.9 Tissue culture media.
DMEM Dulbecco's modified Eagles media supplemented with
0.5%, 2% or 10% FBS, 0.4pg/ml hydrocortisone, 25pg/ml 
streptomycin and 18.75pg/ml penicillin.
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SFM Keratinocyte serum free media supplemented with 5ng/ml
human epidermal growth factor, 2ml bovine pituitary 
extract, 25pg/ml streptomycin and 18.75pg/ml penicillin. 
KGM Keratinocyte serum free media supplemented with
0.1ng/ml human epidermal growth factor, 0.5pg/ml 
hydrocortisone, 2ml bovine pituitary extract, 5pg/ml bovine 
insulin, 50pg/ml gentamicin sulphate, 50ng/ml 
amphotericin-B, 25|ig/ml streptomycin and 18.75pg/ml 
penicillin.
2.1.10 Water.
Deionised water for solutions was obtained from a Millipore MilliRO 15 
system. For nucleic acid, protein and tissue culture manipulations, the 
water was further purified on a Millipore MilliQ system.
2.2 Methods.
2.2.1 Growth and manipulation of eukaryotic cells.
2.2.1 .a Establishment of cell lines from human SCCs.
A total of twenty five cervical SCC biopsies were obtained from patients 
of a wide age group (a gift from Dr Brendan Bolger, Royal Infirmary, Glasgow, 
Scotland.). Half of the samples were snap frozen in liquid nitrogen for 
histological examination and future DNA extraction, while the remaining 
portions were bisected into 1mm3 particles, under sterile conditions. The 
fragments were rinsed in foetal bovine serum (FBS) and, following serum 
drainage, maintained on plastic petri dishes in a non-humidified incubator at 
37°C for 45 minutes, to allow tissue attachment. Subsequently 5ml of DMEM
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containing 10% FBS were added to the dishes and the explants incubated for 5 
days at 37°C in an atmosphere of 7% CO2 until firm attachment to the matrix 
was evident. At the first media change, terminally irradiated Swiss 3T3 
fibroblasts (x3T3) were added to the growing cells in order to minimise 
selection for fitter variants (Rheinwald and Beckett 1981; Edington e ta l 
submitted). The explants were also exposed to 10pg/ml mycoplasma removal 
reagent to prevent and where applicable cure cellular infection during the initial 
stages of culturing. Upon establishment the MS-2 cell line was tested for 
optimal proliferative conditions by varying the serum levels and attempting 
growth in the absence of x3T3 cells.
2.2.1 .b Mammalian cell line culturing.
The BICR and MS-2 cell lines were maintained on 90mm plastic petri 
dishes in the presence of x3T3 cells at 37°C in an atmosphere of 7% CO2. The 
FBS levels were varied in dependence of individual cell line growth 
requirements. At confluence the cells were passaged at a 1:2-1 :5 ratio onto 
fresh x3T3 containing petri dishes, this took place every 3-5 days and was 
determined by the cell type. The same conditions were used for the culturing of 
cell lines A431, SCC12, P-1 and A3, except that they did not require the 
presence of x3T3 fibroblasts. The human foreskin primary keratinocytes 
(HEKs) and TFK104 cells were cultured in keratinocyte serum free media 
(GIBCO or Clonetics) on 90mm plastic petri dishes at 37°C in an atmosphere 
of 7% C 02.
Passaging was carried out by aspiration of the growth media from the 
cell monolayers, followed by two successive exposures to 2 .5 ml of 0.25% 
trypsin solution in CT buffer (see section 2.1.1). The majority of trypsin was
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immediately removed by aspiration and the petri dishes incubated at 37°C until 
the cells detached. In the case of SCCs, the detached cells were resuspended 
in the appropriate DMEM and replated at the required dilution. For the cells 
growing in serum free media, trypsin inactivation was carried out by 
resuspention in ice cold DMEM containing 2-10% FBS, followed by the 
pelleting of cells by centrifugation in a Beckman GP centrifuge at 1000rpm and 
subsequent plating in the appropriate media at the required dilution.
All of the cell lines were routinely examined for mycoplasma infection as 
part of the Beatson Institute mycoplasma test programme (Joe Winnie and 
Mary Freshney, Beatson Institute). Where appropriate, the cells were treated 
for one week with 0.5pg/ml mycoplasma removal reagent or until the complete 
removal of contaminants.
Keratinocyte cell cycle delay was achieved following trypsinisation, 
trypsin inactivation in ice cold DMEM containing 2-10% FBS and subsequent 
plating in DMEM containing 0.5% FBS for 24 hours. Due to increased cell 
death following plating in low serum, to obtain GO arrest, sub-confluent cultures 
of fibroblast cell lines were washed 3-5 times in 10 ml of sterile ice cold PBS 
and subsequently cultured in DMEM containing 0.5% FBS for 72 hours.
For immunocytochemical analysis 1x104-3x104 cells were plated on 
glass chamber slides in 200pl of the appropriate media, depending on their 
growth properties. Culturing took place in humidifying conditions at 37°C in an 
atmosphere of 7% CO2 for 24-48 hours subsequent to which the cells were 
processed for immunocytochemistry as described in section 2.2.4.d. To obtain 
G1 arrest, fibroblast and keratinocyte cell lines were initially cultured in DMEM 
containing 0.5% FBS for 72 or 24 hours, respectively.
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2.2.1.c Frozen cell stocks.
A large frozen stock was maintained for all the examined cell lines. Upon 
trypsinisation, the detached cells were resuspended in 1ml of appropriate 
growth media supplemented with 20% FBS and 10% DMSO at approximately 
1x106 cells/ml. These cells were rapidly aliquoted into 1 or 1.5ml Nunc 
cryotubes and frozen at -70°C, where they were kept for up to one month. 
Subsequently, the frozen cryotubes were placed for long term storage into 
liquid nitrogen.
2.2.1 .d EGF binding assays.
Cells were plated at a density of 1x105 cells/well in 24 well tissue culture 
plates 24 hours prior to the assay. Each well was washed 3 times with PBS 
and duplicates were incubated with increasing amounts of [125l] EGF (typically 
11 concentration points from 0.1|ig/well to 50pg/well) in the presence or 
absence of a hundred fold excess of unlabelled competitor EGF in 0.5ml of 
PBS containing 1% BSA. Incubation was carried out at room temperature for 1 
hour. Cells were subsequently washed 5 times in ice cold PBS containing 5% 
BSA, solubilised in 1 ml of 1M NaOH and the amount of radioactivity 
determined in a Beckman 5500B gamma counter. The amount of specifically 
bound EGF was determined by subtracting the figures obtained by analysing 
the competitor samples (revealing non-specific binding) from the figures 
obtained for wells lacking non-radioactive EGF (total EGF binding). The results 
were processed using the LIGAND programme.
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2.2.2 Transfection, selection and cloning of cell lines.
2.2.2.a Transfection of established SCC12 cells.
SCC12 cells were co-transfected with sense or antisense cyclin D1 
expression constructs in combination with a neomycin resistance conferring 
vector (see section 2.1.4). Lipofection was used as a means of introducing 
exogenous DNA into these cells. Diluted transfection reagent DOTAP (70pJ of 
DOTAP were added to 180pl of HBS buffer, containing 20mmol/l Hepes, 
150mmol/l NaCI, pH7.4) was mixed with 5pg of appropriate DNA in 250pl HBS 
buffer incubated for 10 minutes at room temperature to allow association 
between the DNA and cationic lipid particles. The old tissue culture media was 
subsequently removed SCC12 cells growing in 90mm plastic petri dishes at a 
60-80% confluency and the cells exposed to the transfection mixture diluted in 
14ml of serum free DMEM. Incubation was carried out for 12 hours at 37°C in 
humidifying conditions and an atmosphere of 7% CO2, following which the 
media was replaced by fresh DMEM containing 10%FBS. After a period of 48- 
72 hours, during which plasmid expression took place, SCC12 cells were 
passaged at a 1:10 split into growth media containing 250pg/ml G418. 
Antibiotic resistant colonies were observed following a period of 4-5 weeks, 
during which selection was maintained and media changes were carried out 
every 4-5 days. Resistant colonies were cloned as follows:
(i) A felt-tip mark was made on each petri dish outlining the position of 
selected clones.
(ii) The growth media was removed by aspiration.
(iii) Sterile metal or plastic ring clones were greased with sterile Vaseline and 
placed onto the dish isolating individual clones.
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(iv) 10Ofxl of trypsin solution were applied to each ring and maintained for 
approximately 1 minute at room temperature.
(v) The trypsinised cells were placed into separate wells of a 24 well plate in
1 ml of DMEM containing 10% FBS. This media was replaced with fresh DMEM 
one day from cloning and subsequently at 4-5 day intervals.
(vi) Proliferating clones were sequentially expanded into larger plates, 
maintaining selection throughout culturing.
2.2.2.b Transfection of human foreskin primary keratinocytes.
HEK cells were co-transfected with varying combinations of cyclin D1, 
HPV-16 E6 or E7 expression constructs in the presence or absence of G418 
resistance conferring expression vectors (as depicted in Tables 8 , 9 and 10). 
Lipofection was used as a means for introducing exogenous DNA into the cells 
and the same methods applied as described in section 2.2 .2 .a with a few 
alterations listed bellow:
(i) Lipofection was carried out in GIBCO SFM (HEK124 and HEK34) or 
Clonetics KGM (HEKb).
(ii) The cells were exposed to the transfection mixture only for a period of 8 
hours.
(iii) Transfection of HEK124 cells was carried out in the absence of G418. 
Instead the cells were selected for resistance to senescence and 
differentiation.
(iv) HEK34 and HEKb cells were selected by a 48 hour exposure to 10pg/ml 
G418 followed by culturing in keratinocyte growth media.
(v) Colony formation was evident approximately 10 days from lipofection.
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(vi) Due to previously observed Vaseline toxicity, HEKb transfectants of the »■ 
same type were pooled and maintained on 90mm petri dishes.
2.2.3 Nucleic acid procedures.
2.2.3.a Transformation of competent cells.
Competent E.coli DH5a or INVaF cells were thawed in dry ice and to 
each 20pl aliquot, 100ng of appropriate plasmid DNA were added. Following a 
20 minute incubation on ice, the cells were heat shocked for 2 minutes at 42°C, 
placed on ice for 2 minutes and finally incubated in SOC medium (2% bacto- 
tryptone, 0.5% bacto-yeast extract, 10mM NaCI, 2.5mM KCI, 10mM MgC^, 
10mM MgS04  and 20mM glucose) for 1 hour at 37°C with constant shaking at 
225rpm allowing expression of antibiotic resistance markers. Transformed cells 
were briefly pelleted by spinning for 5 minutes in a microfuge and resuspended 
in 100pl of L-broth. 1:10,1:100 dilutions and the remaining mixture of 
resuspended cells were spread onto separate agar plates (1-2% agar in L- 
broth) containing 100pg/ml of ampicillin. Incubation was carried out at 37°C 
overnight. The following day representative colonies were picked using a heat 
sterilised bacterial loop and bacteria inoculated into 12ml of L-broth containing 
100pg/ml ampicillin and incubated with constant shaking (225rpm) overnight at 
37°C. Subsequent DNA extraction was carried out according to procedures 
described in section 2.2.3.b-1 to identify colonies harbouring the required 
expression vectors. These were expanded into 500ml cultures for the 
preparation of large scale plasmid preparations (as described in section
2.2.3.b-2).
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Storage of transformed bacteria was achieved by mixing 500pl of 
overnight cultures with 500pJ of glycerol in 1 ml Nunc cryotubes which were 
frozen and maintained at -70°C.
Upon transformation with recombinant plasmids containing exogenous 
DNA interrupting the lacZgene, INVaF cells were cultured on agarose plates 
overlaid with 25pJ of fresh X-Gal (40mg/ml stock solution) 1 hour prior to use. 
IPTG was not required since the INVaF cells did not express the lad  
repressor. Following overnight incubation bacteria containing introduced 
successfully ligated plasmids were distinguished by their inability to break down 
the chromogenic X-Gal compound, therefore giving rise to white colonies. 
INVaF' cells harbouring re-ligated, non-disrupted plasmids formed distinct blue 
colonies under the same conditions.
2.2.3.b Preparation of nucleic acids.
2.2.3.b-1 Small scale preparations of plasmid DNA.
Modifications of the alkali lysis methods proposed by Birnboim and Doly 
(1979) and Ish-Horowicz and Burke (1981) were used to extract plasmid DNA 
from small bacterial cultures. Single bacterial colonies expanded overnight in 
12ml of L-broth containing 100pg/ml ampicillin were separated into 1.5ml 
aliquots and spun in Eppendorf tubes at maximum speed for 5 minutes. The 
pellet was resuspended in 200pl of solution I (50mM glucose, 25mM TrisHCI 
pH8.0,10mM EDTA pH8.0, 2mg/ml of lysozyme in water) and kept at room 
temperature for 5 minutes. Cell lysis was continued by the addition of 400pl of 
solution II (0.2M NaOH, 1%SDS) and the Eppendorf tubes stored on ice for 10 
minutes. Lysis was terminated by the addition of 300pl of ice cold solution III 
(3M CF^COONa pH4.8), and the tubes stored on ice for 3-5 minutes
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subsequent to which they were centrifuged at maximum speed for 10-15 
minutes. To induce DNA precipitation 800pl of supernatant were mixed with 
480|il of ice cold isopropanol and the samples frozen at -20°C for a minimum 
of 30 minutes. The precipitate was pelleted by centrifugation at top speed in a 
bench top microfuge at 4°C for 20 minutes. Following supernatant aspiration, 
the pellet was washed in ice cold 70% ethanol and respun at the same 
conditions for 15 minutes. The DNA was dried under vacuum and subsequently 
resuspended in 50pl of MilliQ water at 37°C for 30 minutes. In some cases 
RNase treatment was employed and involved incubation with 50pg/ml RNase 
for 30 minutes at 37°C. 1pJ aliquots were subjected to appropriate restriction 
enzyme digestion (see section 2.2.3.C-1) and electrophoretic analysis (see 
section 2.2.3.d-1), while the nucleic acid concentration was determined by 
spectrophotometric analysis of 1:100 dilutions (see section 2.2.3.e). For short 
term storage the DNA was kept at 4°C.
2.2.3.b-2 Large scale plasmid preparations.
The alkali lysis method proposed by Sambrook eta ! 1989 was used to 
obtain plasmid DNA from large bacterial cultures. Overnight 500-1000ml 
cultures were collected by centrifugation (6000rpm) in polypropylene bottles for 
5 minutes at 4°C using a Beckman J2-21 centrifuge. The pellets were washed 
in 100ml of bugwash solution (150mM NaCI, 10mM TrisHCI and 1mM EDTA 
pH8.0) and respun at the same conditions. Following supernatant removal, the 
pellets were vigorously resuspended in 20ml of solution I (50mM glucose, 
25mM TrisHCI pH8.0 and 10mM EDTA pH8.0) and kept on ice for 5 minutes 
subsequent to which 80ml of solution II (0.2M NaOH and 1% SDS) were 
added. The samples were mixed by gentle inversion at room temperature for 5-
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10 minutes. Lysis was terminated by the addition of 30ml of solution III (5M 
CH3COOK - 60ml, glacial acetic acid -1 1 .5ml and water - 28.5ml), the samples 
kept on ice for 10 minutes followed by centrifugation at 4000rpm, 4°C for 15 
minutes. A 0.6 volume of ice cold isopropanol was mixed with the supernatant 
which had been filtered through gauze and the DNA precipitated at room 
temperature for 10-20 minutes. The DNA was pelleted by centrifugation at 
5000rpm, room temperature for 15 minutes in a Beckman J2-21 centrifuge and 
subsequently washed in 70% ice cold ethanol. The vacuum dried pellet was 
resuspended in 12ml of TE buffer (1mM EDTA, 10mM TrisHCI pH8.0) and 
subjected to CSCI2 gradient nucleic acid separation as follows:
(i) 12ml of resuspended DNA were mixed with 12.9g CSCI2 and 0.8ml of 
ethidium bromide (stock solution 10mg/ml).
(ii) The refractive index was adjusted to 1.39 with CSCI2 or TE buffer and the 
solutions transferred to appropriate centrifuge tubes.
(iii) Centrifugation was carried out at 40,000rpm for 48 hours at 20°C in a 
Beckman L-60 ultracentrifuge (T-50 rotor).
(iv) Removal of closed, circular plasmid DNA was carried out with the use of 
an ultraviolet lamp and blunt ended needles.
(v) The ethidium bromide was discarded by vigorously mixing equal volumes 
of sample and CsCI2 saturated isopropanol, the top red layer removed and the 
process repeated 3-4 times.
(vi) Plasmid DNA was precipitated in glass Corex tubes by adding 3M 
CH3COONa - 1/10th volume, 100% ethanol - 2.5 volumes and placing 
overnight at -20°C.
(v) Precipitates were pelleted by centrifigation at 8000rpm for 30 minutes in a 
Beckman J2-21 centrifuge, washed in 70% ethanol, vacuum dried and
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resuspended in 0.5ml TE buffer (pH8.0) or MilliQ water. They were stored at 
40C.
2.2.3.b-3 Genomic DNA extraction from mammalian cell lines
Preparation of genomic DNA was carried out following the procedure 
suggested by Laird eta ! 1991. Cells grown to confluence on 90mm dishes 
were submerged in 3ml of lysis buffer (100mM TrisHCI pH8.5, 5mM EDTA, 
0.2% SDS, 200mM NaCI and 100pg proteinase K/ml), removed with the use of 
disposable cell scrapers and the samples placed into 5ml plastic sterilin tubes 
where lysis continued at room temperature for up to 2 hours. Upon the addition 
of 3ml cold isopropanol the DNA rapidly precipitated and was removed from 
the solution with the use of a 200pl Gilson pipette. The DNA was further 
resuspended in 0.5ml-3ml of TE buffer (10mM TrisHCI, 0.1 mM EDTA pH7.5) 
and the concentration determined by spectrophotometry of 1:100 dilutes (see 
section 2.2.3.e). The genomic DNA was stored at 4°C.
2.2.3.b-4 Total RNA extraction from mammalian cell lines.
Extraction of total RNA from mammalian cell lines was carried out 
following the manufacturer's protocol for RNasol B (Biogenesis Ltd.) which was 
based on the guanidium thiocyanate-phenol-chlorophorm method established 
by Chomczynski and Sacchi 1987. Sub-confluent cell cultures growing on 
90mm dishes were washed in ice cold PBS which was completely removed by 
aspiration and subsequently lysed in 1ml of RNasol B. A disposable cell 
scraper was implemented to homogenise the cells and the sample added to 
Eppendorf tubes containing 80pJ of chloroform. Following a 5 minute incubation 
on ice the phases were separated by top speed centrifugation in a microfuge
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for 15 minutes at 4°C. The upper colourless layer was removed and the RNA 
precipitated by mixing with 0.4ml of ice cold isopropanol that had previously 
been purified by filtration. The lower blue phase was discarded. RNA 
precipitation was carried out overnight at -20°C and pelleted by centrifugation 
in a microfuge for 20 minutes at 4°C. The supernatant was carefully removed 
by aspiration and the pellet washed once in ice cold 70% ethanol. A 
subsequent 15 minute spin at 4°C reduced the chances of pellet loss upon 
ethanol removal. The RNA was dried under vacuum and resuspended in 40pJ 
of DEPC treated, autoclaved MilliQ water. Spectrophotometric analysis of 
1:250 dilutes determined the sample concentrations (see section 2.2.3.e). They 
were stored at -20°C.
2.2.3.b-5 Oligonucleotide preparation.
Designed oligonucleotides were synthesised on an Applied Biosystems 
mode 381A DNA synthesiser. The 5' methoxy-trytil group remained in place 
after incorporation of the final nucleotide, in order to insure efficient purification 
of the oligonucleotides from any aborted synthetic products. Elution from the 
synthesis column was achieved by overnight incubation of the resins in 
approximately 2ml of concentrated ammonia solution (29%) at 55°C in airtight 
glass tubes, at the same time removing the side chain protective groups. 
Purification of trytil protected oligonucleotides was carried out the following day 
with the use of trytil affinity columns (Cruachem). The columns were 
precleaned with 2ml of concentrated acetonitrile gently drawn through under 
vacuum, followed by 2ml of 2M triethylamine acetate pH7.0. Prepared columns 
were exposed to the oligonucleotide samples which were slowly drawn through 
twice to insure maximum entrapment. Unbound oligonucleotides were removed
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by flushing the columns with 3ml of dilute ammonium hydroxide in water (1:10), 
2ml of MilliQ water, 2ml of 2% trifluoroacetic acid and 2ml of MilliQ water. 
Purified oligonucleotides were eluted with 1 ml of 20% acetonitrile. The DNA 
was collected by lyophilisation in a centrifugal evaporator system (Hectovac) 
and resuspended in 50pl of MilliQ water. Oligonucleotide concentrations were 
determined by spectrophotometric analysis (see section 2.2.3.e), and the 
samples stored in aliquots at -20°C.
2.2.3.C Enzymatic manipulations of nucleic acids.
2.2.3.C-1 Restriction endonuclease digestion of DNA.
Plasmid DNA (usually 1-5pg) was digested using 1-10 units of 
appropriate restriction endonucleases in the presence of buffers supplied by 
individual manufacturers, the total volume of the reaction not exceeding 10pJ. 
Due to the inhibitory effects of high glycerol concentrations, the volume of 
enzyme used never exceeded 1/10th of the total reaction. Incubation was 
carried out for a minimum duration of 30 minutes at 37°C and the reactions 
terminated by the addition of 3pl of DNA loading buffer (0.25% bromophenol 
blue, 30% glycerol in water).
Genomic DNA (25-50pg) was digested following the same principle and 
the volumes were increased in proportion. Following overnight incubation the 
DNA was analysed by gel electrophoresis procedures (see section 2.2.3.d) to 
determine the extent of digestion, where necessary a further aliquot of 
appropriate restriction enzyme was added and the incubation continued 
overnight. The volume of enzyme used never exceeded 1/10th of the total 
volume.
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2.2.3.C-2 PCR amplification.
Two types of polymerase chain reaction (PCR) amplifications were 
carried out and differed in the starting material which was either genomic DNA 
or total RNA extracted from the appropriate mammalian cell lines. In both 
cases the conditions in which the reactions took place were determined 
following manufacturer's suggestions (Perkin Elmer Cetus) (Saiki e ta l 1988; 
White et a /1989).
Genomic DNA isolated from SCC12, P-1 and transfected HEK cells was 
subjected to PCR amplification with the use of 24bp oligonucleotides (b2 and 
y4) that spanned CCND1 exon boundaries 2-3 and 4-5, respectively and were 
therefore specific for exogenously introduced cyclin D1 cDNA (Table 2). A 
master mix containing 200mM concentrations of each nucleotide (dATP, dCTP, 
dTTP and dGTP) in 1x reaction buffer (1 Ox stock contains 100mM TrisHCI 
pH8.3, 500mM KCI, 15mM MgCl2 and 0.01% gelatine) was aliquoted into 
separate capped 0.5ml polypropylene microcentrifuge tubes containing correct 
amounts of double distilled water to make the final reaction volume a total of 
lOOpl. Into each reaction mixture 0.5pg of appropriate genomic DNA was 
added and 100pg of oligonucleotides b2 and y4, with the exception of control 
samples. The samples were heated to 95°C for 6 minutes to inactivate any 
proteases that may be present in the crude DNA extracts, subsequent to which 
0.5pl of AmpliTaq DNA polymerase were added and the mixtures overlayed 
with 10Opil of mineral oil to prevent evaporation. Reactions were carried out at 
high stringency for 40 cycles in a Perkin Elmer Cetus DNA Thermal Cycler as 
follows:
1 minute melt at 95°C 
1 minute anneal at 60°C
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Table 2. Oligonucleotides used in PCR amplification 
reactions.
Oligonucleotides 3 and 4 were homologous to a CCND1 transcript 3' 
untranslated region, while oligonucleotides b2 and y4 were specific for CCND1 
cDNA and were used to distinguish exogenous from endogenous CCND1 DNA 
in transfected cell cultures.
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Table 2
1730 1753
- A T T  CCG TAG G TA  GAT GTG T A A  C C -
1959 1939 3’
-A G G  GCC G TT GGG TAG  A A A  ACC A -
547 573 3.
-G A G  GAG CTG CTG C A A  A TG  GAG C T G -
, 880 856 ,
-T T C  A C A  CTG GGC CTG  ACG GAG G C C -
1 minute extend at 72°C 
The resulting samples were examined by gel electrophoresis (as 
described in section 2.2.3.d-1) and Southern blot analysis (as described in 
section 2.2.3.g). Remaining mixtures were stored at -20°C.
Total RNA isolated from A431 cells was subjected to reverse 
transcription and subsequently PCR amplification following the methods 
suggested by the
RNA PCR kit (Perkin Elmer Cetus). Reverse transcription samples containing 
5mM MgCI2, 1 x PCR buffer II, 1 mM dGTP, 1 mM dCTP, 1 mM dATP, 1 mM 
dTTP, 1mM RNase inhibitor, 1units/pl of reverse transcriptase, 2.5jxM oligo 
d (D 16.1W of total RNA ancJ sterile distilled water to a final volume of 20p.l, 
were placed into capped 0.5ml polypropylene microcentrifuge tubes and 
overlayed with 100pl of mineral oil to prevent sample evaporation or refluxing. 
The tubes were exposed to 42°C for 15 minutes, 99°C for 5 minutes and 5°C 
for 5 minutes for one cycle, to achieve reverse transcription from the poly-A 
RNA species. To each reverse transcription reaction tube 78jj,I of a prepared 
PCR master mix (2mM MgCI2, 1x PCR buffer II, 2.5 units/100^1 of AmpliTaq 
DNA polymerase and water to a final volume of 78^1) were added followed by 
appropriate "upstream" and "downstream" primers (Table 2) each at a final 
concentration of 0.15mM making the total reaction volume 100pJ by the 
addition of sterile water where necessary. The tubes were briefly spun in a 
microcentrifuge and subjected to PCR amplification in a Perkin Elmer Cetus 
DNA Thermal Cycler as follows:
2 minutes at 95°C for 1 cycle 
1 minute at 95°C and 1 minute at 60°C for 35 cycles 
7 minutes at 60°C for 1 cycle
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storage at 4°C until sample retrieval 
The samples were subsequently examined by gel electrophoresis (see 
section 2.2.3.d-1), purified (see section 2.2.3.d-2) and cloned (see section
2.2.3.C-3).
2.2.3.C-3 Ligation of DNA fragments.
PCR products obtained by initial reverse transcription from total RNA 
extracts were cloned taking advantage of the non-template dependent activity 
of AmpliTaq DNA polymerase adding single deoxyadenosines to the 3’-end of 
all duplex molecules provided by PCR. The A-overhangs were used to achieve 
direct ligation of PCR products into the specifically designed linearised vector 
pCR™ II (Invitrogen), that contains single 3' T-overhangs in the central part of 
a multiple cloning site. Ligation reactions contained 1pl 10x ligation buffer,
50ng of linear vector pCR™ II, Xpl of diluted PCR product, 1pl of T4 DNA 
ligase and water to make the final volume 11pl. For maximum efficiency, the 
molar ratio of vector: PCR insert was kept from 1:1 to 1:3. Reactions were 
incubated overnight at 4°C 1 ml of which were used immediately to transform 
bacteria (as described in section 2.2.3.a). The unused ligation mix was stored 
at -20°C.
2.2.3.d Agarose gel electrophoresis and DNA purification.
2.2.3.d-1 Agarose gel electrophoresis.
Non-denaturing 0.8-1.5% agarose gels were used for the visualisation of 
DNA fragments of >200bp. Agarose was dissolved by heating in 50ml (mini- 
gel) or 200ml (maxi-gel) of 1xTAE buffer (10x stock contains 48.4g of Tris,
11.42ml of glacial acetic acid and 40ml of 0.25M EDTA pH8.0 in 11 of water) for
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further DNA purification or 1xTBE buffer (10x stock contains 108g of Tris, 55g 
of boric acid and 9.5g of EDTA in 11 of water) for fragment resolution. The hot 
gel mix was cooled to approximately 50°C upon which ethidium bromide was 
added to a final concentration of 0.4pg/ml. TAE gels were cast at 4°C while 
TBE gels at room temperature. Electrophoresis was carried out in the same 
buffer used for the gel formation, therefore either 1 xTAE or 1 xTBE. Prior to 
loading into the wells, the DNA samples were mixed with 3jil of DNA loading 
buffer (0.25% bromophenol blue and 30% glycerol in water) and subsequently 
electrophoresed in the presence of appropriate size markers at 1-5V/cm. A 
312nm transilluminator was used for the resolution of the fragments and 
records were taken by Polaroid camera photography on Polaroid Type 57 high 
speed film. Further purification of DNA from TAE gels is described in the 
following section.
2.2.3.d-2 Recovery of DNA fragments from agarose gels.
Two distinct methods were employed for the purification of DNA 
fragments!> 200bp from low melting point TAE agarose gels : "Genecleaning" 
(Bio 101 Inc. Statech) which was found to result in smaller yields and "Magic 
Minipreps DNA purification system" or "Magic PCR* Preps DNA purification 
system" (Promega), both equally applicable and effective in DNA purification.
"Genecleaning" involved weighing the gel piece containing the DNA 
fragment of interest and addition of 2V 2 volumes of Nal. The mixture was 
incubated at 60°C up to 10 minutes to induce gel melting, following which 5pl 
of manufacturer's GLASSMILK solution were added and incubation continued 
at 4°C for 5 minutes. The GLASSMILK bound DNA was pelleted by 
centrifugation in a microfuge and washed in 450|il of ice cold NEW wash, 4
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times. Subsequent to the final spin and supernatant removal, the DNA was 
eluted from the resin by resuspending the pellet in 20pl of MilliQ water, the 
sample was heated to 55°C for 5 minutes and centrifuged.
DNA purification using the "Magic systems" involved the addition of 1 ml 
of DNA purification resin to molten agarose and vortexing the mixture for 1 
minute. The resin containing bound DNA was slowly drawn through a mini­
column by applying vacuum and the column subsequently washed with 2ml of 
70% isopropanol. Residual wash solution was removed by centrifugation in a 
microfuge, followed by placing at room temperature for 5-15 minutes allowing 
isopropanol evaporation. Bound DNA was eluted with 50pl of MilliQ water at 
room temperature for 1 minute and the elute collected by centrifugation at top 
speed for 20 seconds. The purified DNA fragments were analysed by gel 
electrophoresis (see section 2.2.3.d-1) and stored at 4°C.
2.2.3.e Nucleic acid quantitation.
A Beckman DU-64 spectrophotometer was used to determine the 
concentrations of individual nucleic acid samples. Typically 1:100 dilutions of 
DNA extracts or PCR products and 1:250 dilutions of RNA extracts were 
subjected to analysis. Each reading was initially calibrated with a blank 
containing the solution the nucleic acids were dissolved in, commonly MilliQ 
water or TE buffer. Optical density readings at A26o of 1 were taken to 
correspond to 50pg/ml for plasmid and genomic DNA, 40pg/ml for RNA and 
30pg/ml for oligonucleotides. The A260/A280 raf ‘°  was calculated to determine 
the degree of protein contamination of the samples and values of 1.8-2.0 were 
taken to indicate a sufficiently pure extract.
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2.2.3.f The construction and purification of radioactive DNA probes.
a[32P]dCTP labelled DNA fragments applied in Southern and northern 
blot analyses were derived by the technique of random priming. In most cases 
a commercially available kit (Pharmacia) was used. The principle of the method 
was based on the synthesis of new DNA strands in the presence of 
radioactively labelled bases (in all cases a[32P]dCTP was used) following 
denaturation of double stranded DNA fragments by boiling. For the 
construction of one probe 50-1 OOng of appropriate DNA were linearised in a 
volume of 34pl and briefly cooled on ice prior to the addition of 10pl of reaction 
buffer (containing required salt concentrations, random primer sequences, 
dATP, dGTP and dTTP), 5pl od a[32P]dCTP (3000Ci/mmol-Amersham) and 
1pl of Klenow fragment. The reaction mix was incubated at 37°C for 30 
minutes -1  hour.
Alternatively, in one case where the use of specific primers was required 
the same reactions were carried out with separately made solutions following 
the protocol suggested by Sambrook et al 1989. The reaction buffer was made 
by combining 100pl of solution A (composed from 1 ml of a 1.25M TrisHCI 
pH8.0 and 0.125M MgCI2 solution, 18pl of neat (3-mercaptoethanol, 5pl of 
100mM dATP pH8.0, 5pl of 100mM dTTP pH8.0 and 5pl of 100mM dGTP 
pH8.0), 250pl of solution B (2M HEPES buffer titrated to pH6.6 with 4M NaOH) 
and 150jil of solution C (0.6p.g of primer 3 and 0.6|ig of primer 4 diluted in TE 
buffer pH8.0) and used in the same way as described above.
Removal of unincorporated nucleotides was carried out by purification in 
Sephadex-G50 columns obtained from Pharmacia (Nick columns) or made with 
the use of Eppendorf tubes. The Nick columns were allowed to drip under the 
force of gravity, they were precleared with approximately 5ml of TE buffer
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(pH8.0) following which the samples were eluted with 400pl aliquots of TE 
buffer. The first radioactive aliquot obtained from each column contained the 
purified probe. Alternatively, Eppendorf tubes pierced at the bottom were 
packed with Sephadex-G50 equilibrated in TE buffer (pH8.0), excess liquid 
was removed by centrifugation at 2500rpm for 2 minutes. Samples containing 
non-purified probes were subsequently spun at 2500rpm for 5 minutes, and the 
unincorporated nucleotides retained in the beads. The degree of a[32P]dCTP 
incorporation was determined by the analysis of 1pl aliquots in a Beckman 
LS5000CE counter.
2.2.3.g Southern blot analysis.
20|ig of restriction endonuclease digested genomic DNA (see section
2.2.3.C-1) were electrophoresed overnight through a 0.8% agarose TBE gel at 
a constant 30V (see section 2.2.3.d-1). The gel was subsequently visualised 
under ultraviolet light and a photographic record taken using Polaroid Type 57 
high speed film. Transfer of the DNA onto Hybond N+ membrane was achieved 
under vacuum (50-60mbar). A piece of membrane the size of the gel was 
immersed in MilliRO water, placed onto a vacuum blotter (Pharmacia) and 
overlayed with the agarose gel. The area not occupied with the gel had been 
covered with a plastic sheet which contained an opening the size of the gel, 1% 
molten agarose was used to seal the gel to the sheet. Depurination of the DNA 
was achieved by the suction of 0 .2M HCI through the gel until the visible 
bromophenol blue representing the dye front changed to a yellow colour, this 
typically took 30-45 minutes. Subsequent DNA denaturation was carried out by 
the suction of a 0.5M NaOH, 1.5M NaCI solution (35 minutes) followed by 
neutralisation with 1M TrisHCI pH7.5,1.5M NaCI (35 minutes). After
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neutralisation the DNA was transferred to the Hybond N+ membrane with 20x 
SSC blotting buffer (3M NaCI, 0.3M CH3COONa, pH 7.0) for 1V 2 hours under 
constant vacuum. The membrane was briefly dried at room temperature and 
the DNA UV-crosslinked using a UV Stratalinker 1800 (Stratagene). 
Hybridisation to specific probes was carried out as described in section 2.2.3.L
2.2.3.h Northern blot analysis.
Prior to electrophoresis all RNA samples were reconcentrated to 4pg/pl 
by lyophilisation in a centrifugal evaporator system (Hectovac) and 
resuspended in appropriate amounts of DEPC treated MilliQ water. 5\i\ of each 
sample (20pg) were mixed with 3 volumes (15pl) of RNA loading buffer (350pl 
formaldehyde, 1pl formamide, 150jil DNA loading buffer, 10pl ethidium 
bromide - stock solution 10pg/jil and 200pl 5x MOPS buffer containing 0.1 M 
MOPS, 40mM CH3COONa and 5mM EDTA, pH7.0 ) and heated at 65°C for 15 
minutes. The prepared samples were subsequently loaded onto a 150ml 1% 
agarose gel containing 30ml of 5x MOPS buffer and 26.3ml of formaldehyde. 
Electrophoresis took place overnight at 30V in 1x MOPS buffer which was 
constantly recirculated. Gel resolution was enabled with the use of a 312nm 
transilluminator and a photographic record taken with a Polaroid camera on 
Polaroid Type 57 high speed film. Transfer of the RNA to a Hybond N+ 
membrane was achieved under vacuum in 20x SCO blotting buffer (3M NaCI, 
0.3M CH3COONa, pH 7.0) for 1V2 hours under constant vacuum. The 
membrane was briefly dried at room temperature, the DNA UV-crosslinked 
using a UV Stratalinker 1800 (Stratagene) and the positions of 18 and 28S 
ribosomal RNA marked with a permanent felt tip marker. Hybridisation to 
specific probes was carried out as described in section 2.2.3.L
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2.2.3.i Hybridisation of labelled DNA probes to membrane bound nucleic 
acids.
The detection of specific DNA or RNA species that had been transferred 
onto Hybond N+ membranes was achieved by hybridisation with appropriate 
radiolabelled probes. The membranes were prehybridised at 42°C for 2 hours 
in sealed plastic bags containing approximately 0.1 ml/cm3 of SCC 
hybridisation buffer (45% deionised formamide, 5% dextran sulphate, 5x SCC, 
0.3% SDS, 0.1 mg/ml boiled salmon sperm DNA, 5x Denhardt's solution {50x 
stock contains 5g ficoll, 5g polyvinyl pyrolidone, 5g bovine serum albumin in 
500ml} and 50mM Na-phosphate buffer pH6.6 {1M stock contains 35.2ml of 
1M Na2HP0 4  and 64.8ml of 1M NaH2P0 4 }), upon which probes denatured by 
boiling for 10 minutes were added to the mixture. Hybridisation was carried out 
overnight at 42°C in a shaking water bath. Following the disposal of the 
radioactive solution, the membranes were washed at high stringency (two 10 
minute washes at room temperature in copious amounts of 2x SCC, 0 .1% SDS 
followed by two 30 minute washes at 65°C in copious amounts of 0 .2x SCC, 
0.1% SDS) or low stringency (two 10 minute washes at room temperature in 
copious amounts of 2x SCC, 0 .1% SDS followed by one 35 minute wash at 
room temperature in copious amounts of 0 .2x SCC, 0 .1% SDS). The 
membranes were then dried on 3mm Whatman paper to remove excess fluid, 
wrapped in Saran wrap, placed in a cassette with a suitable X-ray film and 
subjected to autoradiography at -70°C.
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2.2.3.j Stripping membranes of radioactive label.
In cases when re hybridisation of a Southern or northern blot with a 
different probe was required, the previously bound probes were removed as 
listed | below:
(i) Southern blots were stripped by shaking in 0.1% SDS that had been heated 
to 100°C when applied to the membranes and subsequently cooled during a 
period of 30 minutes to 1 hour. The process was repeated twice where 
required.
(ii) Northern blots were stripped at 65°C for 1 hour while shaking in a 5mM 
TrisHCI pH 8.0, 2mM EDTA and 0.1 x Denhardt's solution. The process was 
repeated once where required.
2.2.3.k Sequencing of double stranded DNA.
Sequencing of DNA was carried out to determine the authenticity of 
PCR amplification products according to the chain termination reaction of 
Sanger eta ! 1977 adapted into a marketed kit (Sequenase version 2.0 - 
U.S.B.). Plasmid DNA (4pg) purified from contaminating RNA by RNase 
treatment (see section 2.2.3.b-1) was denatured in 0.2mM NaOH, 2mM EDTA 
at 37°C for 30 minutes. The mixture was neutralised by the addition of 0.1 
volume of 3M CH3COONa pH4.5-5.5 and the DNA precipitated using 2-4 
volumes of 100% ethanol at -70°C for 15 minutes. The precipitated DNA was 
pelleted in a microfuge at 4°C for 15 minutes, washed in 70% ethanol, respun, 
briefly dried and resuspended in 7pl of MilliQ water. To this solution 1pl of M13 
(-40) oligonucleotide sequencing primers and 2pl of 5x sequenase buffer were 
added, incubation was initially carried out at 65°C (2 minutes), followed by a 
slow cool to <35°C for approximately 30 minutes allowing annealing to take
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place. The tubes were stored on ice. Sequencing was carried out following the 
manufacturer’s instructions and with the use of provided reagents. The 
labelling reaction consisted of 10pl of ice cold annealed DNA mixture, 1 jllI of 
0.1 M DTT, 2 |il of diluted labelling mix (4pl of dGTP, 16pl of double distilled 
water), 0.5|il [35S] dATP (600Ci/mmol), 2pl of sequenase (1:8 dilution in TE 
buffer). Incubation took place for 2-5 minutes at room temperature. 
Subsequently 3.5pl of the labelling reaction were transferred into 4 termination 
tubes containing ddA, ddT, ddC or ddG mixes and incubated at 37°C for 5 
minutes. The addition of 4pl of Stop solution (95% formamide, 20mM EDTA, 
0.05% bromophenol blue and 0.05% xylene cyanol FF) and a 2 minute boil, 
prepared the samples for electrophoresis. Denaturing 6% polyacrylamide gels 
(containing 42% urea) were used to separate the labelled, terminated 
fragments and electrophoresis was carried out at 1500V/30-40mA for 2-4 
hours. The gels were fixed in a solution of 12% methanol and 10% acetic acid 
for 1 hour at room temperature and dried under vacuum at 80°C for 
approximately 2 hours. Autoradiography was carried out as described in 
section 2.2.3.i.
2.2.4 Protein procedures.
2.2.4.a Protein extraction from mammalian cell lines.
Sub-confluent cell cultures growing on 90mm plastic dishes were 
washed in ice cold PBS and lysed in appropriate solutions, depending on the 
identity of analysed proteins. For the future detection of cyclin D1, lysis was 
carried out with 1 ml of a) 100mM NaCI, 50mM TrisHCI pH7.4,1% Triton X-100,
0 .1% SDS, 0.5% sodium deoxycholate, 5mM CaCI2, 25pg/ml aprotinin,
10pg/ml pepstatin, 0.5mM PMSF and 10pg/ml leupeptin or b) 50mM TrisHCI
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pH7.4,150mM NaCI, 20mM EDTA, 0.5% NP-40,1mM PMSF, 25pg/ml 
leupeptin, 25pg/ml aprotinin, 10pg/ml pepstatin, 1mM benzamidine, 10pg/ml 
trypsin inhibitor and 1 mM sodium ortho-vanadate. For the detection of cdk4, 
PCNA and HPV-16 E7, cells were lysed in 1 ml of 50mM TrisHCI pH7.4,
150mM NaCI, 20mM EDTA, 0.5% nonidet P-40 (NP-40), 1mM PMSF, 25pg/ml 
leupeptin, 25pg/ml aprotinin, 10pg/ml pepstatin, 1mM benzamidine, 10pg/ml 
trypsin inhibitor and 1 mM sodium ortho-vanadate, while for the detection of 
pRb cells were lysed in 1 ml of 50mM HEPES pH7.0, 250mM NaCI, 0.1% NP- 
40, 1mM PMSF, 25pg/ml aprotinin, 25pg/ml leupeptin, 5mM NaF and 1mM 
sodium ortho-vanadate. Lysis was carried out ice for 20-30 minutes, the 
extracts transferred to Eppendorf tubes with the use of disposable cell scrapers 
and the supernatants collected by centrifugation in a microphuge at 4°C for 5 
minutes. The protein extracts were stored in aliquots at -20°C.
Protein concentration was determined by analysis of original sample and 
1:10 dilution aliquots (1 Opil) with the use of a Dynatech MR7000 
spectrophotometer. Calibration was carried out with a range of BSA standards 
(Ong/pl, 80ng/pl, 100ng/pl, 200ng/pl, 400ng/pl, Ipg/pl, 2jig/pl). 10|il of each 
standard were aliquoted into specific position on a 96 well plate, 200|il of 
reaction mix (1 volume of CuS04 and 50 volumes of bicinchroninic acid) were 
added to every well and the colour allowed to develop at 37°C for 30 minutes-1 
hour. Spectrophotometric analysis was carried out at A590nm.
2.2.4.b Acrylamide gel electrophoresis.
The acrylamide concentration in the gels was varied depending on the 
identity of the analysed proteins, therefore 10% gels were used for the 
resolution of cdk4, cyclin D1, PCNA and HPV-16 E7, while 7.5% gels were
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used for the resolution of pRb. The components listed bellow apply for the 
formation of one 10% gel, the same ingredients were used for 7.5% gels that 
differed only in the amount of acrylamide and water used:
3M TrisHCI pH8.8 6.25ml
30% acrylamide/b/'s-acrylamide 16.75ml
MilliQ water 26.63ml
20% SDS 0.25ml
10% ammonium persulphate 0.25ml
Temed 0 .1ml
The mixture was poured inbetween two glass plates, overlayed with 
water saturated butanol and allowed to polymerase at room temperature for 
approximately 30 minutes. Following the removal of butanol traces by washing 
with MilliRO water, the gel was overlayed with the stacking gel (4% 
acrylamide/bis-acrylamide mix in 50mM TrisHCI pH6 .8) and appropriate combs 
inserted. The polymerised gel was placed into an electrophoresis tank and 
covered with 1x Tris-glycine electrophoresis buffer (5mM Tris, 50mM glycine 
pH8.3, 0 .02% SDS in MilliRO water) taking care to remove air bubbles caught 
in the wells.
Aliquots containing 20-50pg of extracted protein were mixed with an 
equal volume of 2x SDS protein loading buffer (100mM TrisHCI pH6 .8 , 4% 
SDS, 0 .2% bromophenol blue, 20% glycerol, 2% (3-mercaptoethanol in MilliRO 
water) and the samples boiled for 5 minutes prior to loading onto the 
denaturing gel. B.R.L. high molecular weight markers were included on all gels. 
Electrophoresis was carried out for 6 hours at 30mA/gel or 24 hours at 10- 
30mA/gel. Overnignt protein transfer onto Immobilon P membranes was 
carried out in Towbin buffer (24mM Tris, 192mM glycine 20% methanol, 1.2ml
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conc. HCI, pH8.3) using a Bio Rad Trans-Blot Cell according to the 
manufacturer’s instructions. Western blot was carried out as described in the 
following section.
2.2.4.C Western blot analysis.
Following protein transfer, the Immobilon P membrane was pre-blocked 
in PBS containing 5% marvel, 0.1% Tween-20 at room temperature for 30 
minutes. The same solution was used to dilute the appropriate primary 
antibody (see section 2.1.6) small volumes of which (typically 2.5-5ml) were 
sealed with the membrane into a plastic bag and incubated at 4°C for a 
minimum of 3 hours with constant vigorous shaking. The membrane was 
washed in PBS containing 5% marvel, 0.1% Tween-20 1x10 minutes and 3x 5 
minutes at room temperature with constant shaking, followed by incubation in 
the presence of the appropriate horseradish peroxidase labelled secondary 
antibody (see section 2.1.6) at room temperature for 45-60 minutes. The final 
wash was carried out in PBS containing 0 .1% Tween-20 1x10 minutes and 3x 
5 minutes following which the membrane was incubated with an equal volume 
of ECL detection reagents 1 and 2 for 1 minute at room temperature. Upon 
removal of excess fluid, the membrane was covered in Saran wrap and placed 
in a cassette including an X-ray film for 1 second-15 minutes.
2.2.4.d Immunological staining procedures.
2.2.4.d-1 Bromodeoxyuridine incorporation and immunocytochemical 
detection.
Growing cells were cultured on Nunc glass chamber slides in the 
presence of 10pM bromodeoxyuridine (BrdU) for a minimum of 1 hour. Prior to
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fixation, cells were washed two times in ice cold PBS and once in a 1:1 mix of 
methanol: acetone. Fixation in a 1:1 mix of methanol: acetone was carried out 
for 10 minutes at room temperature upon which the slides were air dried for 10- 
15 minutes. The slides were either used immediately or stored at -20°C in 
airtight conditions.
Prior to the detection of BrdU, the cells were permeabilised in PBS 
containing 0.25% Tween-20 for 5 minutes at room temperature. The slides 
were washed three times in PBS for a total of 10 minutes and incubated at 
60°C in 1M HCI for 5-10 minutes to denature the DNA and therefore allow 
antibody binding. PBS rinsed slides (3 washes lasting 10 minutes in total) were 
rapidly exposed to diluted anti-Brdll antibody (1 :2000 dilution in PBS 
containing 0.5% BSA) and incubated at room temperature in humidifying 
conditions for a minimum of 3 hours. Unbound antibody was washed off by 
shaking the slides 3x 10 minutes in PBS containing 0.1% Tween. They were 
subsequently exposed to 1:100 diluted biotin bound anti-mouse antibody in 
PBS containing 0.5% BSA with constant gentle shaking at room temperature 
for 45 minutes. Washed slides were exposed to a avidin, biotinylated 
horseradish peroxidase amplification mix (solutions A and B from the 
Vectastain ABC kit) for 45 minutes, washed as previously described and the 
colour developed using a Ni-DAB solution (4ml of PBS and 1.67pl of 30% 
hydrogen peroxide were added to 1 ml of a 0.07% NiCI2, 0.025% 
diaminobenzidine-tetrahydrochloride solution) for 10 minutes. The cells were 
dehydrated by sequential immersion into 70% ethanol, 90% ethanol, 2x 100% 
ethanol and 100% xylene, overlayed with DPX and a glass coverslip.
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2.2.4.d-2 Cyclin D1 immunocytochemical and immunohistochemical 
detection.
Expression of the cyclin D1 protein in cell lines and tissue biopsies was 
examined with the use of the rabbit Vectastain ABC kit (Vector Laboratories) 
following the manufacturer's methods. Cells grown on Nunc glass chamber 
slides or tissue sections were washed two times in ice cold PBS and 
subsequently fixed following the same procedures described in section 2.2.4.d-
1. 200pJ of blocking serum (1 drop of goat serum in 1 ml of PBS containing 
0.5% BSA) were added to the cells and incubation took place at room 
temperature in humidifying conditions for 30 minutes. The serum was drained 
off and the excess fluid gently removed using a tissue. The primary antibody 
was added at a 1:3000 dilution to half of the wells while the same dilution of 
pre-immune rabbit serum was added to the other half (both were made up in 
PBS containing 0.5% BSA) and the cells incubated at room temperature for a 
minimum of 3 hours. The slides were then washed 3x10 minutes in PBS 
containing 0.1% Tween-20 and 0.15-0.2M NaCI to eliminate undesirable ionic 
interactions. A biotinylated anti-rabbit secondary antibody provided by the kit 
was diluted (1 drop in 10ml of PBS containing 0.5% BSA) and added to the 
cells. Subsequent manipulations were the same as previously described in 
section 2.2.4.d-1 with the exception of the wash solution which was kept at a 
higher stringency.
I l l
RESULTS
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CHAPTER 3 : The establishment of new cell lines derived 
from human carcinomas.
3.1 Introduction.
The incidence of CCND1 gene amplification in human cancer, reviewed 
in sections 1.2.1 .c and 1.2 .2 , has been most extensively analysed in breast 
carcinomas and in fewer cases of SCCs, oesophageal and colorectal 
carcinomas (Lammie e ta l 1991, Jiang e ta l 1992, Schuuring e ta l 1992a, Faust 
and Meeker 1992, Buckley et a /1993, Leach et a /1993). Currently, only two 
separate studies have concentrated in greater detail on the analysis of human 
HNSCC, revealing CCND1 gene dosage and/or transcript levels determined by 
Southern and northern blot analysis, respectively (Table 3) (Lammie et al 1991, 
Schuuring et al 1992a). Unfortunately, seven out of the eight SCC cell lines 
examined overlapped in the two reports. In addition, little was known of the 
culture conditions used for their establishment and therefore if they were good 
representatives of the original tumours. Due to the above mentioned reasons 
and the lack of published CCND1 data on cervical or vulvar tumours (only 
HeLa and A431 cell lines have been examined), an attempt was made in this 
study to derive and analyse cell lines from human cervical carcinomas using 
methods established for the growth of primary keratinocytes (Edington eta I 
submitted, Rheinwald and Becket 1981). A panel of HNSCC independently 
derived by Kirsten Edington (Beatson Institute) using the same methods, were 
also examined (Edington et al submitted).
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3.2 The MS-2 cervical carcinoma cell line.
An attempt was made to develop a panel of cell lines derived from 
primary cervical tumours isolated from patients of a wide age group. 
Unfortunately the success rate was very small, consistent with previous reports 
stating the infrequent outgrowth of cells from such types of tumours. A total of 
25 biopsies were dissected and further subjected to methods favouring the 
growth of primary keratinocytes (described in section 2 .2.1 .a), in this way 
avoiding selection of fitter variants (Edington et al submitted). Under these 
conditions approximately 50% of the samples revealed outgrowth of cells 
during the initial period of two weeks. However, the subsequent deterioration 
and inviability of the majority of cells attributed to crisis, senescence or terminal 
differentiation, resulted in the loss of all but one sample. The newly derived cell 
line, MS-2 (named after the first initials of the two establishers), had exhibited a 
remarkably rapid outgrowth from the tumour tissue (3-4 days following 
dissection) which had originated from a 21-year old patient with severe 
neoplasia. The presence of terminally irradiated Swiss 3T3 fibroblasts (x3T3) 
was found to be necessary for the growth of MS-2 cells in media containing 
10% foetal bovine serum (FBS), however, x3T3-free culturing was achievable 
in conditions of low serum (2% FBS). In 10% FBS a population of the MS-2 
cells took up a more spindle-type, fibroblast cell-like morphology that was 
lessened or lost with the reduction of serum, when all the cells flattened out 
and assumed the typical "paving stone" morphology observed for keratinocyte 
cells (Edington et al submitted).
Subsequent examination using PCR techniques revealed the presence 
of HPV-16 specific sequences integrated into the genome of MS-2 cells (work 
carried out by Dr Garry Sibbet, Beatson Institute). These results were
114
confirmed by the detection of the E7 oncogene using Southern blot analysis of 
\EcoR1 restriction endonuclease digested genomic DNA (Figure 5), while 
transcripts of the ESand E 7oncogenes were detected by northern blot 
analysis (the northern blots were carried out by Angeliki Malliri, Beatson 
Institute). Human primary keratinocytes and two HNSCC cell lines (BICR6 and 
BICR18) were used as controls for the absence of HPV-16 specific sequences. 
A commercially available mouse monoclonal antibody raised against E7 
revealed expression of this 21 kD onco-protein in MS-2 cells and HPV-16 E6, 
E 7 immortalised human keratinocytes (TFK104, a kind gift from Dr Karen 
Vousden, Ludwig Institute for Cancer Research, London, England) the latter of 
which were analysed for control purposes (Figure 5). The MS-2 cell line also 
exhibited a five-fold over-expression of EGFRs at the cell surface, which was 
observed with the use of an EGF binding assay and Scatchard analysis, as 
described in section 2.2.1 .d. Injection of 107 cells into the flanks of three 
immunodeficient nude mice revealed these cells to be tumourigenic in all three 
cases (Table 4).
3.3 The HNSCC cell lines, BICR.
The BICR (Beatson Institute for £ancer Research) cell lines were 
derived and analysed by Kirsten Edington and Dr Ken Parkinson, Beatson 
Institute. Tumour staging, caryotyping, the detection of keratinocyte specific 
markers, optimal growth conditions in tissue culture and growth in 
immunodeficient mice were determined using a variety of different techniques 
(Table 4 represents the most relevant results for this study) (Edington e ta l 
submitted).
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Table 3. Previously examined SCC cell lines.
Eight SCC derived cell lines were examined in two previous studies for CCND1 
gene dosage and mRNA expression levels (Lammie e ta l 1991, Schuuring e ta l 
1992a).
a>oca>
k .0«♦—0
0
CD ^  
-  CDE CD
E c . 0
0
0
O)
•E cmCD CD=J13
O
C O
0
a>
o>.—. 
c  c\i 
c  CD 3 <3 3 T-_c —o
CO
<
ZQC
E
Q
£O
O
co
<o0
0k_QlX
?k.
0
>o
co
0
»- o
Q *£;
£ Q.
O EO n
</>0
0O
0
0 q5 
Q> O)
.9 E
1 j
I I
< i -  CsJ
o
o
CO
co C\J CO CD CM CO
CM
o
O
CO
oo
CO
CO
oo
C O
o•M-
o
o
C O
COCMCMoo
C O
=)
CO■'d-
<
CO
oo
C O
Figure 5. Detection of the HPV-16 £7 DNA sequences and 
protein product in the MS-2 cell line.
20pg of genomic DNA from primary keratinocytes and cell lines MS-2, BICR6 
and BICR18 were electrophoresed through a 0.8% agarose gel, blotted and 
probed with a 313bp fragment of the E7 ORF (as described in materials and 
methods). The same membrane was stripped from radioactivity and reprobed 
with a 1.3kb fragment of Cyl-1 cDNA as a control for DNA loading (as 
described in materials and methods). Arrows point to the ~3.5kb E 7sequences 
and the 4kb, 2.2kb and 2kb CCND1 bands obtained upon EcoR1 restriction 
enzyme digestion of the genomic DNA.
15pg of protein extracts from primary keratinocytes, TFK104 and MS-2 (25pg 
of extracts) cell lines were electrophoresed through a 10% denaturing 
polyacrylamide gel, blotted and exposed to an anti-HPV-16 E7 monoclonal 
antibody at a 1:10 dilution (as described in materials and methods). The E7 
21 kD protein was detected in both TFK104 and MS-2 cells. In the figure the 
band is pointed to with an arrow.
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Table 4. The origin and characteristics of BICR and MS-2 
cell lines.
TNM as tumour, node, metastasis staging (UICC 1987). 
b = recurrent tumours.
(Edington et al submitted).
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3.4 Discussion.
To date only a few cervical cell lines have been established, of which the 
adenocarcinoma HeLa cell line is the most commonly described, however, 
despite the extensive analysis of these cells, very little is known of how they 
were originally derived. From the literature it is evident that most SCC cell 
lines have been obtained from recurrent or irradiated tumours and were 
cultured under conditions that favour the growth of fitter or more aggressive 
cells, therefore resulting in the growth of cell lines that are poor representatives 
of the original tumours (Easty et al 1981 a, Easty et al 1981 b, Rheinwald and 
Beckett 1981). For these reasons attempts were made to derive cell lines from 
primary, untreated cervical tumours using non-selective conditions optimal for 
the growth of primary keratinocytes (Rheinwald and Beckett 1981, Edington et 
al submitted). The low success rate of cell line establishment from cervical 
tumours (only 4% in this study) and the lack of good correlations between the 
number of HNSCC and derived cell lines with CCND1 amplifications in 
published literature, triggered the analysis of CCND1 gene dosage and 
expression levels in seven newly established HNSCC cell lines (Edington e ta l 
submitted).
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CHAPTER 4 : Characterisation of CCND1 gene dosage and 
expression levels.
4.1 Introduction.
In two previous reports, the frequency of CCND1 amplification observed 
in HNSCC cell lines (83% or 100%), was considerably greater than that 
detected in unrelated HNSCC tumour samples (44% showed CCND1 
amplifications), a phenomenon that was postulated to reflect growth selection 
during the establishment of cell lines (Lammie e ta l 1991, Schuuring e ta l 
1992a). The MS-2 and BICR cells examined in this study, were derived under 
conditipns of low stringency (described in the previous chapter), therefore 
Southern blot analysis was a means of determining whether the frequency of 
CCND1 amplification was equivalent for the new and previously established 
cell lines. Similarly, northern blot analysis was used to determine if over­
expression of the cyclin D1 gene was restricted to those cells which had 
amplified CCND1. To date, the level of expression or intracellular localisation of 
the cyclin D1 protein (termed p34°ycD1), has not been reported for any human 
tumours, a surprising fact considering the potential post-transcriptional and 
post-translational modifications of this protein. The presence of p34°ycD1 in 
the BICR and MS-2 samples was demonstrated by western blot, 
immunocytochemical and immunohistochemical analyses.
4.2 CCND1 amplification.
Southern blot analysis was performed on DNA extracts from MS-2 and 
BICR cell lines (as described in section 2.2.3.g) with the aim to look for the 
presence of CCND1 amplifications and 11 q13 rearrangements. Genomic DNA 
isolated from the new cell lines, A431, human primary epithelial keratinocytes
120
(HEK) and an HPV-16 E6, E7 immortalised, non-transformed keratinocyte cell 
line (TFK104), was subjected to digestion with restriction endonuclease 
BamH1, electrophoresed, transferred onto a membrane and the resulting blot 
sequentially hybridised with probes for CCND1 and ets-1 (Figure 6). From this 
analysis CCND1 amplification was evident in cell lines BICR6, BICR18,
BICR22 and A431, while, no increased gene dosage was detected in the 
remaining cell lines, HEK or TFK104. There was also no evidence for 
rearrangements of 11 q13. The ets1 transcription factor gene is located on 
chromosome 11, band q23, the dosage of which was analysed with the aim to 
look for chromosomal duplication or aneuploidy. The observed constant gene 
dosage of c-ets1 indicated that the CCND1 amplification did not extend to 
11q23. Densitometric analysis was used to quantitate the degree of CCND1 
amplification, the extent of which was based on the ratio of CCND1 to c-ets1 
(Table 5). From the data it is evident that the frequency of CCND1 
amplifications in the examined BICR cell lines (48%) corresponds better to the 
figures previously reported for tumour samples rather than established cell 
lines.
4.3 CCND1 mRNA expression.
Cyclin D1 mRNA species of 4.4-4.8kb and 1.7kb have previously been 
reported in cells of human origin (Xiong et al 1991, Motokura et al 1991,
Withers e ta l 1991). The predominating larger transcripts were shown to 
contain the full-size message, while loss of the 3' non-coding sequences 
resulted in shorter species. Both small and large CCND1 mRNAs were found to 
contain a full length protein coding region (Xiong et al 1991, Withers e ta l 1991, 
Seto e ta l 1992). In cells harbouring rearrangements of chromosome 11q13,
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other CCND1 transcripts were detected all of which showed loss of 3' 
sequences, while the 5* regions remained intact. A 2.5kb cyclin D1 mRNA was 
reported in a chronic lymphocytic leukaemia (CLL) cell line (MO2058), while 
3.4kb and 2.6kb species were observed in a B-cell lymphoma cell line (SP-49). 
Both cell lines were characterised by the t(11 ;14)(q13;q32) translocation 
(Withers efa/1991, Seto e ta l 1992). Alternative splicing and differential 
polyadenilation were the two mechanisms suggested to cause the presence of 
CCND1 mRNA species of diverse lengths (Xiong et a! 1991, Motokura et al 
1991, Withers et al 1991).
Northern blot analysis was used to examine the CCND1 mRNA in the 
BICR, MS-2 and control cell lines (as described in section 2.2.3.h). A larger 
4.5kb transcript was predominant in all of the tested cell lines, while the 1.7kb 
specie was evident only in cases of mRNA over-expression (Figure 7). 
Transcripts were barely detectable in the HEK and TFK104 cells, which served 
as an indication of how low keratinocyte CCND1 mRNA baseline expression 
levels actually are. Interestingly, two additional mRNA species of 4.0 and 3.5kb 
were also observed in MS-2 and all of the BICR cell lines, while in HEK, 
TFK104 and A431 cells these bands were absent (Figure 7). Southern blot 
analysis had shown the lack of chromosome rearrangements in the new cell 
lines, suggesting that this had not been the cause of divergent transcripts. To 
minimise growth selection the BICR and MS-2 cell lines were cultured on 
lethally irradiated mouse feeder cells (x3T3). Murine macrophage cells were 
previously reported to contain Cyl-1 mRNA species of 4.5 and 3.8kb in size 
(Matsushime e ta l 1991), however northern blot analysis of the Swiss 3T3 cells 
revealed high levels of 4.0 and 3.5kb Cyl-1 transcripts, which corresponded to 
the additional species observed in the BICR and MS-2 cell lines. The extensive
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levels of Cyl-1 mRNA expression observed in the Swiss 3T3 fibroblasts would 
suggest that the presence of only a few contaminating cells was sufficient for 
transcript detection on the northern blots, therefore despite the effort made to 
remove most of the x3T3 cells from the cell line cultures, it was concluded that 
the most likely source of the 4.0 and 3.5kb cyclin D1 transcripts were the 
murine feeder cells. To determine the level of feeder contamination in the BICR 
and MS-2 RNA extracts, decreasing amounts of x3T3 total cellular RNA were 
subjected to northern blot analysis and probed with cyclin D1 cDNA or GAPDH, 
demonstrating that Cyl-1 mRNA was detectable in 5pg of x3T3 RNA (Figure 8). 
Densitometric analysis of the signals allowed an estimation of feeder 
contamination in the human cell extracts and subsequent correction for CCND1 
expression levels.
In previous reports levels of GAPDH expression were used as a control 
for equal RNA loading in northern blot analysis (Lammie e ta l 1991, Schuuring 
e ta l 1992a). In this study differential expression of the GAPDH gene was 
evident in most of the examined cell lines, rendering the use of this probe as a 
control in northern blot analysis unsatisfactory. For these reasons ribosomal 
28S and 18S RNA or actin probes were used to determine the loading of 
extracted cellular RNA, supported by the ethidium bromide (EtBr) staining of 
the gel (Figure 7). After correction for x3T3 contamination, the ratio of the 
human 4.5kb transcript to 18S RNA was used as an estimate of CCND1 
expression levels in the examined cell lines. The figures were determined as 
an average of several northern blots. Greatest CCND1 over-expression was 
evident in cell lines BICR6, BICR18 and BICR22, which was lower in BICR3, 
BICR10, BICR16 and BICR19, while MS-2 consistently had "normar CCND1 
mRNA levels, similar to those observed for HEK cells (Table 5). Although the
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Figure 6. CCND1 gene dosage in the examined SCC cell 
lines.
20pg of BamH1 restriction endonuclease digested genomic DNA from primary 
keratinocytes, TFK104, BICR3, BICR6, BICR10, BICR16, BICR18, BICR19, 
BICR22, MS-2, A431 and SB (a pre B-cell leukaemia) cell lines were 
electrophoresed through a 0.8% agarose gel, blotted and probed with a 1.3kb 
fragment of Cyl-1 cDNA (as described in materials and methods). Arrows point 
to the 12kb, 4kb, and 1.75kb bands specific to the human CCND1 gene (the 
two bands marked 3T3 were of x3T3 origine). The membrane was stripped 
from radioactivity and reprobed with a 810bp fragment of human ets-1 cDNA 
as a control of equal loading. Amplification was observed in cell lines BICR6, 
BICR18, BICR22 and A431.
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Figure 7. CCND1 mRNA expression varies between the 
examined SCC cell lines.
20|xg of total RNA from TFK104, BICR3, BICR6, BICR10, BICR16, BICR18, 
BICR19, BICR22, MS-2, A431, primary keratinocytes and 3T3 cell lines were 
electrophoresed through a 0.8% acrylamide gel containing formaldehyde and 
probed with a 1.3kb fragment of Cyl-1 cDNA. Arrows point to the 4.5kb and 
1.7kb human CCND1 mRNA specific species and the 4.0kb murine Cyl-1 
specific transcript. The membrane was stripped from radioactivity and reprobed 
with a 1.36kb fragment of human skeletal muscle actin and a 7kb fragment 
specific to 28S RNA as a control for RNA loading and transfer (as described in 
materials and methods). Ethidium bromide staining of the agarose gel was also 
used as control for RNA loading.
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Figure 8. Concentration gradient analysis of Cyl-1 
expression in x3T3 cells.
Decreasing amounts of total RNA from x3T3 cells (20|ig-0.5pg) were 
electrophoresed through a 0.8% agarose gel containing formaldehyde, blotted 
and probed with a 1.3kb fragment of Cyl-1 cDNA (as described in materials 
and methods). Arrows point to the 4.0kb and 3.5kb murine specific Cyl-1 
mRNA species. The membrane was stripped from radioactivity and reprobed 
with a 0.7kb GAPDH probe as a control for RNA loading (as described in 
materials and methods).
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Figure 8.
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presence of x3T3 RNA complicated quantitation, from the data it was evident 
that the cell lines that had amplified the CCDN1 gene exhibited the greatest 
degree of CCND1 mRNA expression, however increased gene dosage was not 
the only means for over-expression, as elevated transcripts were also detected 
in cells that did not display CCND1 amplifications.
In an attempt to overcome the species cross-reactivity problem, a 
human specific probe was isolated. Previous reports have revealed a greater 
than 90% identity of the CCND1 and Cyl-1 cDNAs (Xiong et al 1991, 
Matsushime et a /1991). Comparison of human and mouse cyclin D1 mRNA 
sequences revealed extensive homology in the 5' protein coding regions and 
divergence at the 3' ends of full length transcripts (Matsushime eta ! 1991, 
Xiong et al 1991, Withers et al 1991, Motokura et al 1991). For these reasons 
five short fragments (200-380bp in length) were isolated by PCR techniques 
from the 3' non-coding regions of the human CCND1 cDNA. The amplified 
regions were subsequently cloned, sequenced and tested for human specificity 
by northern blot analysis. One fragment (termed 3,4) was used for the 
determination of CCND1 mRNA expression levels in the examined tumour and 
control cells (Figure 9). From the northern blot analysis of total RNA extracts, 
the most extensive over-expression of CCND1 transcripts was evident in 
BICR6, while BICR18 and BICR22 also had elevated expression of cyclin D1 in 
comparison to HEK and TFK104 cells, which was in agreement with previous 
results. The ratio of the human 4.5kb transcript to 7S RNA was used as an 
estimate of CCND1 expression levels in all the examined cell lines (Figure 10, 
Table 5).
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4.4 Expression of p34cycD1.
The predicted molecular masses of mouse and human cyclin D1 
proteins based on cDNA sequences, were estimated to be 33.4k and 33.7k, 
respectively (Matsushime et al 1991, Xiong et al 1991, Motokura et al 1991). 
Both species were shown to migrate on denaturing SDS-polyacrylamide gels at 
approximately 34kD, relative to molecular weight standards. However, in 
several studies the cyclin D1 protein is referred to as p36 or p35 due to its 
slower migration than that of p34cc*c2 (Matsushime et al 1991, Xiong et al 
1992b, Quelle et a /1993, Baldin e ta l 1993). The human and mouse 
counterparts show a high degree of identity, react specifically with the same 
antibodies and are considered functionally interchangeable (Matsushime e ta l 
1991, Withers e ta l 1991, Dr Gordon Peters, ICRF, London, England, personal 
communication).
To date no reports have analysed the expression levels of CCND1 
protein (in this study referred to as p34°ycD1) in human tumours. Western blot 
analysis with a polyclonal antibody, 287-3 (a kind gift from Dr Gordon Peters, 
ICRF, London, England), raised against the C-peptide of the mouse Cyl-1 
protein (p34cy,_1) was used to analyse p34cYcD1 expression in the various cell 
lines (Figure 11). Due to the species cross-reactivity of the antibody it was 
necessary to determine the degree of x3T3 contribution to the p34 band 
observed in the western blots. Fortunately, a fibroblast cell type specific protein 
of approximately 100kD was recognised by antibody 287-3 and was present at 
higher levels than p34cy,"1 in murine fibroblast extracts. The ratio of ~100kD to 
p34cyl-1 protein bands was determined by densitometric analysis of a western 
blot with varying amounts of feeder cell extracts (Figure 12). This ratio was 
used to correct for the contribution of x3T3 cells to the observed level of
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Figure 9. DNA sequencing of a PCR amplified fragment 
from the 3' non-coding region of CCND1 mRNA.
A 320bp fragment of the 3' non-coding region of CCND1 mRNA was amplified 
using the technique of PCR, subcloned and sequenced as described in 
materials and methods. The diagrammatic representation highlights the 
amplified region within the full length CCND1 transcript.
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Figure 10. CCND1 mRNA expression in the examined SCC 
cell lines.
20pg of total RNA from primary keratinocytes, TFK104, BICR3, BICR6,
BICR10, BICR16, BICR18, BICR19, BICR22, MS-2, A431 and T45 cell lines 
were electrophoresed through 0.8% agarose gel containing formaldehyde, 
blotted and probed with a CCND1 4.5kb mRNA-specific 320bp fragment (as 
described in materials and methods). The membrane was stripped from 
radioactivity and reprobed with a 0.6kb fragment homologous to 7S rRNA as a 
control for equal RNA loading and transfer.
130
Figure 10.
Northern : CCND1
*
LD
X
S O CO 00 O) CM CO CO T- ^  -t- CM^t rcrcrccarcrcncM
g y o o o y o o c / j
i ~ c o c o m m c o m c o 5
CO in 
<  h-
m
Figure 11. p34cycD1 expression in the examined SCC cell 
lines.
Protein extracts were prepared from primary keratinocytes, TFK104, BICR3, 
BICR6, BICR10, BICR16, BICR18, BICR19, BICR22, MS-2 and A431 cell lines 
and TFK104. 35|ig of extracts were electrophoresed through a 10% denaturing 
polyacrylamide gel and blotted, as described in materials and methods. A 
rabbit polyclonal antibody (287-3) was used at a 1:500 dilution to analyse for 
the expression levels of p34cy°D1. Arrows point to a murine specific ~100kD 
peptide and the cyclin D1 specific 34kD protein.
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Figure 12.The expression of p34cyl-1 and an unknown 
~100kD peptide in x3T3 cells.
Varying amounts of protein extracted from x3T3 cells (35-1 pg) and 35pg of 
protein isolated from the BICR6 cell line were electrophoresed through a 10% 
denaturing polyacrylamide gel and further subjected to western blot analysis as 
described in materials and methods. The intensities of the ~100kD and 34kD 
proteins, determined and compared by densitometric analysis, are 
diagramatically represented.
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Table 5. CCND1 gene dosage, mRNA and protein 
expression levels in the SCC cell lines.
Figures represent the levels of CCND1 amplification, transcript and protein 
expression in the examined cell lines, when compared to human foreskin 
primary keratinocytes. 
h.s. = human specific
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p34cycD1 in the western blots of tumour cell lines. Corrections were necessary 
only in cases where the murine specific ~100kD band was detectable. The 
greatest over-expression of p34cy°D1 was evident in BICR6, BICR18 and 
BICR19, increased expression was also present in BICR10, BICR16, BICR22, 
A431 and MS-2, while BICR3 appeared to have equal or lower levels of 
p34cy°D1 than that observed in HEK and TFK104 cells (Table 5).
The western blot analysis was repeated using a different cell lysis buffer 
and p34°ycD1 specific antibodies as a means to test for the exactness of the 
obtained data. The alternative lysis method used was recommended by Xiong 
et al 1992b and revealed similar results to those previously observed. 
Unsuccessful attempts were made to use a monoclonal antibody raised against 
the human p34cycD1 peptide (kindly provided by Dr Ed Harlow, Massachusetts 
General Hospital, Boston, USA), while a commercially available polyclonal 
antibody did yeald results although also exhibited a high degree of protein 
cross-reactivity.
In summary, parallel with the data obtained for CCND1 mRNA levels, 
tumour cell lines with the highest CCND1 gene dosage also revealed increased 
amounts of the protein product, however amplification was not a prerequisite 
for over-expression as exemplified by BICR19 cells.
4.5 Nuclear localisation of p34cYcD1.
Previous reports have revealed the subcellular localisation of cyclins A, 
B1 and B2 in human primary fibroblasts, HeLa cells and chick embryo 
fibroblasts (Pines and Hunter 1991, Gallant and Nigg 1992). 
Immunofluorescence analysis with the use of appropriate antibodies had 
revealed a predominantly nuclear localisation of cyclin A from S phase
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onwards, while the B cyclins accumulated in the cytoplasm of interphase cells, 
only entering the nucleus at the beginning of mitosis. Assynchronously growing 
tumour and normal cell lines were examined in this study with the aim to 
determine the subcellular distribution of p34°ycD1. Immunocytochemical 
detection of p34cycD1 in methanol/acetone fixed cells with the antibody 287-3, 
revealed predominantly nuclear localisation of the protein (Figure 13). The 
variation in intensity of staining observed within individual cell lines was 
attributed to their passage through the cell cycle, with the most intensely 
stained cells residing in late G1 (supporting data is described in chapters 5 and 
6). Recent reports have confirmed these observations in normal diploid human 
fibroblasts by the techniques of indirect immunofluorescence and the use of 
polyclonal anti-cyclin D1 antibodies (Baldin efa/1993).
The expression and subcellular localisation of p34cy°D1 was also 
examined in original tumour biopsies (BICR3, BICR6 and BICR18), biopsies of 
xenograft tumours (BICR10, BICR16, BICR19, BICR22 and MS-2) and normal 
human skin (Figure 14). Immunohistochemical analysis revealed similar levels 
and patterns of staining as were observed in the established cell lines. No 
obvious staining was seen in normal skin and MS-2 xenografts, presumably 
due to the undetectable basal levels of expression. The results obtained from 
western blots had suggested a higher level of p34cy°D1 in BICR19 than what 
was observed in immunological analysis of both cell line and tumour 
xenografts. This phenomenon was attributed to reduced permeability and/or 
epitope masking of p34cy°D1 in BICR19. To test this hypothesis, 
immunocytochemical analysis was repeated on cells fixed in paraformaldehyde 
and with the use of an alternative antibody. Unfortunately in both cases the
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Figure 13. p34°ycD1 localises primarily in the nucleus.
Assynchronously growing cells were fixed in a methanol:acetone solution and 
subjected to immunocytochemical analysis for p34cy°D1 with the use of an 
anti-cyclin D1 rabbit polyclonal antibody, 287-3 (as described in materials and 
methods). The analysed cell lines are depicted by letters : HEK (a,b); TFK104 
(c,d), BICR3 (e.f), BICR6 (g,h), BICR10 (i,j), BICR16 (k,l), BICR18 (m,n), 
BICR19 (o,p), BICR22 (q.r), MS-2 (s,t) and A431 (u,v). In a, c, e, g, i, k, m, o, 
q, s and u pre-immune rabbit serum was at a 1:3000 dilution, as a control for 
nonspecific binding. In b, d, f, h, j, I, n, p, r, t and v antibody 287-3 was used 
at a 1:3000 dilution to detect p34cy°D1. Arrows point out strongly positive cells 
for p34cy°D1.
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Figure 14. Nuclear localisation of p34cycD1 jn tumour 
xenografts and original biopsies.
Immunohistochemical analysis using the 287-3 antibody was carried out on 
tumour sections fixed in a methanol:acetone solution as described in materials 
and methods, a) original biopsies of normal skin (a,b), BICR3 (c,d), BICR6 (e,f) 
and BICR18 (g,h) were incubated with pre-immune rabbit serum (a, c, e and g) 
to determine the extent of non-specific staining; levels of p34°ycD1 were 
undetectable in normal skin nevertheless clearly nuclear in the remaining 
sections (b, d, f and h). b) tumour xenografts BICR10 (i,j), BICR16 (k,l), 
BICR19 (m,n), BICR22 (o,p) and MS-2 (q,r) were incubated with pre-immune 
serum (i, k, m, o and q) or anti-cyclin D1 antibody (j, I, n, p and r). Arrows 
point out strongly positive cells for p34cy°D1.
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antibodies were unable to detect p34cYc^ 1 even in highly expressing cell lines 
such as BICR6, potentially due to epitope distruction.
4.6 cdk4 and pRb protein expression levels in the tumour cell lines.
The recently detected interactions between p34cYcD1 and cdk4 and the 
potential action of this complex or of p34cy°D1 alone on pRb initiated the 
examination of cdk4 and pRb levels in the BICR and MS-2 cell lines (Xiong et 
al 1992b, Matsushime efa/1992, Kato e ta l 1993, Dowdy eta ! 1993).
Detection of the two proteins was achieved by western blot analysis of extracts 
from assynchronously growing cells and the use of a mouse monoclonal or 
rabbit polyclonal antibody raised against pRb orcdk4 peptides, respectively 
(both antibodies were a generous gift from Dr Li Huei Tsai, Massachusetts 
General Hospital, Boston, USA). cdk4 protein levels did not significantly vary 
between the tumour cell lines, confirming the suggestions of specific post- 
translational regulations of cdk4 activity by cyclin D1 or other cyclins (Figure 
15). However, with the exception of MS-2, levels of apparently wild type pRb 
exhibited an increase in most of the tumour cell lines, of which BICR6, BICR18 
and BICR22 were most dramatic (Figure 16). Upregulated pRb expression is a 
phenomenon that has not yet been reported in literature, in this study the levels 
correlated well with CCND1 amplification and expression status. The absence 
of detectable pRb in the HPV-16 positive cell line (MS-2) was not thought to be 
due to the viral oncoprotein E7, but to independently occurring mutations in the 
Rb gene.
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Figure 15. cdk4 expression in the SCC cell lines.
40jig of protein extracted from TFK104, BICR3, BICR6, BICR10, BICR16, 
BICR18, BICR19, BICR22, MS-2 and A431 cell lines were subjected to western 
blot analysis, as described in materials and methods. A 1:1000 dilution of an 
anti-cdk4 rabbit polyclonal antibody was used for the detection of cdk4 
expression levels. Arrows specify the cdk4 protein and an unknown ~43kD 
peptide.
139
Figure 15.
Western : cdk4
O  CD 00 O) CM 
O c O C D r - i - T - i - C M  
T Z C C C C C C e C C C C L C C W ' r -
h c q g q c o c o c o c q c o ^ E c
43kD >
cdk4 >
Figure 16. pRb expression is upregulated in cells 
containing CCND1 amplification.
45pg of protein extracts from TFK104, BICR3, BICR6, BICR10, BICR16, 
BICR18, BICR19, BICR22, MS-2 and A431 were subjected to western blot 
analysis as described in materials and methods. An anti-pRb monoclonal 
antibody (XZ77) was used at a 1:10 dilution to detect the expression levels and 
different pRb phosphorylation forms present in the examined cell lines.
In this experiment the levels of pRb in the SCC cell lines were compared to 
those seen in TFK104 cells which were used as a normal control.
Subsequent studies carried out by Angeliki Malliri (Beatson Institute), showed 
equivalent expression levels of pRb in human foreskin primary keratinocytes 
and TFK104 cells, suggesting that the over-expression of pRb observed in 
some of the BICR cell lines was real.
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4.7 Discussion.
The previously reported levels of CCND1 gene dosage in HNSCC cell 
lines have not been obtained from comparisons with primary keratinocytes but 
with other cell lines or unrelated tissues (Lammie et al 1991, Schuuring et al 
1992a). In the most extreme case cell line UMSCC1, judged to be normal in 
one report (Lammie et al 1991) was subsequently shown to exhibit a low level 
of CCND1 amplification and over-expression (Schuuring et al 1992a). For 
these reasons especial care was taken in this study to include human primary 
keratinocytes and an HPV-16 E6, E 7 immortalised, non-transformed 
keratinocyte cell line (TFK104), in this way determining the CCND1 gene 
dosage in normal and "near-to-normal" squamous epithelial cells. In several 
previous reports A431, a vulvar carcinoma cell line, was demonstrated to 
contain a two-fold amplification of CCND1 and was therefore included in this 
study for comparative purposes (Lammie et al 1991, Withers et al 1991, 
Schuuring et al 1992a, Faust and Meeker 1992, Jiang et a /1992). Upon 
examination of the BICR and MS-2 cell lines, only three (BICR6, BICR18 and 
BICR22) revealed increased CCND1 gene dosage, corresponding well to the 
frequency of CCND1 amplifications previously observed in tumour samples 
rather than established cell lines (Lammie et a /1991, Schuuring et al 1992a). 
The degree of amplification in the cell lines ranged from tree- to twelve-fold 
relative to primary keratinocytes and the gene dosage of c-ets1, representing 
the highest range of amplification when compared to previous studies (Lammie 
et al 1991, Schuuring et al 1992b, Faust and Meeker 1992, Jiang et al 1992).
It is becoming evident that CCND1 fulfils the prerequisites for the key 
gene of the chromosome 11 q13 amplicon by revealing transcript over­
expression in cells that have increased gene dosage (Lammie e ta ! 1991,
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Schuuring et al 1992b, Faust and Meeker 1992). In one report a parallel was 
drawn between the levels of CCND1 gene amplification and mRNA 
upregulation observed in cell lines derived from breast and HNSCCs 
(Schuuring et al 1992a). In this study over-expression of CCND1 was observed 
in all three cell lines that had amplified the gene, confirming the potential "key" 
status of CCND1 within chromosome 11q13. However, increased transcript 
levels were not only caused by amplification, demonstrated by cell lines BICR3, 
BICR10, BICR16 and BICR19, coupled with previous reports (Schuuring e ta l 
1992a). Again the levels of cyclin D1 mRNA expression were compared with 
human foreskin primary keratinocytes, a measure not used in previous studies, 
while more appropriate probes than differentially expressed GAPDH were used 
as a determinant of RNA loading.
To date there have been no reports on the CCND1 protein levels in 
human tumours. As with the mRNA, this study revealed a good correlation 
between the degree of amplification and expression of p34°ycD1, although 
examples such as BICR19 indicate that upregulation of protein levels can take 
place in the absence of increased gene dosage. Furthermore, p34cy°D1 
predominantly localised in the nuclei of examined cells with no apparent 
differences in the frequency of positively staining tumour derived and "normal" 
cells. The pattern of subcellular p34°ycD1 distribution observed in the cell lines 
was mimicked in the tumour biopsy specimens whether they originated from 
the primary samples or xenografts. With the exception of MS-2, most tumour 
biopsies exhibited elevated levels of p34°ycD1 in comparison to normal skin, 
possibly reflecting the low rate of proliferation in the basal layers of skin. The 
observed predominant nuclear localisation of p34cycD1, regardless of the
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degree of transformation, is consistent with its role as a cell cycle regulator and 
effector or target of other nuclear regulatory proteins.
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CHAPTER 5 : Cyclin D1 oscillations during the fibroblast 
cell cycle.
5.1 Introduction.
The pattern of cyclin D1 mRNA appearance following release of 
arrested cells was initially described in CSF-starved mouse macrophages and 
subsequently shown in human fibroblast cell lines (Matsushime et al 1991, 
Surmacz et al 1992, Won et al 1992, Baldin et al 1993). In all of the examined 
cases cyclin D1 mRNA levels peaked in late G1, suggesting a role for the 
protein during this stage of the cell cycle (see chapter 6. for further details). To 
date, very little work has been carried out on the protein product of the cyclin 
D1 gene and its oscillation patterns in different cell types (Matsushime e ta l 
1991, Baldin e ta l 1993). Only one recent report has addressed the question of 
p34°ycD1 levels and subcellular localisation following stimulation of human 
diploid fibroblasts, the results of which confirmed the observations made in this 
study (Baldin e ta l 1993).
The advantage of using fibroblast cell lines in cell cycle analysis is their 
ability to respond to serum starvation by arresting in GO. In all the examined 
cases subsequent serum stimulation resulted in Cyl-1 mRNA and protein 
upregulation at the expected stages of G1. The study was extended to 
examine c-fos and v-fos over-expressing cell lines with varying degrees of 
transformation, aiming to determine whether Cyl-1 expression is dependent on 
fos levels and/or the activity of the AP-1 transcriptional factor (Hawker e ta l 
1993).
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5.2 Cyl-1 mRNA levels in quiescent and growing rodent fibroblasts.
To obtain GO synchrony, the analysed rodent fibroblast cell lines were 
cultured in conditions of reduced serum (0.5% FBS) for a period of 72 hours, a 
method used for achieving cell cycle arrest in several previous reports (Won et 
a! 1992, Surmacz e ta l 1992, Baldin e ta l 1993). Extracts of total RNA obtained 
from assynchronously growing and GO arrested cells were examined by 
northern blot analysis for Cyl-1 transcript expression, as described in section 
2.2.3.h. Figure 17 represents the comparison of four murine 3T3 cell lines 
(Balb3T3, Swiss3T3, NIH3T3 and T45) of which T45 are Swiss3T3 cells that 
had received and survived high doses of irradiation, thought to approximate 
60Gy. In all four cases a reduction in the levels of both murine specific Cyl-1 
transcripts (4.0 and 3.5kb) were observed in quiescent cells. Arrested Balb3T3 
fibroblasts exhibited a greatest decline (9-fold) of Cyl-1 mRNA expression, 
determined by densitometric analysis, while this decrease was less evident in 
T45 cells.
The same type of analysis was repeated for six rat fibroblast cell lines, 
the characteristics of which are described in Table 6. Again, comparison of 
growing and arrested cells revealed a clear correlation of Cyl-1 mRNA levels 
and the state of cell growth (Figure 18). Detection of 28S or 7S ribosomal RNA 
levels were used as determinants of RNA loading and transfer for rat and 
murine cell line extracts, respectively. Densitometric analysis allowed 
calculation of the ratio of rodent 4.0kb Cyl-1 mRNA to 28S or 7S RNA in the 
appropriate cell lines and subsequently the expression levels of Cyl-1 
transcripts, presented in Table 6.
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5.3 p34cyl-1 expression in arrested and growing fibroblasts.
Western blot analysis was used to determine the levels of Cyl-1 protein 
in quiescent and assynchronously growing murine and rat fibroblast cell lines 
described in the previous section. Total protein cell extracts were 
electrophoresed through denaturing 10% SDS-polyacrylamide gels, transferred 
to a membrane and subsequently exposed to antibody 287-3 for the detection 
of p34cy,"1 (see section 2.2.4.C). Upon examination, the murine fibroblast cell 
lines revealed significantly reduced p34cY^1 expression in arrested cells, a 
similar pattern to the one observed for the cyclin D1 transcripts. Balb3T3 cells 
responded to serum starvation with the greatest decrease of p34°yl'1 levels (6- 
fold), determined by densitometric analysis. T45 cells had upregulated 
expression of this cyclin in comparison to parental Swiss3T3 fibroblasts, 
suggesting an irradiation induced effect (Figure 19). Subsequent examination 
of 208F, MMV, A1C, FBR, Rat-1 and 1302 cell lines did not reveal such 
dramatic down-regulation of p34cy,~1 during GO. Perplexingly, expression of 
this cyclin decreased (MMV, FBR), remained unaltered (208F, A1C, 1302), or 
even fractionally increased three fold (Rat-1) in arrested cells, potentially 
reflecting their ability to quiesce (Figure 20).
MMV and FBR fibroblasts contain the highest levels of fos expression, 
although only the later were transformed, in both cases down-regulation of 
p34cyl-1 was evident in GO, however, the cell line A1C an intermediate 
between MMV and FBR cells in the degree of transformation, expressed 
elevated levels of p34°yl"1 and lacked the ability to down-regulate this cyclin. 
Therefore, attempts to correlate fos expression levels or induced 
transformation with the loss of p34°yl“1 down-regulation were unsuccessful. 
Table 6 represents comparison of p34cyl-1 expression levels in the examined
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Figure 17. Cyl-1 mRNA expression is downregulated in 
quiescent murine fibroblasts.
20pg of total RNA were obtained from assynchronously growing or GO arrested 
murine fibroblast cell lines Balb3T3, Swiss3T3, NIH3T3 and T45 and subjected 
to northern blot analysis for Cyl-1 mRNA expression using a [32P]dCTP- 
labelled 1.3kb fragment of the Cyl-1 cDNA (as described in materials and 
methods). Rehybridisation of the membrane with a 7S homologous probe was 
used as a control for equal RNA loading and transfer.
Q = GO arrested cells.
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Figure 18. Cyl-1 mRNA is downregulated in quiescent rat 
fibroblast.
20pg of total RNA were extracted from GO arrested and assynchronously 
growing rat fibroblast cell lines 208F, MMV, A1C, FBR, Rati and 1302, blotted 
and probed with a 1.3kb Cyl-1 cDNA fragment. The blot was stripped from 
radioactivity and reprobed with a 28S rRNA homologous fragment as a control 
for equal loading.
Q = GO arrested cells.
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Figure 18.
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Figure 19. p34cyl-1 expression is reduced in quiescent 
murine fibroblasts.
35pg of protein were extracted from assynchronously growing and GO arrested 
Swiss 3T3, Balb3T3, NIH3T3 and T45 cell lines and subjected to western blot 
analysis, as described in materials and methods. Arrows point to the p34cy1-1 
protein doublet and the fibroblast specific ~100kD band.
Q = GO arrested cells.
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Figure 19.
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Figure 20. p34cyl-1 expression in quiescent and growing 
rat fibroblast cell lines.
p34cyH expression in assynchronously growing and GO arrested 208F, MMV, 
A1C, FBR, Rati and 1302 rat fibroblast cell lines were compared to murine 
NIH3T3 fibroblasts. 35pg of protein extracts were subjected to western blot 
analysis using the 287-3 anti-cyclin D1 polyclonal antibody. p34cyl_1 and the 
~100kD peptide are labelled with arrows.
Q = GO arrested cells.
The degree of GO arrest was based on the results obtained from separate 
experiments (see Figures 23 to 27) therefore full cell cycle synchrony may not 
have been obtained.
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Table 6. Comparison of Cyl-1 mRNA and protein 
expression levels in GO arrested and assynchronously 
growing rodent fibroblast cell lines.
Gr = assynchronously growing cells 
Q = GO arrested cells.
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Table 6
cell lines origin
Cyl-1
mRNA Gr/Q 
expression
cyl-1 
p34 Gr/Q
expression
208F rat fibroblast cell line 3 1
MMV
c-fos
over-expressing 
208F cells
1 3
A1C
FBJ
infected 
208F cells
2 1.5
FBR
FBR 
infected 
208F cells
2 4
Rati
rat fibroblast 
cell line 1 0.4
1302
FBJ
infected 
Rati cells
3 1
NIH3T3
murine 
fibroblast 
cell line
4 2
Balb3T3
murine 
fibroblast 
cell line
9 6
Swiss3T3
murine 
fibroblast 
cell line
4 4
T45
irradiated
Swiss3T3
cells
1 1.5
Figure 21. cdk4 levels do not oscillate with the cell cycle.
35|ig of protein extracts from assynchronously growing and GO arrested Swiss 
3T3, Balb3T3, NIH3T3 and T45 murine fibroblasts were subjected to western 
blot analysis as described in materials and methods. cdk4 was detected with 
the use of a 1:1000 dilution of an anti-cdk4 rabbit polyclonal antibody.
Q = GO arrested cells.
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Figure 21.
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Figure 22. cdk4 expression levels in quiescent and 
growing rat fibroblast ceil lines.
cdk4 expression levels in GO arrested and assynchronously growing 208F, 
MMV, A1C, FBR, Rati and 1302 cell lines were compared to the expression 
levels observed in NIH3T3 murine fibroblasts. 35pg of protein extracts were 
electrophoresed through a 10% denaturing polyacrylamide gel, blotted and 
subjected to cdk4 western blot analysis as described in materials and methods. 
The position of the cdk4 protein is shown.
Q = GO arrested cells.
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Figure 22.
W estern : cdk4
0
LL LL
00 00 O O 
C\J CM
0
> 0o  o  DC OC 
t— ■»— CD OQ 
<  <  LL LL
0 
CO CO
0  h- H
CO CO 
X  X
cdk4 >
0
0  O CO CO h  h
^ t- c m <m l l l l c o c o
■ y + i O O C O O O I I
^ C O C O O O - -
D C O C i- t- w o j Z Z
cdk4 >
assynchronously growing and GO arrested fibroblast populations, determined 
by densitometric analysis.
Subsequent western blot analysis of the same cell extracts for cdk4 
expression, revealed no differences between growing and arrested cells 
(Figure 21 and Figure 22). Interestingly, in comparison to parental 208F 
fibroblasts, cdk4 expression was upregulated two fold in v-fos transformed cell 
lines A1C and FBR, however the same was not true for 1302 and Rat-1 cells 
(Figure 22). The eight to ten fold higher levels of detectable cdk4 in the murine 
cell lines was proposed to result from differences in the basal expression 
levels, or more probably due to increased antibody affinity for mouse 
sequences.
NIH3T3 cell extracts were included in all the western blots, allowing 
densitometric analysis and the comparison of p34cyl_1 and cdk4 expression 
levels in the examined cell lines.
5.4 p34cyl-1 levels oscillate with the fibroblast cell cycle.
The subcellular distribution and oscillation patterns of the cyclin D1 
protein were examined in both murine and rat fibroblast cell lines with the use 
of western blot and immunocytochemical analyses (as described in sections 
2.2.4.C and 2.2.4.d-2). Representative cell lines (208F, FBR, NIH3T3, Rati and 
T45) were synchronised to GO by serum starvation (as described in section 
2.2.1.b) and were subsequently released following exposure to 10% FBS. The 
degree of cell synchrony was assessed by 5-bromodeoxyuridine (BrdU) 
incorporation over a 24 hour period, revealing on average less than 5% of 
growing cells in the arrested populations. Initiation of DNA synthesis took place 
at approximately 12 hours post-stimulation, with the exception of NIH3T3
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fibroblasts that exhibited a 2-4 hour delayed entry into the S phase. At 24 hours 
from exposure to serum more than 80% of the cells were synthesising DNA 
(Figures 23, 24, 25 and 26).
Antibody 287-3 was used to detect p34cy,_1 in methanol/acetone fixed 
cells (Figures 23, 24, 25, 26 and 27) or by western blot analysis (Figure 28) of 
cell extracts derived at set time intervals from stimulation. p34cyl"1 was evident 
in the nuclei of Balb3T3, T45, 208F and FBR cell lines 4 hours post-stimulation, 
peaking during the 8-12 hour interval and subsequently declining at 24 hours 
(Figures 24, 25, 26 and 27). The previously determined cell cycle delay of 
NIH3T3 fibroblasts was also evident in p34cy l'1 expression, in this case 
maximum levels were observed at 12-16 hours following release from GO 
(Figure 23). In T45 cells the analysis was extended to 56 hours from exposure 
to serum, during which period cells were postulated to have re-entered 
subsequent cell cycles and loss of synchrony was observed (Figure 27). In all 
the examined time points the dramatic decline of detectable p34cyl“1 observed 
in GO was not repeated, suggesting that cycling cells retain basal levels of the 
CCND1 protein throughout proliferation.
5.5 Discussion.
Prior reports have suggested minimum oscillations of Cyl-1 mRNA levels 
throughout the mouse macrophage or mammalian fibroblast cell cycles, in one 
case drawing a parallel with the behaviour of CLN3 transcripts that remain 
relatively constant throughout the S.cerevisiae cycle (Wittenberg et al 1990, 
Matsushime e ta l 1991, Won et al 1992, Surmacz et al 1992, Lew et al 1992). 
To date all reports have detected a reduction of cyclin D1 transcript levels in 
GO arrested cells, in agreement with observations made for rodent fibroblasts
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Figure 23. Immunocytochemical analysis of NIH3T3 
fibroblasts.
GO arrested NIH3T3 murine fibroblasts were stimulated with serum and at the 
same time half of the samples were exposed to 10pM BrdU. The cells were 
subsequently fixed in a methanol:acetone solution at set time points from 
stimulation (as described in materials and methods). Immunocytochemical 
analysis with an anti-BrdU mouse monoclonal antibody or an anti-cyclin D1 
antibody 287-3 was used to determine the timing of S phase and the 
expression levels and subcellular localisation of p34cy*_1, respectively. Minus 
signs represent negative controls in which the primary antibody was not 
included and in the case of p34°yl"1, pre-immune rabbit serum was used at the 
same (1:3000) dilution as antibody 287-3; -Br represents cells that did not 
contain incorporated BrdU and were exposed to the anti-BrdU antibody. 
Numbers specify hours from serum stimulation.
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Figure 24. Immunocytochemical analysis of 208F 
fibroblasts.
GO arrested cells were stimulated with serum and at the same time half of the 
samples exposed to 10pM BrdU. Cells fixed at set time intervals from 
stimulation were subjected to immunocytochemical analysis for BrdU 
incorporation and p34cyl_1 cell cycle dependent oscillation pattern and 
subcellular localisation, as described in materials and methods. Minus signs 
represent negative controls in which the primary antibody was not included and 
in the case of p34cyl"1, pre-immune rabbit serum was used at the same 
(1:3000) dilution as antibody 287-3; -Br represents cells that did not contain 
incorporated BrdU and were exposed to the anti-BrdU antibody. Numbers 
specify hours from serum stimulation.
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Figure 25. Immunocytochemical analysis of FBR 
fibroblasts.
GO arrested FBR rat fibroblasts were subjected to the experimental analysis 
described in Figures 23 and 24 and in materials and methods. Minus signs 
represent negative controls in which the primary antibody was not included and 
in the case of p34cY*'1, pre-immune rabbit serum was used at the same 
(1:3000) dilution as antibody 287-3; -Br represents cells that did not contain 
incorporated BrdU and were exposed to the anti-BrdU antibody. Numbers 
specify hours from serum stimulation.
158
Fi
gu
re
 
25
.
=>"O
CQ
•oc03
>>
HrCOQ.
CO
E0
JZoo
ooc
E
E
CO
1
5> •
»
•  •  *  *
u
•
CO
,  t
CM
CO
f
S i •  *  m 
*  • . » <
•  • •  5  
1  •  •  1
% M J
rt
*  *  ,
k #  . *
#  *
%  >
co
CM
t
W wk
w
CO a ® ®
CM 1  f l
•  J
|  •
•  •
*  #  •
O
H
dAr
♦  " *
O
•»
•
&  ♦
*  /
*>
< •
^  « T  .
?  •  A
1 1 CM CM
**"
♦
••4^ jy^  ^ A- •
GC
m
LL
3"Ok.00
>*u
I
3T>k-CO
Figure 26. Immunocytochemical analysis of Rati 
fibroblasts.
GO arrested Rati fibroblasts were subjected to the experimental analysis 
described in Figures 23 and 24 and in materials and methods. Minus signs 
represent negative controls in which the primary antibody was not included and 
in the case of p34cyl_1, pre-immune rabbit serum was used at the same 
(1:3000) dilution as antibody 287-3; -Br represents cells that did not contain 
incorporated BrdU and were exposed to the anti-BrdU antibody. Numbers 
specify hours from serum stimulation.
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Figure 27. Immunocytochemical analysis of T45 
fibroblasts.
GO arrested T45 murine fibroblasts were stimulated with serum and fixed in 
methanol:acetone at set time intervals from stimulation, depicted by numbers 
of hours (as described in materials and methods). Immunocytochemical 
analysis was carried out with a 1:3000 dilution of antibody 287-3. Minus sign 
represents the control sample for nonspecific binding, these cells were 
exposed to preimmune rabbit serum at a 1:3000 dilution.
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Figure 28. Cell cycle dependent oscillation pattern of 
p34cyl-1 in rat fibroblasts.
Western blot analysis for expression was carried out on protein
extracts derived from GO arrested and stimulated 208F (top) or FBR (bottom) 
rat fibroblast cell lines (as described in materials and methods). Numbers 
represent hours from serum stimulation when the extracts were obtained. 
Arrows specify the p34cyl_1 protein and the ~100kD fibroblast-specific 
polypeptide of unknown origin.
Figure 28.
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in this study. Unexpectedly, the same was not evident for p34cy|"1 expression 
in a portion of analysed rat fibroblasts in culture where similar levels of the 
cyclin protein were observed in growing and arrested cells. No correlations 
were found between cyclin D1 levels and the degree of fos expression or 
induced transformation in the fibroblast cell lines, suggesting that the lack of 
p34cy*"1 down-regulation in GO was due to the frequency of arrest in the 
examined populations. Subsequent analysis of cells at specific time points from 
serum stimulation confirmed previous observations in CSF-stimulated mouse 
macrophages, where metabolic labelling with [32P]orthophosphate or 
p 5S]methionine revealed that the level and overall phosphorylation of p34cyl'1 
(referred to as p s e ^ 1 in this report) increased before the G1/S transition phase 
and declined thereafter (Matsushime et al 1991).
The cellular substrates of the cyclin D1 protein remain unclear. To date 
most of the predicted targets such as pRb, p107, PCNA and p53 function in the 
nucleus (Morris and Mathews 1989, Bravo and Macdonald-Bravo 1985, 
Goodrich efa/1991, Hamel eta! 1992, Cobrinik e ta l 1992, Lane 1992). The 
exclusive nuclear localisation of p34cy|’ 1 at all stages of the cell cycle in 
fibroblast cell lines examined in this study and one previous report coupled with 
the observed peak in expression during late G1, supports the predicted 
functioning of cyclin D1 during the G1 to S transit (Baldin e ta l 1993). Further 
evidence for this proposal was obtained from interference with cyclin D1 
expression by microinjection of antisense plasmids or antibodies into serum 
stimulated fibroblasts emerging from quiescence (Baldin e ta l 1993). The 
reported cell cycle arrest following injections prior to or eight hours from serum 
stimulation and the lack of similar responses in cells injected sixteen hours 
post-stimulation, suggested that a critical cyclin D1-induced event(s) had taken
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place early to mid G1 and was essential for DNA synthesis, thus providing 
sound support for a specific G1 /S role of cyclin D1 (Baldin et al 1993).
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CHAPTER 6 : p34CYcD1 oscillations during the 
keratinocyte cell cycle.
6.1 Introduction.
To date there have been no reports of p34cyc^1 expression levels and 
oscillation patterns in normal or transformed keratinocyte cells. In humans 
amplification and subsequent over-expression of the CCND1 gene is linked 
predominantly to this cell type in head and neck, breast, lung, colon and 
oesophageal carcinomas (Lammie e ta l 1991, Faust and Meeker 1992, Jiang 
e ta l 1992, Schuuring e ta l 1992a, Buckley efa/1993, Leach e ta l 1993). Due 
to their inability to efficiently arrest in response to serum starvation, cell cycle 
analysis of SCC-derived cell lines is potentially problematic.
Under certain circumstances, a SCC cell line analysed in this study 
(SCC12-F) was able to slow down proliferation in response to low serum 
conditions for a sufficient time period to determine the oscillation pattern of 
p34cycD1. Further examination of cervical or HNSCC-derived cell lines, 
revealed different levels of serum requirement that could not be correlated with 
their tumourigenicity potential orTNM (tumour, node, metastasis staging) of 
the original biopsies.
6.2 The SCC12-F AC3 cells.
The SCC12-F cell line was derived from a facial SCC of a 60-year old 
male kidney transplant recipient who had been treated with immunosupressive 
agents for a period of seven years (Rheinwald and Green 1975). Upon 
establishment, the cell line was tested for growth properties, revealing a 
reduced dependence on fibroblast support and the ability to form colonies in
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semi-solid methylcellulose medium with an efficiency of approximately 0.02%. 
Injection of 3x106 cells into immunodeficient mice resulted in the formation of 
well differentiated cysts that did not progress during the life of the mouse 
(Rheinwald and Beckett 1981). Subsequent subcloning of cells was carried out 
to select for variants with the most similarities to primary keratinocytes leading 
to the derivation of cell line SCC12-F AC3, some properties of which were 
examined in this study (Dr Ken Parkinson, Beatson Institute, personal 
communication).
SCC12-F AC3 cells (subsequently referred to as SCC12) were cultured 
in the absence of x3T3 fibroblasts in 10% FBS containing growth media. 
However, upon trypsinisation and plating in low serum (0.5% FBS) an 
approximately 100 hour delay in growth was observed (Figure 29) that was 
subsequently overcome, suggesting a long-term low growth factor requirement 
of these cells for proliferation.
The temporary delay in cell cycle progression was used in this study as 
a means to obtain partial cell cycle synchrony. SCC12 cells that had been 
exposed to low serum for 24 hours were stimulated with 10ng/ml EGF and 
pulsed for 1 hour with BrdU prior to fixation in methanol/acetone, as described 
in section 2.2.4.d. Increased BrdU incorporation was evident at 16 hours from 
growth factor stimulation and was maximal by 24 hours, suggesting that the 
majority of cells had entered the S phase (Figure 30). Therefore, the temporary 
arrest caused by serum starvation was proposed to have taken place in SCC12 
cells during G1. Detection of p34cycD1 expression by western blot (Figure 31) 
or immunocytochemical (Figure 30) analyses in starved and stimulated SCC12 
cells revealed a similar pattern to the one previously described in rodent 
fibroblasts (section 5.4). Starved cells exhibited a reduction in detectable
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p34cy°D1, the expression of which increased four hours from growth factor 
stimulation, peaking at eight hours and subsequently declining. Equivalent to 
prior observations, minimal levels of p34cycD1 were observed only during 
arrest, while in proliferating cells a basal level of the protein appeared to be 
retained regardless of their cell cycle positions.
6.3 Effects of serum starvation on some tumour cell lines.
Cell lines BICR6, BICR16, BICR18, BICR22, MS-2 and A431 were 
subjected to the same type of analysis as previously described for SCC12 cells 
(section 6.2). Protein extracts were obtained from assynchronously growing 
populations and cells that had been exposed to reduced serum conditions for 
24 or 48 hours. Examination of PCNA expression in BICR16 and MS-2 cells by 
western blot analysis, revealed a fractional reduction in the levels of this protein 
following 24 hours of starvation in comparison to the cells treated with low 
serum for 48 hours, suggesting at least a partial although very short cell cycle 
delay. The increase in PCNA protein levels at 48 hours in the absence of any 
stimulation, revealed the low requirement of these cell lines for growth factors. 
BICR6, BICR18, BICR22 and A431 cells exhibited unaltered PCNA expression 
upon serum deprivation, with A431 cells revealing increased levels of this 
protein in comparison to assynchronously growing populations (Figure 32). 
Examination of p34cy°D1 levels in the same extracts revealed largely 
unaltered expression of this cyclin upon serum removal, with slight decreases 
evident in BICR16 and MS-2 cells (Figure 33). The overall conclusions 
obtained from these studies implied that serum deprivation was not a good 
means to induce cell cycle synchrony in most SCC cell lines.
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Figure 29. The growth properties of SCC12 cells in low 
serum.
3x102 cells were plated onto 24 well dishes in low serum and the rate of growth 
monitored at set time intervals by the use of a Coulter counter. The rate of 
growth is represented diagramatically.
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Figure 30. Immunocytochemical analysis of the SCC12 cell 
line.
SCC12 cells were exposed to 10ng/ml of EGF 24 hours after plating in low 
serum. Half of the samples were exposed to 10pM BrdU 1 hour prior to fixation 
in methanol:acetone. Fixation was carried out at different time intervals from 
stimulation and the cells were subjected to immunocytochemical analysis for 
BrdU incorporation. The other half were immunocytochemically analysed for 
p34cYcD1 subcellular localisation and cell cycle dependent oscillation pattern. 
Minus signs represent negative controls in which the primary antibody was not 
included and in the case of p34cy°D1, pre-immune rabbit serum was used at 
the same (1:3000) dilution as antibody 287-3; -Br represents cells that did not 
contain incorporated BrdU and were exposed to the anti-BrdU antibody. 
Numbers specify hours from serum stimulation and as. were assynchronously 
growing cells.
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Figure 31. Cell cycle dependent oscillation pattern of 
P34cycD1.
SCC12 cells were exposed to 10ng/ml of EGF 24 hours from plating in low 
serum and protein extracts were obtained at set time intervals from stimulation 
(hours from stimulation are depicted by numbers). 40pg of each protein extract 
were electrophoresed through a 10% denaturing polyacrylamide gel, blotted 
and subjected to western blot analysis as described in materials an methods. 
The position of p34cy°D1 is shown.
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Figure 32. Serum requirement of SCC cell lines.
Cell lines BICR6, BICR16, BICR18, BICR22, MS-2 and A431 were plated in 
low (0.5%) serum and protein extracts obtained 24 and 48 hours from plating.
t
35p.g of extracts were electrophoresed through a 10% denaturing 
} polyacrylamide gel in parallel with protein samples obtained from
j assynchronously growing cells, blotted and subjected to western blot analysis
i
| (as described in materials and methods). PCNA was detected with the use of
1:1000 dilution of an anti-PCNA mouse monoclonal antibody.
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Figure 33. p34cycD1 expression in serum deprived SCC 
cell lines.
The same protein extracts described in Figure 32 were subjected to western 
blot analysis with the use of an anti-cyclin D1 rabbit polyclonal antibody 287-3 
Arrows point to the p34cyc^1 protein band and the contaminating fibroblast- 
specific ~100kD polypeptide.
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6.4 Discussion.
The oscillation pattern of the cyclin D1 protein, following growth factor 
stimulation of some serum deprived human keratinocyte cell lines, is consistent 
with previous observations made for fibroblast cultures. This would imply that 
upon serum starvation these cells delay further cell cycle progression and 
temporarily reside in the G1 phase, a proposal reinforced by the appearance of 
BrdU incorporation approximately 12 hours from stimulation. However, the 
proliferative delay revealed for SCC12 cells was absent from the majority of 
HNSCC derived cell lines. BICR18 and BICR22 originated from metastatic 
tumours and in tissue culture exhibited optimal growth in 2%FBS containing 
media. Consequently the cells were not highly growth factor dependent and 
exposure to 0.5%FBS had no apparent effect on their rate of proliferation. The 
BICR6 HNSCC cell line was derived from a T4 stage tumour and exhibited 
preference for 10% FBS for optimal growth. However, the cells were able to 
multiply in low serum, had a low requirement for the presence of x3T3 cells, 
were the only cell line that formed large colonies in soft agar and were highly 
tumourigenic in nude mice (Edington et al submitted). Subsequently detected 
increased expression of EGFr, pRb and CCND1 and mutations of the p53 
gene, coupled with the previously listed observations, clearly points out the 
high proportion of accumulated abnormalities of BICR6 cells and several 
potential causes for growth factor independence (Stanton et al submitted, Dr 
Ken Parkinson, Beatson Institute, personal communication).
Cell cycle delay by serum starvation was achieved in only two cell lines 
BICR16 and MS-2, with evidence of recovery within 48 hours from treatment. 
For these reasons serum deprivation was not considered suitable for cell cycle 
arrest of the BICR and MS-2 cell lines and subsequent analysis of p34cYcD1
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ioscillation patterns were not performed. In future, other methods, such as drug
treatment would have to be employed to achieve G1 synchrony.
Currently, predictions of p34cyc^1 oscillation patterns in keratinocytes can
therefore be based on the data obtained from the analysis of the SCC12 cell
line.
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CHAPTER 7 : The effects of CCND1 over-expression.
7.1 Introduction.
To date, over-expression of cyclin D1 in recipient cells following stable 
transfection experiments has been reported in only one study. Clones derived 
from the two transfected murine fibroblast cell lines, NIH3T3 and Rat-2, 
exhibited reduced generation times and morphological alterations in response 
to increased Cyl-1 transcript and protein levels (Quelle et a /1993). Clinical 
studies have revealed amplification and subsequent over-expression of 
CCND1 in a significant proportion of SCCs, rendering the analysis of artificially 
increased cyclin D1 gene dosage essential in these cell types.
The previously described SCC12 cell line was observed to express low 
(equivalent to normal) levels of cyclin D1 (section 6.2). Upon injection into 
immunodeficient mice the cells exhibited a poor tumourigenicity potential 
(Rheinwald and Beckett 1981). These two characteristics made SCC12 cells a 
good target for transfection analysis and over-expression of CCND1 was 
achieved with the use of lipofection techniques. However, despite a resulting 
three-fold excess of p34cy°D1, the derived cell line exhibited no alterations in 
the oscillation pattern of the cyclin D1 protein nor in its tumourigenicity 
potential, suggesting a role for cyclin D1 in earlier stages of cellular 
transformation. Highly increased constitutive expression of CCND1 was 
thought to have toxic effects on proliferating cells, an observation confirmed in 
later studies of fibroblast cell lines (Quelle et al 1993).
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7.2 Expression of exogenous cyclin D1 in SCC12 cells.
The SCC12 cell line was co-transfected (as described in section 2.2.2.a) 
with one of two Cyl-1 cDNA expression vectors, in which expression of the 
coding region of Cyl-1 in the 5'-3' or 3'-5f orientation was under the control of 
an internal cytomegalovirus (CMV) promoter (a kind gift from Dr Clive Dickson, 
ICRF, London, England; Smith et al unpublished data) and the neomycin 
expression construct pHSG274 (Brady eta! 1984).
The first attempt to obtain geneticin sulphate resistant (G418R) colonies 
was unsuccessful due to cell death, correlating well with the proposed function 
of p34cy°D1 as a cell cycle regulator and with later reports of cyclin D1 toxicity 
when constitutively expressed from the same type of vector (Quelle et a /1993). 
However, subsequent attempts to transfect the cells did) yield a low success 
rate. Ninety six colonies were ring cloned from cells transfected with Cyl-1 
cDNA antisense and sense expression vectors of which 4% and 12% grew out 
into established cell lines, respectively.
Genomic DNA was prepared from the cell lines (as described in section 
2.2.3.b-4), digested with restriction endonuclease EcoR1 that was able to 
release a 1.3kb Cyl-1 cDNA fragment from the CMV expression vector and 
subjected to Southern blot analysis. The presence of a 1.3 kb band specific to 
the cyclin D1 expression vector was detected only in one cell line, termed P1 
(Figure 34). The low frequency of stable cyclin D1 cDNA transfections (only 
one positive cell line out of 48 clones) was consistent with the previous 
observations reported for NIH3T3 and Rat-2 fibroblasts (Quelle et a /1993). In 
the published report, introduction of several vectors in which cyclin D1 
expression was governed by strong promoters such as the Moloney murine 
leukaemia virus (MuLV) long terminal repeat (LTR), myeloproliferative sarcoma
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virus LTR and an internal CMV promoter, caused cell death. However, 
transfections using weak promoters (such as the avian Rous sarcoma virus 
promoter) from which cyclin D1 expression was regulated did not appear to 
harbour toxic effects on the cells, suggesting that high constitutive over­
expression of this protein is fatal for cell viability (Quelle et al 1993).
Northern blot analysis was used for the detection of cyclin D1 transcripts 
in the examined cell lines (as described in section 2.2.3.h). Increased 
hybridisation of the labelled Cyl-1 cDNA probe (previously used in Southern 
blot analysis) to RNA species of 1.1-1.7 kb was observed for the P-1 and E3 
cell lines, both of which had been transfected with cyclin D1 sequences in the 
correct orientation. Interestingly a ~2.0kb transcript was also evident 
exclusively in the P-1 and E3 cell lines the origin of which is unknown (Figure 
34). Reduced levels of the 4.5kb CCND1 mRNA species were observed in one 
clone (D2) into which exogenous Cyl-1 cDNA in the antisense orientation had 
been introduced (Figure 34). The same membrane was subsequently 
hybridised with a GAPDH specific probe to determine RNA loading.
Western blot analysis of extracts obtained from assynchronously 
growing cells was carried out with the use of the previously described cyclin D1 
protein specific polyclonal antibody, 287-3. This revealed a three fold over­
expression of the protein in cell line P-1, while the levels were equal to those 
observed for SCC12 cells in all the remaining clones (Figure 34). The reduction 
in CCND1 transcript levels previously observed for cell line D2 were not 
followed by similar behaviour of the protein, suggesting poor or absent 
interference of the 3’-5' Cyl-1 sequences with the endogenous expression of 
CCND1.
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7.3 Analysis of two SCC12-derived clones P-1 and A3.
Microscopic analysis of confluent and subconfluent SCC12 cells and 
derived clones revealed morphological differences. Previous reports had 
suggested a cyclin D1 mediated reduction in cell size in fibroblast cultures that 
were over-expressing exogenous Cyl-1 (Quelle e ta ! 1993). Paradoxically, a 
significant increase in cell volume was observed for the P-1 clone that 
exhibited a three fold over-expression of exogenous cyclin D1 (Figure 35). 
Examination of the parental SCC12 cell line revealed considerable variation 
between individual cell sizes, suggesting clonal selection as a cause of the 
diversity observed in the newly derived cell lines.
In an attempt to compare growth factor requirements of the individual 
cell lines, the same type of assay as described in section 6.2 was used.
SCC12, P-1 and A3 cells were trypsinised and cultured in conditions of 
reduced serum (DMEM containing 0.5% FBS). Cells were harvested at regular 
time intervals and subjected to Coulter counter analysis to determine their rate 
of proliferation. The examination revealed no differences in the growth patterns 
of all the cell lines from those previously described for SCC12 (see section 
6.2). A temporary cell cycle delay was observed during the initial 100 hours 
from starvation which was subsequently overcome, regardless of the 
differences in cyclin D1 expression (Figure 36).
The cell cycle position of serum starved SCC12 cells, determined by the 
degree of BrdU incorporation coupled with the oscillation pattern of the 
p34cy°D1 protein, were described in section 6.2, Figure 30. Exposure of P-1 
and A3 cells, that had been plated in 0.5% FBS, to 10ng/ml of human EGF and 
subsequent BrdU pulsing one hour prior to fixation, revealed the same pattern 
and timing of DNA synthesis as described for SCC12 cells (Figures 37 and 38).
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Previous reports on Cyl-1 over-expressing fibroblast cultures had suggested 
cyclin D1 mediated reductions in cell generation time caused by a 2-4 hour 
shortening of G1 (Quelle eta ! 1993). The data obtained in this study did not 
reveal similar observations for the P-1 cell line.
The temporary G1 delay induced by serum starvation was used to 
compare p34cYcD1 oscillation patterns in the parental and derived subclones. 
Results obtained from western blot and immunocytochemical analyses of the 
SCC12 cells were described in section 6.2. Although the basal levels of 
p34cYcD1 were greater in the P-1 cell line, the cell cycle dependent expression 
pattern, determined by western blot analysis, had remained unaltered (Figure 
39). The same p34cy°D1 oscillation patterns were observed in A3 cells (Figure 
39). Immunocytochemical analysis of serum starved cells that had been 
stimulated with EGF and subsequently fixed at set time intervals (as described 
in section 2.2.4.d-2), revealed exclusively nuclear localisation of the cyclin D1 
protein and the same pattern of cell cycle dependent appearance as 
determined by western blot analysis (Figures 37, 38 and 39). The conclusions 
that can be drawn from these experiments are that increased levels of 
P34cycD1 d0 not alter the time of appearance or subcellular localisation of the 
cyclin D1 protein, however, some indications were found for a reduction in 
growth factor independence in SCC12 cells (A3) transfected with 3'-5' Cyl-1 
cDNA expression vectors (Figure 36).
7.4 The effects of cyclin D1 over-expression on tumourigenicity.
The incidence of CCND1 over-expressing HNSCC and breast 
carcinomas is high, suggesting that increased levels of cyclin D1 may confer a 
growth advantage to a developing tumour. The tumourigenicity potential of the
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Figure 34. Over-expression of exogenous cyclin D1 in 
SCC12 cells.
G418 resistant clones obtained from transfection experiments in which SCC12 
cells were lipofected with 5'-3' or 3’-5' Cyl-1 cDNA expression vectors were 
analysed for the presence and expression of exogenous cyclin D1. SCC12 = 
parental SCC cell line; P-1 and E3 = 5'-3' Cyl-1 cDNA transfected clones; A3 
and D2 = 3’-5’ Cyl-1 cDNA transfected clones.
20pg of genomic DNA were digested with EcoR1 restriction endonuclease and 
subjected to Southern blot analysis (as described in materials and methods). 
Arrows point to the endogenous (4.0kb, 2.3kb and 2.0kb) and exogenous 
(1.3kb) CCND1 bands.
20pg of total RNA extracts were subjected to northern blot analysis, as 
described in materials and methods. The blot was rehybridised with GAPDH as 
a control for equal loading. Arrows point to the endogenous 4.5kb and 1.7kb 
transcripts, exogenous 1.1-1.7kb transcripts and an ~2.0kb mRNA specie of 
unknown origin.
40pg of protein extracts were subjected to western blot analysis, as described 
in materials and methods. The position of p34cy°D1 is shown.
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Figure 34.
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Figure 35. Morphological comparison of SCC12 cells and 
derived clones.
Monolayer morphology of parental SCC12 cells and derived clones (P-1 = 5’-3’ 
Cyl-1 cDNA transfectants and A3 = 3'-5' Cyl-1 cDNA transfectants).
«*»tr.S
Figure 36. The growth properties of SCC12 cells and 
derived clones in low serum.
SCC12, P-1 and A3 cells were plated into 24 well dishes (3x102 per well) in 
conditions of low serum and subsequently monitored for rates of proliferation. 
The diagrammatic representation reveals the growth properties and serum 
requirement of these cell lines.
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Figure 37. Immunocytochemical analysis of the P-1 cell 
line.
P-1 cells were exposed to 10ng/ml of EGF 24 hours after plating in low serum. 
One hour prior to fixation, half of the samples were exposed to 10pM BrdU. 
Immunocytochemical analysis was used to detect BrdU incorporation and 
P34cycD1 ce|| CyC|e dependent oscillation pattern and subcellular localisation 
as described in materials and methods. Minus signs represent negative 
controls in which the primary antibody was not included and in the case of 
p34cycD11 pre-immune rabbit serum was used at the same (1:3000) dilution as 
antibody 287-3; -Br represents cells that did not contain incorporated BrdU and 
were exposed to the anti-BrdU antibody. Numbers specify hours from serum 
stimulation and as. were assynchronously growing cells.
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Figure 38. Immunocytochemical analysis of the A3 cell 
line.
A3 cells plated in low serum were subjected to the experimental analysis 
described in Figures 30 and 37 and in materials and methods. Minus signs 
represent negative controls in which the primary antibody was not included and 
in the case of p34cy°D1, pre-immune rabbit serum was used at the same 
(1:3000) dilution as antibody 287-3; -Br represents cells that did not contain 
incorporated BrdU and were exposed to the anti-BrdU antibody. Numbers 
specify hours from serum stimulation and as. were assynchronously growing 
cells.
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Figure 39. Cell cycle dependent p34cycD1 expression 
levels in P-1 and A3 cell lines.
a) P-1 and A3 cells were exposed to 10ng/ml of EGF 24 hours after plating in 
low serum and protein extracts were obtained at set time intervals from 
stimulation (hours from stimulation are depicted by numbers). 40pg of each 
protein extract were electrophoresed through a 10% denaturing polyacrylamide 
gel, blotted and subjected to western blot analysis as described in materials an 
methods. Arrows specify the p34cycD1 protein.
b) Protein extracts from P-1 and SCC12 cell lines were compared for levels of 
P34cycD1 expression at 0, 4, 8,12 and 24 hours from EGF stimulation.
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SCC12 cell line had previously been examined and was shown to form well 
differentiated cysts in immunodeficient mice that failed to progress throughout 
the rodent life span (Rheinwald and Beckett 1981). It was therefore necessary 
to examine if a three fold over-expression of cyclin D1 in these cells had 
increased their ability to proliferate in nude mice. Table 7 represents the 
number of cells injected into the flanks of immunodeficient mice and the 
subsequent frequency of outgrowth. From the obtained data no alterations 
were evident in the tumourigenicity potential of the P-1 or A3 cell lines when 
compared to SCC12 cells, suggesting that increased expression of CCND1 
may not be advantageous at this stage of transformation. Conversely, a three 
fold over-expression of the protein may have not been sufficient to alter the 
tumourigenicity of these cells.
7.5 Discussion.
Currently only two reports have concentrated on determining the 
function and necessity of the cyclin D1 protein in proliferating mammalian cells 
(Quelle e ta /1993, Baldin e ta l 1993). p34cYcD1 was shown to be essential for 
the transit from G1 to S phases in human and rodent fibroblasts while 
constitutive over-expression of cyclin D1 was suggested to result in premature 
DNA synthesis and subsequent generation shortening of the same cell types. 
To date no data has been published on p34cYcD1 in keratinocyte cell types.
The previously determined characteristics of SCC12 cells and the three 
fold over-expression of p34cYcD1 achieved in this study, rendered this cell line 
and the derived P-1 clone excellent comparative material (Rheinwald and 
Beckett 1981). Interestingly, the subsequent observations largely contradicted 
previous reports made for fibroblast cells, potentially reflecting the differences
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Table 7. Tumourigenicity potential of SCC12 cells and 
derived clones.
1x107 cells from each cell line were injected into immunodefficient mice and 
the degree of tumour formation recorded within two months.
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Table 7
cell line no.
mice
no.
injections
no.
tumours
SCC12 7 11 1
P1 7 11 1
A3 7 11 0
in cell type or the experimental methods used (Quelle e ta l 1993). Over­
expression of p34cYc^1 may have altered the growth properties of P-1 cells, 
however the reduced growth factor requirement characteristic of most SCC 
derived cell lines could have hampered the detection of any marginal changes. 
The induced cell size observed for the P-1 clone opposed previous 
suggestions of cyclin D1 mediated reduction of rodent fibroblast cell volumes 
(Quelle e ta l 1993). However, clonal selection of the SCC12 cells which are 
characterised by differences between individual members within a population, 
were thought to be responsible for the morphological alterations of the P-1 and 
A3 cell lines, although clearly the P-1 cells did not exhibit reduced volumes. 
The use of further methods such as flow cytometry and detailed serum 
requirement analysis, would be necessary to address the cell size and growth 
factor requirement inconsistencies between fibroblast and keratinocyte cell 
lines.
To date several unsuccessful attempts have been made to obtain 
CCND1 transgenic mice with detectable phenotypes (Vladimir Grigorijev, 
Beatson Institute, unpublished data; Dr Clive Dickson and Dr Gordon Peters, 
ICRF, London, England, personal communication). In this study the injection of 
P-1 cells into the flanks of immunodeficient mice did not alter the poor 
tumourigenicity potential of the SCC12 cells. The conclusions drawn from both 
types of experiments would suggest that cyclin D1 over-expression alone is 
insufficient to cause transformation or increase the ability of immortal cells to 
form tumours. A more likely explanation for the frequently observed over­
expression of p34cy°D1 in HNSCC and breast carcinomas is a growth 
advantage (such as shortened G1 or reduced serum requirement) conferred to 
these cells at early stages of transformation, contributing to immortalisation.
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CHAPTER 8 : The effects of CCND1 over-expression on 
immortalisation.
8.1 Introduction.
Normal diploid vertebrate cells have a limited capacity to proliferate, a 
phenomenon termed replicative senescence characterised by a decreasing 
mitogen responsiveness and eventual cellular arrest in G1 (Hayflick and 
Morehead 1961, Wright and Shay 1992). However, in vitro transformed cells or 
cell lines derived from tumour tissues are able to proliferate indefinitely.
Species comparative studies have revealed a greater tendency for rodent 
fibroblast and keratinocyte cell types to overcome senescence than their 
human counterparts (Wright and Shay 1992). The only agents consistently 
shown to immortalise human epithelial cells are DNA tumour viruses such as 
papillomavirus HPV-16 or HPV-18, adenovirus and SV40 (Ruley 1983, Durst et 
al 1987, Schlegel e ta l 1988, Woodworth e ta l 1989, Pecoraro e ta l 1989, Kaur 
and McDougall 1989, Wright eta l 1989, Shay and Wright 1989, Wright and 
Shay 1992).
A model has been proposed for the programmed mechanism of cellular 
senescence that consists of two distinct stages (Wright et al 1989, Shay and 
Wright 1989, Wright and Shay 1992; Shay e ta l 1993). Mortality stage 1 (M1) is 
a process commonly viewed as in vitro senescence and involves loss of 
mitogen responsiveness, the production of a DNA synthesis inhibitor and arrest 
in G1. Introduction of oncogenes HPV-16 E6/E7, adenovirus-5 E1a/E1b or 
SV40 T antigen into primary human keratinocytes was shown to frequently 
bypass or overcome M1 (Ruley 1983, Hawley-Nelson e ta l 1989, Munger e ta l 
1989, Wright et al 1989, Halbert et al 1991, Shay et al 1993). The second
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mortality stage (M2) encompasses a mechanism(s) that prevents proliferation. 
Phenomena such as telomere shortening and alterations in DNA methylation 
are believed to be involved in cell death during M2 (Catania and Fairweather 
1991, Harley 1991, Counter et al 1992, Wright and Shay 1992, Holliday and 
Grigg 1993). Inactivation of M2 is postulated to be a mutational event, 
independent of M1, that may lead to subsequent activation of telomerase (a 
ribonucleoprotein believed to be responsible for maintaining constant telomere 
lengths during DNA replication), or an equivalent phenomenon that will free the 
cells from proliferative control (Wright e ta l 1989, Wright and Shay 1992, Shay 
et al 1993).
p53 and pRb proteins represent direct or indirect host targets for 
inactivation by the above mentioned viral onco-proteins, implicating the tumour 
suppressors as functional contributors to M1 and M2 (Whyte e ta l 1989, 
Scheffner et al 1990, Band et al 1991, Hubbert et al 1992, Vousden et al 1993). 
Both pRb and p53 operate as cell cycle regulators during the G1 phase and 
are considered potential substrates of the cyclin D1 directed kinase(s) 
(Goodrich et al 1991, Cobrinik et al 1992, Lane 1992, Wang and Eckhart
1992). Constitutive over-expression of p34cYcD1 may therefore cause the 
previously observed shortening of G1 by inactivating the two growth 
suppressory proteins (Quelle e ta l 1993). In the long term this may cause the 
cells to overcome M1 and potentially lead to immortalisation.
The immortalisation properties of p34cy°D1 were investigated in this 
study by transfection of Cyl-1 expression vectors alone or in combination with 
HPV-16 E6 and/or E 7 into primary human foreskin keratinocytes. The aim was 
to determine the effects of p34cy°D1 over-expression on the lifespan of normal 
keratinocytes and whether it may function in co-operation with viral E6 and/or
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E7 onco-proteins. The observed bypass of M1 was the first evidence for a role 
of cyclin D1 in early stages of cellular transformation.
8.2 Transfection analyses of HEK cells.
Two types of transfections were carried out on HEK cells, derived from 
three individuals. Cells were selected for longevity or for clone formation in the 
presence of G418, the results from which are described below.
8.2.1 HEK cells with extended life spans over-express p34cycD1.
HEK124 cells, derived from human foreskin (kindly provided by Dr Ken 
Parkinson, Beatson Institute) were co-transfected at passage five with various 
combinations of Cyl-1 cDNA, E6and E 7expression vectors as described in 
Table 8. In view of previous reports on the toxicity of cyclin D1 (Quelle e ta l
1993), two alternative expression systems were used : the CMV vector 
described in section 2.1.4 and the same 1.3kb Cyl-1 cDNA fragment inserted 
downstream of the inducible MMTVLTR in the plasmid pJ5Q (a kind gift from 
Dr Clive Dickson and Dr Gordon Peters, ICRF, London, England). The HPV-16 
E6and E7expression constructs pJ4Q16.E6 and pJ4Q16.E7, respectively, 
contained open reading frames of the two viral oncogenes linked to the 
Moloney murine leukaemia virus LTR and were a kind gift from Dr Lionel 
Crawford (Storey et al 1988).
Upon lipofection, the cells were cultured in GIBCO keratinocyte serum 
free media in the absence of selection (as described in section 2.2.2.b). 
Samples were frozen at -70°C followed by immersion into liquid nitrogen (as 
described in section 2.2.1 .c) for subsequent comparative purposes with later 
passages. Initially, rapid outgrowth was observed for HEK124 cells transfected
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with E6/E7, E6 alone and the two cyclin D1 expression systems, however the 
growth advantage of cells into which pJ5£2-D1 or pJ4Q16.E6 were introduced 
was lost after one month of growth. Non-transfected control HEK124 cells 
entered crisis at passage twelve and subsequently rapidly died. Keratinocytes 
lipofected with pJ4Q16.E6, pJ5Q-D1 and pJ4Q16.E6/pJ7Q-D1 stopped 
proliferating in M1 at passages sixteen, seventeen and nine, respectively, 
following the same fate as HEK124 cells. However, extended lifespan was 
observed for the remaining cultures of which cells lipofected with 
pJ4Q16.E7/pJ7Q-D1, pJ7Q-D1 and pJ4Q16.E7/pJ4Q16.E6 survived the 
longest, although no immortalisation was evident (Table 8).
Genomic DNA and total RNA were extracted from proliferating 
keratinocytes at early passages following transfection, with the aim to carry out 
Southern and northern blot analyses for the presence of exogenous cyclin D1 
DNA and transcripts, respectively. Unfortunately, the two methods proved to be 
inappropriate for the analysis of these cells, probably due to the mixed 
populations and the low titre of transfected cells in culture. For these reasons 
the more sensitive technique of PCR was employed with the use of short 
primer sequences specific to cyclin D1 cDNA. The primers were designed to 
span exon/intron junctions of the CCND1 gene, joining exons 2 and 3 (primer 
b2), or 4 and 5 (primer y4), in this way specifically binding to exogenous cDNA 
at high stringency (Figure 40) (Motokura and Arnold 1993). Optimal conditions 
(as described is section 2.2.3.C-2) for the cyclin D1 cDNA amplification were 
established with the use of SCC12 and P-1 cell extracts. Figure 41 represents 
the results obtained from PCR reactions with the use of primers b2 and y4 on 
genomic DNA isolated from these two cell lines. The amplified DNA sequences 
specific to P-1 extracts were of the expected 332bp size and hybridised to
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1.3kb [a 32P]dCTP labelled Cyl-1 cDNA probes at conditions of high stringency 
(Figure 42). The same methods were used for the examination of transfected 
keratinocyte cultures. Southern blot analysis of 1:10 dilutions of the PCR 
amplification products revealed the presence of exogenous cyclin D1 
sequences in early passages of the Cyl-1 lipofected cell populations (Figure 
43).
In confirmation of the previously observed decline of CCND1 mRNA 
expression in senescent human diploid fibroblasts (Won ef a/1992), western 
blot analysis of parental and transfected HEK cells revealed reduced p34°ycD1 
levels in extracts obtained from later passages (Figure 44). Interestingly, up- 
regulated expression of p34cycD1 was not only observed in cells lipofected 
with Cyl-1 cDNA expression vectors, but also in keratinocytes into which HPV- 
16 sequences had been introduced. Coupled with the recently reported 
associations between HPV-16 E7 and cdk2 and the functioning of E7 during 
the G1 to S transition phase, the results of this study suggest direct or indirect 
action of viral transforming sequences on the function and regulation of the 
cyclin D1 protein (Banks e ta l 1990, Tommasino e ta l 1993). Conversely, a 
transient induction of p34cy°D1 levels may be due to a lipofection artifact.
Unfortunately, expression of the viral onco-proteins by western blot 
analysis was not successful, probably due to low protein levels and 
heterogeneous cell populations. For these reasons subsequent co-transfection 
experiments were carried out in the presence of G418R markers allowing 
selection of resistant cells.
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Table 8. Transfection experiments in HEK124 cells.
The expression vectors used to tranfect HEK124 keratinocytes and the lifespan 
of individual populations prior to reaching crisis are represented.
Table 8
Expression
vectors
passage no. 
reached
none 12
pj£216.E6 16
pj£216.E7 21
p ja i6 .E 6  
pj£>16.E7
19
pJ7£2-D1 26
pJ5£2-D1 16
pJ4£216.E6 
pJ7^-D1 9
pJ4Q16.E7
pJ7£2-D1 27
Figure 40. The origin of CCND1 cDNA-specific primers.
24bp primer sequences were designed to span the boundaries between exons 
2 and 3 (primer b2) or exons 4 and 5 (primer y4) resulting in an 332bp 
amplified region from CCND1 cDNA. The diagram represents the location of 
the primers and the amplified sequence in the CCND1 cDNA. Arrow heads 
mark the exon boundaries.
Figure 40.
1 GCAGTAGCAG CGAGCAGCAG AGTCCGCACG CTCCGGCGAG GGGCAGAAGA
51 GCGCGAGGGA GCGCGGGGCA GCAGAAGCGA GAGCCGAGCG CGGACCCAGC
101 CAGGACCCAC AGCCCTCCCC AGCTGCCCAG GAAGAGCCCC AGCCATGGAA
151 CACCAGCTCC TGTGCTGCGA AGTGGAAACC ATCCGCCGCG CGTACCCCGA
201 TGCCAACCTC CTCAACGACC GGGTGCTGCG GGCCATGCTG AAGGCGGAGG
251 AGACCTGCGC GCCCTCGGTG TCCTACTTCA AATGTGTGCA GAAGGAGGTC
301 CTGCCGTCCA TGCGGAAGAT CGTCGCCACC TGGATGCTGG AGGTCTGCGA
351 GGAACAGAAG TGCGAGGAGG AGGTCTTCCC GCTGGCCATG AACTACCTGG
401 ACCGCTTCCT GTCGCTGGAG CCCGTGAAAA AGAGCCGCCT GCAGCTGCTG
451 GGGGCCACTT GCATGTTCGT GGCCTCTAAG ATGAAGGAGA CCATCCCCCT
b2— ►
501 GACGGCCGAG AAGCTGTGCA TCTACACCGA CGGCTCCATC CGGCCCGAGG
551
. y
AGCTGCTGCA AATGGAGCTG CTCCTGGTGA ACAAGCTCAA GTGGAACCTG
601 GCCGCAATGA CCCCGCACGA TTTCATTGAA CACTTCCTCT CCAAAATGCC
651 AGAGGCGGAG GAGAACAAAC AGATCATCCG CAAACACGCG CAGACCTTCG
701 TTGCCTCTTG TGCCACAGAT GTGAAGTTCA TTTCCAATCC GCCCTCCATG
751 GTGGCAGCGG GGAGCGTGGT GGCCGCAGTG CAAGGCCTGA ACCTGAGGAG
801 CCCCAACAAC TTCCTGTCCT ACTACCGCCT CACACGCTTC CTCTCCAGAG
\ / A
851 TGATCAAGTG TGACCCAGAC TGCCTCCGGG CCTGCCAGGA GCAGATCGAA
901 GCCCTGCTGG AGTCAAGCCT GCGCCAGGCC CAGCAGAACA TGGACCCCAA
951 GGCCGCCGAG GAGGAGGAAG AGGAGGAGGA GGAGGTGGAC CTGGCTTGCA
1001 CACCCACCGA CGTGCGGGAC GTGGACATCT GAGGGGCCCA GGCAGGCGGG
1051 CGCCACCGCC ACCCGCAGCG AGGGCGGAGC CGGCCCCAGG TGCTCCACAT
1101 GACAGTCCCT CCTCTCCGGA GCATTTTGAT ACCAGAAGGG AAAGCTTCAT
1151 TCTCCTTGTT GTTGGTTGTT TTTTCCTTTG CTCTTTCCCC CTTCCATCTC
1201 TGACTTAAGC AAAAGAAAAA GATTACCCAA AAACTGTCTT TAAAAGAGAG
1251 AGAGAGAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA
1301 AAAAAAAAAA AAAAAAAAAA AAAAA
Figure 41. Specific amplification of CCND1 cDNA.
1pg of genomic DNA isolated from SCC12 and P-1 cell lines was subjected to 
PCR amplification with the use of primers b2 and y4 (as described in materials 
and methods). A control sample was included in the analysis that lacked the 
presence of primer sequences (blank). DNA molecular weight markers (BRL 
DNA-VI) were used to determine the size of the amplified DNA product specific 
to the P-1 cell line.
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Figure 42. Southern blot analysis of the PCR amplification 
products.
0.5pg of genomic DNA obtained from SCC12, P-1 f TFK104 and Saos2 cell 
lines was subjected to PCR amplification with the use of CCND1 cDNA specific 
primers b2 and y4.1pl aliquots of 1:500 diluted products were analysed by 
Southern blot analysis and probed with a 1.3kb Cyl-1 cDNA fragment. 1pl of 
1:100 diluted PCR product from P-1 cells was included as a strong positive 
control. The arrow points to the 332bp band specific for P-1 cells.
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Figure 43. Southern blot analysis of the PCR amplification 
products from HEK124 transfectants.
0.5|j.g of genomic DNA isolated from Cyl-1 cDNA transfected HEK cells were 
subjected to PCR amplification with the use of primers b2 and y4. Two blank 
control samples were also included : one lacking the primers (blank) and one 
lacking the genomic DNA (blank-o). The products were compared to those 
obtained for SCC12 and P-1 cell lines as negative and positive controls 
respectively, by Southern blot analysis. 1(il aliquots of 1:10 diluted PCR 
products were probed with a 1.3kb Cyl-1 cDNA fragment, revealing a CCND1 
cDNA specific 332bp band. A 1:500 diluted PCR amplification product from P-1 
cells was also included for comparative purposes. Letters a, b and c mark 
individual extracts of the analysed HEK transfectants.
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Figure 44. p34cycD1 expression in the HEK124 
transfectants.
50pg of protein extracts were subjected to western blot analysis with the use of 
an anti-cyclin D1 rabbit polyclonal antibody 287-3, as described in materials 
and methods. The position of the p34cy°D1 protein band is shown. Roman 
figures depict the passage number of the cell populations from which the 
extracts were made.
Figure 44.
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8.2.2 Clone formation frequencies of transfected HEK cells.
HEK34 cells, derived from a different individual than HEK124, were co­
transfected with the same expression vectors as described in section 8.2.1 
(Table 9) and the G418R conferring vector pHSG274 (as described in section 
2.2.2.b). Clone formation was evident 29 days from transfection and the 
greatest number of resistant cells were present in pJ4Q16.E7/pJ7£2-D1, pJ7£2- 
D1, pJ4Q16.E7/ pJ5Q-D1 and pJ4Q16.E6 lipofected cells (see Table 9). 
Contrary to expectations, a low number of resistant cells was evident in 
keratinocytes co-transfected with pJ4£216.E7/pJ4Q16.E6 expression vectors 
suggesting plasmid toxicity or incompatibility, although such observations had 
not been previously reported (Storey e ta l 1988). However, the HPV-16E6 
open reading frame cloned into the pJ4£2 plasmid did harbour an abnormality. 
The C-terminal Leu residue was replaced in the expression system by His-Gly 
that may have caused loss or altered function of the E6 onco-protein and 
unexpected results in this study (Storey e ta l 1988). None of the clones 
survived to form immortal cell lines.
Subsequently, a third lipofection was attempted on a newly derived HEK 
cell population, HEKb (a kind gift from Caroline Chapman, Beatson Institute), 
with the use of two different HPV-16 E6 and E7 expression vectors pMoE6 and 
pMoE7, respectively (a kind gift from Dr Karen Vousden, Ludwig Institute for 
Cancer Research, London, England) (Hawley-Nelson e ta l 1989; Edmonds and 
Vousden 1989, Vousden and Jat 1989). HEKb cells, cultured in Clonetics 
serum free media, were co-transfected at passage four with the expression 
vector combinations depicted in Table 10, including Cyl-1 cDNA in the incorrect 
3'-5’ orientation linked to the CMVearly promoter (pJ7Q-D13'-5'). Due to a 
degree of lipofection reagent toxicity, geneticin selection was carried out one
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month from co-transfections during which period the control cells senesced and 
died. pMoE6 transfected cells initially revealed an increased rate of 
proliferation that appeared to be temporary, the cells exhibited entry into crisis 
approximately one month from lipofection (Table 10), in agreement with the 
previously reported inability of E6 to overcome M2 (Vousden e ta l 1988, 
Hawley-Nelson e ta l 1989). Significant growth advantage was also temporarily 
evident for keratinocytes transfected with pJ7Q-D1 expression vectors, 
predominantly exhibiting islands of tightly packed cells that outlived the control 
samples (Figure 45). Transfection with Cyl-1 expression vectors alone proved 
to be insufficient to cause immortalisation. Perplexingly, after a period of delay, 
cells lipofected with pJ7£2-D13'-5' expression vectors alone or in combination 
with pMoE6 expression constructs exhibited
successful growth in tight clusters and a reduction in cell size (Figure 45). The 
same phenomenon was absent from pMoE7/pJ7£2-D13'-5' co-transfected cells, 
suggesting lack of co-operation between the two expression vectors in 
overcoming growth abortion of primary keratinocytes. The most successful 
HEKb transfectants are listed in Table 10
Due to the preliminary state of this data no further analysis has been 
carried out on the transfected keratinocytes. Further examination of 
proliferative rates, degrees of immortality and exogenous DNA expression 
levels will be necessary to determine with greater certainty the function and 
potential co-operation of cyclin D1 and viral onco-proteins in the initial stages of 
transformation.
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Table 9. Transfection experiments in HEK34 cells.
The expression vectors used to transfect HEK34 cells and colony formation 
efficiencies are represented.
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Table 9
Expression
vectors
no. clones 
formed
pHSG274 4
pJ4Q16.E6
pHSG274 29
pJ4^16.E7
pHSG274 10
pJ4Q16.E6
pJ4m6.E7
pHSG274
7
pJ7Q-D1
pHSG274 9
pJ5ft-D1
pHSG274 9
pJ4Q16.E6
pJ7ft-D1
pHSG274
12
pJ4Q16.E6
pJ5f2-D1
pHSG274
26
pJ4Q16.E7
pJ7£>D1
pHSG274
22
pJ4Q16.E7
pJ5Q-D1
pHSG274
23
Table 10. Transfection experiments in HEKb cells.
The expression vectors used to transfect HEKb cells and the lifespan of 
individual populations are depicted. Blank spaces indicate cells that are still 
proliferating.
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Table 10
Expression
vectors
no.days  
survived
pHSG274 41
pMoE6
pHSG274 50
pMoE7
pHSG274 60
pMoE6
pMoE7
pHSG274
pJ7fl-D1
pHSG274 52
pJ50-D1
pHSG274 55
pMoE6
pJ7Q-D1
pHSG274
pMoE6
pJ5Q-D1
pHSG274
pMoE6 3..g, 
pJ7ft-D1 ’ 
pHSG274
pMoE7
pJ7Q-D1
pHSG274
47
pMoE7
pJ5Q-D1
pHSG274
pMoE7 
PJ7Q-D13'5’ 
pHSG274
38
Figure 45. Morphological comparison of Cyl-1 cDNA and 
HPV-16E6 and/or £ 7 transfected HEKb cells.
Monolayer cultures of Cyl-1 cDNA and HPV-16 E6 and/or E 7 transfected HEKb 
cells were compared, a - cells transfected with the pJ7Q-D1 vector containing 
Cyl-1 cDNA sequences in the 5’-3' orientation; b -differentiating cells 
characteristic of all populations; c - cells co-transfected with vectors pJ5Q- 
D1/pMoE7, representing the morphology characteristic of primary HEK cells 
and pMoE6/pMoE7or pMoE6/pJ5Q-D1 co-transfectants; d - cells transfected 
with the pJ5H-D1 expression vector; e - cells transfected with the pJ7Q-D13’-5‘ 
vector containing Cyl-1 cDNA sequences in the 3'-5' orientation, characteristic 
of cells co-transfected with pMoE6/pJ7Q-D1 (3'-5') vectors.
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8.3 Discussion.
The ability of viral oncogenes to immortalise human keratinocytes has 
on several occasions been linked to their ability to bind and inactivate host 
suppressor proteins p53 and pRb (Band et al 1991, Hubbert et a l 1992, 
Pagano et al 1992a, Tedesco et a /1993, Vousden et a /1993), although some 
contradictions do exist (Jewers et al 1992). In the case of HPV-16, co­
operation of onco-proteins E6 and E7 is thought to result in the highest 
frequency of immortalisation when compared to the effects of E6 or E7 alone 
(Hawley-Nelson eta! 1989, Munger et a /1989). The E6 onco-protein was 
shown to in vitro and in vivo cause rapid degradation of the host p53 protein via 
the ubiquitin-dependent protease system, resulting in a significant decrease in 
the half life (from 4 hours to 15-30 minutes) of the tumour suppressor protein 
(Scheffner et al 1990, Crook et al 1991, Band et al 1991, Hubbert et al 1992, 
Lechner et a /1992). Onco-protein E7 contains a sequence motif (LXCXE) that 
allows tight binding to the host pRb protein and subsequently resulting in the 
release of free, transcriptionally active E2F (Pagano et al 1992a).
A variety of mammalian proto-oncogenes contain the ability to 
immortalise murine primary cells, however only one case of ras-mediated 
immortalisation of human epithelial cells has been reported (Sager 1984, 
Yoakum et a /1985). The recently derived nucleotide sequences of the CCND1 
gene have revealed the presence of a pRb-binding LXCXE motif, making it the 
first mammalian gene harbouring this region and implicating cyclin D1 as a 
potentially immortalising protein (Dowdy eta! 1993). The proposed functioning 
of p34cy°D1 during the G1 to S phase transition, frequent over-expression in 
certain types of cancer and potential association with pRb provides indirect 
evidence for the contribution of deregulated cyclin D1 to immortalisation.
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Results obtained from this study have contributed the first indications for the 
effects of constitutively over-expressed p34cycD1 on the life span of human 
primary keratinocytes. Preliminary results may suggest cyclin D1-induced 
bypass or blockage of M1.
In view of the proposed pRb-p34cyc^1 binding and the known effects of 
E6 on p53, a co-operation of the two onco-proteins was looked for in 
keratinocyte immortalisation. The E6 expression constructs in two of the 
transfection assays were not satisfactory, rendering interpretation of the 
obtained results uncertain. However, the results of the most recent transfections 
of HEKb cells, using a different E6 expression vector (Vousden and Jat 1989, 
Edmonds and Vousden 1989, Hawley-Nelson et al 1989) may suggest a joint 
effect of E6 and cyclin D1 on cell longevity.
Co-operation between the major HPV-16 immortalising oncogene, E7 and 
cyclin D1 in overcoming M1 and M2 was also hypothesised. In preliminary 
support for this theory the cells transfected with Cyl-1 cDNA and E7 expression 
vectors revealed a degree of longevity in comparison with the controls. However, 
the results must be treated with caution and further analysis is essential before 
any conclusions can be made. A likely disadvantage of the experiments in this 
study were the low numbers of cells lipofected with each expression vector 
combination, in this way decreasing the chances of observing positive results. 
Subsequent co-transfection repeats will therefore be carried out to a larger 
scale.
The observations obtained following transfection of antisense Cyl-1 cDNA 
expression vectors may contradict the concept of cyclin D1 as a proto-oncogene, 
raising a new aspect to the study. The functional roles of cyclin
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D1-directed kinases most likely lie within the catalytic subunits which are only
regulated by cyclin D1 association. Due to the observed wide diversity in
subunit association, the cyclin D1/cdk kinases may differ greatly in substrate
specificity and function. The reduction in cyclin D1 levels at certain points
during the cell cycle may allow normally less probable associations between
the free cdk subunits and other cyclins and/or new substrates which may in
turn contribute to immortalisation, however these findings are currently highly 
| speculative and extremely uncertain, it would be necessary to examine
i
I established cell lines to show the efficiency and effects of the transfections with 
I antisence Cyl-1 expression vectors.
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CHAPTER 9 : Discussion.
9.1 CCND1 dosage and expression in the newly derived SCC cell lines.
The significance of CCND1 over-expression in transformation currently 
remains unclear, most conclusions have been speculative and often 
contradictory. To date only two reports have analysed the gene dosage and 
transcript levels of CCND1 in human HNSCCs, although frequent chromosome 
11q13 amplifications in these types of tumours were observed (Zhou etaI 
1988, Berenson e ta l 1989, Somers efa/1990, Lammie efa/1991, Schuuring 
et al 1992a). A major aim of the thesis was to examine and understand the 
consequences of up-regulated p34°ycD1 in SCCs. A number of omissions 
made in the two preceding reports influenced the approaches and enquiries 
used in this study:
(i) Repeated data was generated with regards to the examined HNSCC cell 
lines of which all were the same, with the exception of UMSCC14B. 
Furthermore, cell line UMSCC1, initially reported to have normal CCND1 gene 
dosage and therefore used as a control (Lammie et al 1991), subsequently 
revealed a two fold amplification of this gene (Schuuring e ta l 1992a). In this 
study the amplification levels in SCC cell lines were compared to the CCND1 
gene dosage in human foreskin primary keratinocytes,.
(ii) The recorded incidence of CCND1 amplifications in tumours (30-50%) did 
not correlate well with observations made in SCC cell lines (~100%) (Schuuring 
et al 1992a). This phenomenon is thought to be due to the conditions in which 
the cell lines were established. Most of the existing SCC cell lines have been 
derived from recurrent or irradiated tumours and have been cultured under 
conditions that favour growth of fitter variants, generating cell lines which may
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be non-representative of the original tumour tissues. The advantage of the 
BICR and MS-2 cell lines is that they were derived and cultured under 
conditions favouring the growth of normal keratinocytes (Edington et al 
submitted). The frequency of CCND1 amplifications was -40%, consistent with 
the previously reported values in SCC tumours.
(iii) Inappropriate controls were used for RNA loading and transfer during 
northern blot analysis. Normal cells such as primary keratinocytes were not 
included in the CCND1 expression studies. Work carried out in this study 
revealed differential expression of GAPDH in the examined SCC cell lines, an 
observation supported by the analysis of fibroblast cell types (Dr Bob 
Hennigan, Beatson Institute, personal communication). For these reasons 
hybridisation with GAPDH-specific probes was carried out only in the analysis 
of clones derived from the same parental cell line. In the case of the SCC cell 
lines, hybridisation with ribosomal RNA-specific probes was used for control 
purposes.
(iv) There has been no published data concerning expression levels, oscillation 
patterns and subcellular localisation of the CCND1 protein product in SCCs or 
any transformed tissues and cell lines. Therefore, part of this study was 
directed at the analysis of p34°ycD1 in the newly derived SCC cell lines and 
tumour or xenograft biopsies. Previous analysis of murine macrophages 
revealed a peak in p34cycD1 expression evident during the second part of G1 
(Matsushime e ta l 1991), while only one study has examined the subcellular 
localisation of this protein in human diploid fibroblasts (Baldin et a /1993). The 
SCC cell lines analysed in this study appeared not to have altered the 
exclusive nuclear localisation and G1 specific appearance of p34cycD1, 
although problems were encountered attempting to synchronise the cells by
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serum starvation (see section 6.3). For these reasons, the cell cycle dependent 
oscillation patterns of p34cy°D1 in the tumour cell lines would in future have to 
be examined in cells arrested by other means, such as the use of blocking 
reagents, TGFp or anti-EGFR antibodies.
In this study the observed CCND1 gene dosage ranged from tree- to 
twelve-fold higher than the levels recorded in primary human foreskin 
keratinocytes, representing the highest range of amplification when compared 
with previous reports (Lammie efa/1991, Schuuring e ta l 1992a). CCND1 
transcript and protein over-expression were evident in all cases exhibiting 
increased gene dosage, supporting the previously proposed key status of 
CCND1 in the 11 q13 amplicon (Lammie efa/1991, Schuuring e ta l 1992a). 
However, amplified CCND1 was not a prerequisite for over-expression, as 
observed for cell line BICR19 and in previous reports, indicating alternative, 
although rarer mechanisms for cyclin D1 upregulation in SCCs (Shuuring e ta l 
1992a).
Comparisons between the derived CCND1 sequences from several 
independent studies has revealed single base changes within the coding 
region of this gene when compared to normal sequences obtained from human 
placenta (Motokura et al 1991, Withers et al 1991, Motokura and Arnold 1993). 
This observation would suggest other potentially modulating events that could 
affect the function, kinase subunit and subsequently substrate specificity of 
P34cycD1 Recently in vitro constructed dominant-negative cyclin B mutants 
were able to compete with wild type forms of the protein and successfully 
abolish the functioning of the cyclin B-directed kinase (Zheng and Ruderman 
1993). In vivo occurring mutations of CCND1 may have the reverse effect and 
result in a dominant positive mutation which could lead to transformation.
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However, this hypothesis was recently partially disproved by the sequence 
comparison of two CCND1 transcripts derived from a benign parathyroid 
adenoma and a malignant centrocytic lymphoma with the previously 
determined normal CCND1 sequences; no mutations were revealed (Motokura 
et al 1991, Rosenberg et al 1993). In this study Southern blot analysis of the 
restriction enzyme digested SCC cell line genomic DNA did not disclose any 
alterations in the specific CCND1 banding pattern (Figure 6). Subsequent 
sequence analysis could be employed to look for the presence of potential 
point mutations within the SCC CCND1 genes, which may account for the high 
levels of p34cycD1 jn the BICR19 cell line, potentially altering the half life of 
this protein.
A more frequently observed CCND1 abnormality is the shortening of 
transcript 3' non-coding regions by alternative splicing or additional 
polyadenylation sequences, suggested to cause an altered stability of the 
cyclin D1 mRNA (Withers e ta l 1991, Seto e ta l 1992, Motokura and Arnold 
1993). In this study northern blot analysis revealed full length CCND1 mRNA 
species in all the examined SCC cell lines regardless of the expression levels, 
therefore indicating the absence of abnormal CCND1 transcripts (Figures 7 
and 10). One of the ways to examine for the potential contributions of mutated 
CCND1 to the development of transformation is the in vitro construction of 
mutants and subsequent transfection into primary cells or non-transformed 
immortal keratinocytes such as the SCC12 cell line (see section 6.2). 
Subsequent analysis of proliferation rates, longevity and tumourigenicity of the 
surviving cells would contribute to our understanding of the cyclin D1 role in 
cell cycle regulation and transformation. Conversely, it is not impossible to 
postulate a cooperative nature of pRb and p34cycD1 interactions in cellular
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growth regulation during G1 which may account for the over-expression of pRb 
in tumours that have amplified CCND1. A contradiction to this hypothesis the 
apparent absence of pRb over-expression in BICR19 cells which lack CCND1 
amplification but do not exhibit over-expression of p34cy°D1.
Interestingly the three HNSCC cell lines exhibiting increased CCND1 
gene dosage and expression levels, also harboured pRb over-expression, a 
phenomenon that has not been previously reported. In view of the recently 
proposed targeting of p34cy°D1 by pRb, it could be hypothesised that tumours 
BICR6, BICR18 and BICR22 had upregulated production of the pRb protein in 
an attempt to over-come the increased p34cy°D1 expression during earlier 
stages of transformation (Dowdy e ta l 1993). Conversely, it is not impossible to 
postulate a cooperative nature of pRb and p34cy°D1 interactions in cellular 
growth regulation during G1 which may account for the over-expression of pRb 
in tumours that have amplified CCND1. A contradiction to this hypothesis is the 
apparent absence of pRb over-expression in BICR19 cells which lack CCND1 
amplification, but do exhibit over-expression of p34cy°D1, therefore the former 
hypothesis would appear more likely. Clearly, high levels of apparently wild 
type pRb in cell lines BICR6, BICR18 and BICR22 were not sufficient to 
prevent tumour development, probably due to the accumulation of other 
abnormalities as a consequence of p53 mutations which were evident in all of 
the BICR cultures (Edington et al submitted). The cervical SCC cell line MS-2 
exhibited no detectable pRb in the western blot analysis (Figure 16), potentially 
due to the presence of integrated HPV-16 early regions into the host genome. 
However, E7 onco-protein expression is commonly low in infected cells and 
thought not to be sufficient to sequester all of the endogenously expressed
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pRb, suggesting mutations may cause the loss of detectable pRb (Vousden 
and Jat 1989).
p34cycD1 is currently the only discovered mammalian protein that 
contains the viral onco-protein specific amino acid motif (LXCXE) thought to be 
essential for the binding of pRb (Dowdy e ta l 1993). This would imply that at 
least one aspect of cyclin D1 functioning may be mimicked by transforming 
viral onco-proteins, potentially to a more successful level. Following this 
argument, the presence of E7 in the MS-2 cell line may have rendered over­
expression of endogenous CCND1 unnecessary. The same explanation could 
account for the low frequency of CCND1 amplifications observed in cervical 
cancer, taking into account the high incidence of HPV-16, -18 and -33 
infections in these carcinomas (DiPaolo e ta l 1993). Furthermore, upon SV40 
transformation, normal human diploid fibroblasts exhibited a two- to three-fold 
down-regulation of p34cycD1 and the same was observed in HPV-16 infected 
HeLa cells and adenovirus transformed primary rat kidney cells (Xiong and 
Beach 1993). None of the viral oncogene containing cells exhibited p34cy°D1 
association with the cdk catalytic subunits, suggesting complete loss of the 
cyclin D1-directed kinases (Xiong and Beach 1993). However, the observed 
increase in cyclin D1 protein expression in this study following transfection of 
primary keratinocytes with E6 and/or E 7expression vectors, lies in 
contradiction of the above described proposal. Nevertheless, the presence of 
E6 and E7 onco-proteins was not shown in transformants potentially due to low 
expression levels, suggesting that p34°ycD1 upregulation might represent a 
transient effect of the lipofection experiments. A more likely explanation is the 
requirement of other viral genome sequences for specific p34cy°D1 
down regulation. This inconsistency can be explained by the expression of viral
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oncogenes from vector promoters in the transfected cells. The apparently 
"normal" expression levels of p34cy °D1 in the TFK104 cells is consistent with 
this proposal. Further examination will be necessary to address these 
phenomena such as transfection of cells with expression vectors containing 
different parts of the HPV-16, SV40 or adenovirus-5 genomes.
It is not unlikely that cell cycle regulators such as cyclin D1 may exhibit 
similar types of self-regulation as observed for cyclin B during mitosis. The 
entry into and progression of a cell through the M phase depends on a 
negative feedback loop in which cyclin B binds to and activates cdc2. This 
complex will in turn initiate the cyclin destruction system allowing anaphase 
completion and the onset of G1. It is widely thought that the negative feedback 
loop is regulated by specific and currently unknown domains of the cyclin B 
protein (Prof. Joan Ruderman, Harvard Medical School, Boston, USA, personal 
communication). The previously observed down-regulation of p34cy°D1 in 
virally transformed cells may reflect the activation of the cyclin D1 negative 
feedback loop induced by the replacement of p34°ycD1 with highly active viral 
onco-proteins in specific kinase complexes. Therefore, due to sequence and 
functional similarities between p34cy°D1 and viral transforming onco-proteins, 
p34cy°D1 may represent the only exception to the general viral-induced cyclin 
upregulation as part of the mechanism of increased cellular proliferation (Xiong 
and Beach 1993). However, the proposal directly contradicts the observed 
p34cy°D1 increase in this study of HPV16 E6 and/or E7transfected human 
foreskin primary keratinocytes and is therefore considered unlikely. Analysis of 
normal human primary keratinocytes and their virally immortalised and /or 
transformed counterparts, would contribute to the verification of this 
hypothesis. In previous reports p34cycD1 was isolated from a diploid human
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lung fibroblast cell line (WI-38) complexed with one of the catalytic subunits 
(cdk2, cdk4 or cdk5), PCNA and an unknown p21 protein (Xiong and Beach 
1993). However, SV40, HPV16 or adenovirus transformed WI-38 cells 
exhibited a loss of these complexes, revealing association of cdk4 and an 
unknown p16 protein. The same was true for p53 deficient cells derived from 
Li-Fraumeni patients carrying no known tumour viruses, suggesting an altered 
cyclin D1 role during transformation.
P34cycD1 jS currently the most promiscuous cyclin with regards to 
catalytic subunit specificity and associates with five related but distinct proteins, 
cdc2, cdk2, cdk4, cdk5 and cdk6 (Motokura et al 1991, Xiong et al 1992b,
Xiong and Beach 1993, Dr Gordon Peters, ICRF, London, England, personal 
communication). Transformation specific expression of two cyclin D1 regulated 
catalytic subunits cdk5 and cdk6 has recently been proposed (Peters e ta l 
1993). Increased expression of the cdk5 protein (normally expressed only in 
neurones) as a response to v-fos transformation of a rat fibroblast cell line 
confirmed the previous observations (Lew e ta l 1992, Dr Bob Hennigan, 
Beatson Institute, unpublished data). To date the general opinion has been that 
the inactive kinase subunits reside in the nucleus of a cell until the synthesis of 
a specific cyclin which will in turn regulate the timing and activity of the kinase 
(Minshull 1993, Pines 1993, Solomon 1993). However, differential expression 
of certain kinase subunits that may exhibit an increased specificity for cyclin 
binding or be present at higher concentrations, could successfully compete 
against normally associated subunits (such as cdk2 or cdk4) leading to altered 
substrate specificity of the functionally active kinase and subsequent 
transformation. Over-expression of cyclin D1 observed in several types of 
tumours may serve to enhance this effect. In this study altered cdk4 expression
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was not observed in the BICR and MS-2 cell lines when compared to primary 
keratinocytes (see section 4.6). However, the examination of cdk5 and cdk6 
levels and degree of cell cycle dependent association with p34cy°D1 jn the 
newly derived SCC cell lines would contribute to the understanding of the 
involvement of these proteins in transformation. Transfection experiments of 
mammalian primary fibroblast or keratinocyte cell types with cdk5 or cdk6 
expression systems alone or in combination with cyclin D1 cDNA expression 
vectors, would reveal any immortalising or transforming properties of these 
kinase complexes. Subsequent immunoprecipitation analysis of the derived 
clones may determine specific substrates of the different cyclin D1-directed 
kinases.
9.2 The potential consequences of elevated p34cYc^ 1.
9.2.1 Over-expression of exogenous cyclin D1.
Co-transfection of Cyl-1 cDNA and neomycin sulphate expression 
vectors into a poorly tumourigenic SCC cell line (SCC12) exhibiting normal 
levels of p34cy°D1 and the absence of increased CCND1 gene dosage 
(described in section 7.2), was used to address the significance of CCND1 
over-expression in transformation.
Consistent with previous reports, constitutive over-expression of cyclin 
D1 was observed to have toxic effects on proliferating cells (Quelle e ta l 1993). 
Only one clone (P-1) was derived that exhibited a three-fold increase of 
p34cycD1 levels at all stages of the cell cycle when compared to parental 
SCC12 cells, reflecting a low (2%) success rate (see section 7.2). Introduction 
of Cyl-1 cDNA in the incorrect orientation also proved to be toxic and the two 
derived cell lines, D2 and A3, did not contain any detectable plasmid DNA by
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Southern blot analysis, suggesting stable transfection only of neomycin 
sulphate expression vectors. The extensive cell death observed for both sense 
and antisense types of transfections, implicated tight regulation of endogenous 
CCND1 expression levels and the requirement for p34cycD1 in normal 
proliferating cells. The observed tolerance of extensively over-expressed 
p34cYcD1 in some of the examined BICR tumours (described in section 4.4) is 
therefore somewhat perplexing. However, these cells also harbour many 
additional abnormalities that may have abolished the toxicity of increased 
cyclin D1 levels (such as the increased levels of pRb), reflecting the 
progressive stages of transformation. In previous reports five to ten-fold 
induction of p34cy,’ 1 was achieved in normal human diploid fibroblasts, 
following the optimisation of transfection conditions, implying that under certain 
circumstances higher expression of this cyclin can be achieved avoiding any 
toxic effects (Quelle e ta l 1993). Transfection into keratinocyte cell types is 
further complicated by their sensitivity to metal ions or calcium which induce 
differentiation, therefore methods such as previously employed calcium 
phosphate precipitation techniques cannot be used with these cells (Quelle et 
al 1993). Lipofection as a means of introducing foreign DNA is tolerated by 
keratinocytes, however this technique generally gives a low copy number of 
inserted expression vectors per cell and is therefore less efficient. Recently a 
new, more effective lipofection product has appeared on the market (GIBCO) 
and could be used to repeat the above described transfection experiments, in 
addition, electroporation or retroviral infection are two other applicable 
techniques. Inducible cyclin D1 expression systems could also be used in 
transfection analysis, potentially achieving higher expression levels in
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keratinocyte cells coupled with a more precise means of analysing the levels 
and effects of cyclin D1 toxicity.
Contrary to previous reports, no reduction in cell size, generation time or 
serum requirement were evident as a consequence of upregulated cyclin D1 
expression, although additional experiments should be carried out to determine 
the serum responsiveness of these cells and the timing of DNA synthesis 
(Quelle e ta l 1993). Paradoxically, the cyclin D1 over-expressing cells (P-1) 
had increased in volume (Figure 35). The obvious explanation for this 
discrepancy is clonal selection of the parental SCC12 cells, the populations of 
which are characterised by size differences between individual members. 
However, taking into account the large volumes of the P-1 cells it is hard to 
imagine that they may have originated from an even larger parental cell. The 
low levels of over-expression may have been insufficient to cause any 
alterations, although none of the HNSCC derived BICR cell lines containing 
extensive p34cy°D1 over-expression exhibited exceptionally small cells, 
casting some doubt on cyclin D1-induced morphological changes in 
keratinocyte cell types.
9.2.2 Cyclin D1 expression during the cell cycle.
The previously described cell cycle dependent oscillation pattern of the 
cyclin D1 protein in mouse macrophages and normal human diploid fibroblasts 
was confirmed in this study (Matsushime et al 1991, Baldin et al 1993). Serum 
starved, quiescent murine fibroblasts were nearly completely devoid of p34cyl"
1 expression, as described in section 5.3. Upon serum stimulation, p34cyl_1 
levels increased, peaking at eight to twelve hours post-stimulation and 
subsequently declining. The same observations had previously been made in
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human diploid fibroblasts and mouse macrophage cell lines, although studies 
on mouse macrophages had revealed constantly elevated cyclin D1 transcript 
levels, the down-regulation of which only took place following removal of CSF-1 
from the growth media (Matsushime et al 1991, Baldin et al 1993).
The difficulties in achieving keratinocyte cell cycle synchrony by serum 
starvation in this study were described in sections 6.2 and 6.3. Fortunately, the 
skin SCC cell line SCC12 exhibited a temporary although vastly reduced rate of 
proliferation following trypsinisation and culturing in conditions of low serum (as 
described in section 6.2). Consequently, the levels of p34cYcD1 declined, while 
subsequent induction of this protein was achieved by the exposure of the cells 
to saturating amounts of human EGF and exhibited a similar cell cycle 
dependent pattern to that observed in fibroblasts (see section 5.4). Over­
expression of cyclin D1 in the P-1 cell line did not alter the oscillation pattern of 
this protein, as described in section 7.3. Specific induction of cyclin D1 
transcripts following the exposure to this mitogen had previously been 
observed in normal human diploid fibroblast cultures synchronised to GO by 
serum deprivation (Won e ta l 1992).
9.2.3 The effects of cyclin D1 on tumourigenicity.
Despite the substantial supporting evidence for the proto-oncogenic 
properties of CCND1 and its activation through gene rearrangement or 
amplification, the ability of CCND1 to transform cells in culture or induce 
tumours in vivo has not yet been established. An insufficient number of HNSCC 
cell lines were examined in this study to determine any correlations between 
cyclin D1 over-expression and tumour staging (UICC 1987). However, all three 
BICR cell lines exhibiting increased CCND1 gene dosage, transcript and
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protein levels (BICR6, BICR18 and BICR22) were derived from either T4 or 
metastatic SCCs (Table 4). The only examined early stage (T2) tumour-derived 
cell line (BICR3) lacked detectable CCND1 amplification or increased 
expression of the mRNA and protein products, implying that over­
representation of p34°YcD1 may be advantageous at later stages of 
transformation (Edington et al submitted). However, an insufficient number of 
cells were examined to allow general conclusions to be made. In view of the 
cyclin D1 induced lifespan of primary keratinocytes observed in this study, it 
would appear more likely that cyclin D1 amplification and over-expression 
confers a growth advantage at the initial stages of immortalisation and that this 
advantage may extend to later stages of transformation, maintaining the 
selection for CCND1 over-expressing cells.
Injection of P-1 and SCC12 cells into immunodeficient mice was carried 
out in this study, with the aim of testing for potentially induced tumour formation 
by cyclin D1 over-expression. No alterations were observed in the ability of P-1 
cells to form tumours in comparison to parental SCC12 cells (described in 
section 7.4), suggesting that cyclin D1 over-expression alone is insufficient to 
induce tumourigenesis, consistent with the above proposal. An alternative 
explanation is based on the low increase of cyclin D1 expression in the P-1 
cells when compared to the levels observed in the HNSCC derived cell lines 
(Table 7). BICR6, BICR18 and BICR22 were the most highly transformed cell 
lines and formed tumours in nude mice with relatively short latency periods 
(Edington et al submitted). All three cell lines exhibited CCND1 amplifications 
and higher transcript and protein expression levels than were achieved in P-1 
cells. Contrary to this hypothesis, BICR10-derived cells also exhibited a high 
tumourigenicity potential but contained equivalent p34cYcD1 expression levels
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to those observed in P-1 cells (see section 4.4). However, the BICR10 cell line 
was derived from a recurrent T2 stage tumour and contained a heterogeneous 
mixture of two cell types in the one BICR10 population, therefore rendering the 
analysis of one cell line impossible (Edington et al submitted). The two B1CR10 
cell types were recently sub-cloned and subsequent analysis will reveal the 
individual properties of the two derived cell lines (Edington et a l submitted). In 
summary, from the currently available data, it is impossible to accurately 
determine at what stage of cellular transformation increased expression of 
cyclin D1 is most likely to confer growth advantage.
9.3 The firs t links between cyclin D1 and the signal transduction 
pathway.
Extracellular growth factors and repressors act during the G1 phase by 
binding to cell surface receptors and triggering a cascade of cytoplasmic 
reactions which will eventually regulate the nuclear cell cycle machinery. 
Recently the pheromone induced S.cerevisiae arrest was shown to involve a 
set of yeast MAP-kinase and MAP-kinase-kinase homologues which 
specifically affected the functioning of the CLN cyclins and CDC28 complexes 
(Peter e ta l 1993). In several studies a parallel has been drawn between the a 
and a factor induced pathways in S.cerevisiae and TGFp action in mammalian 
keratinocytes (Marsh e ta l 1991, Peter e ta l 1993). The recently described 
TGFp-induced effects on cyclin E regulated kinase have confirmed in part 
these suggestions (Koff et a /1993). Exposure of mink lung epithelial cells 
(Mv1 Lu) to TGFp was not shown to affect cyclin E or cdk2 protein levels, 
however the loss of cyclin E-directed histone H1 kinase activity suggested loss 
of functional cyclin E/cdk2 complexes, supported by the absence of detectable
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active cdk2 forms (Koff e ta l 1993). TGFp induced G1 arrest was therefore 
hypothesised to results from the abolishment of cyclin/catalytic subunit 
associations and potentially could apply to all cyclins. However, preliminary 
results have revealed opposite effects of TGFp on cyclin D1 in normal and non­
transformed epithelial cells (Angeliki Malliri, Beatson Institute, unpublished 
data). TGFp induced increase of p34cycD1 levels determined by western blot 
analysis, was observed in human foreskin primary keratinocytes following a 
twenty four hour exposure to this growth inhibitory factor. The same 
phenomenon was not observed following the TGFp treatment of the most 
highly transformed SCC cell lines, therefore appearing to depend on the 
degree of transformation (Angeliki Malliri, Margareta Nikolic, Beatson Institute, 
unpublished data). Furthermore, recent reports on Mv1 Lu cells revealed 
specific TGFp inhibition of cdk4 expression potentially resulting in loss of cdk2 
kinase activity and subsequent cellular arrest in G1 (Ewen et al 1993b). No 
alterations of cyclin D1 or D2 protein levels were observed. Perplexingly, the 
decrease in cdk4 levels observed in contact inhibited Mv1 Lu cells was not in 
agreement with the constant expression levels seen in quiescent and growing 
fibroblast cell lines examined in this study, a phenomenon that could reflect 
species and/or cell type differences (Ewen e ta l 1993b). These observations 
would imply a diversity in TGFp induced cellular responses, potentially 
reflecting a dual role of cyclin D1 in cell cycle regulation or the alteration of 
specific TGFp induced pathways as a result of transformation. Alternatively, 
keratinocyte exposure to TGFp causes arrest in middle to late G1, exactly the 
period during which p34cYcD1 levels are at their highest. The increase in 
p34cy°D1 observed in normal cells may simply reflect the stage of the cell 
cycle they have arrested at. Transformed SCC cultures have often acquired
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TGFp resistance, a characteristic that may account for the lack of detectable 
increase of p34cYcD1 in these cells. However, preliminary examinations have 
only revealed TGFp resistance of one SCC cell line analysed in this study 
(BICR19) (Angeliki Malliri, Beatson Institute, unpublished data),suggesting that 
the former hypothesis is more likely. Further analysis is required to resolve this 
controversy.
In mammalian systems, mitogens such as EGF, FGF, BB form of PDGF 
but not IGF-1 were able to activate GO arrested fibroblasts and induce cyclin 
D1 expression (Won e ta l 1992, Surmacz e ta l 1992). This study revealed a 
similar response upon EGF stimulation of SCC cell lines (SCC12 and clones P- 
1 and A3) that exhibited a temporary decline in their rate of proliferation, 
following serum starvation (see section 6.2). The three-fold elevation in basal 
p34cycD1 levels had no effect on the response of P-1 cells to this mitogen. 
Unfortunately, little is known of the signal transduction pathways that are 
activated following mitogenic stimulation of epithelial cells. Currently the MAP- 
kinase pathway represents one recognised system linking extracellular, 
cytoplasmic and nuclear events in mammalian cells, however the mechanism 
by which cyclins are induced is unclear.
9.4 The contribution of p34cYcD1 to cellular immortalisation.
Immortalisation of mammalian cells is thought to represent the first step 
in the development of cancer. Cells that have escaped normal proliferative 
limitations are predisposed to the accumulation of other abnormalities which 
may subsequently lead to transformation. To date, only viral onco-proteins are 
known to harbour the ability to modulate human primary keratinocyte 
regulatory systems, avoiding programmed host cell death and inducing
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proliferation, presumably with the aim of promoting expansion of the viral 
population. In contrast, the over-expression of individual mammalian genes has 
not been shown to effectively cause a similar response in human primary 
keratinocytes.
In comparison with rodent cells, human keratinocytes exhibit a strong 
resistance against longevity, with currently only a few reported cases 
describing spontaneous resistance to M1 and M2 growth restriction points 
(Baden et al 1987, Boukamp et a /1988, Rice et a /1993). The most recent and 
significant finding revealed increased expression of cyclins A and B and cdk2 in 
a human line of spontaneously immortalising Keratinocytes (SIK cells) (Rice et 
al 1993). These cells had been derived from a sample of normal human 
foreskin and cultured in the presence of x3T3 fibroblasts, under standard 
growth conditions. A six- and four-fold elevation in cyclin A or B expression, 
respectively was noted between passages ten and sixteen remaining so 
apparently indefinitely. Coupled with the gradual increase in cdk2 levels 
(passage twenty four exhibited a seven-fold elevation of this protein), these 
observations suggested a direct involvement of cyclin directed kinases in SIK 
cell immortality. During the early stages of cell line development, the 
chromosome complement was indistinguishable from normal keratinocytes, 
however, by passage seventy eight several abnormalities were evident 
involving chromosomes 6p, 7 and 8q. This finding suggests the ability of cyclin 
over-expressing cells to overcome the growth inhibitory effects of M1. Escape 
from the second, more restrictive regulation point (M2) is allowed by the 
occurrence of other abnormalities involving the cellular chromosome content. 
Nevertheless, late passage SIK cells had retained unaltered growth properties 
such as response to the inhibitory effects of TGFp and TPA, lack of growth in
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suspension and strong requirement for EGF, suggesting that the cells had only 
achieved longevity and were not malignantly transformed (Rice et al 1993).
The discovery of G1 cyclins introduced a new set of likely targets in 
immortalisation, of which cyclin D1 is a strong contender. Despite this, the 
ability of cyclin D1 to immortalise and/or transform cells in culture has not yet 
been established. Co-transfection experiments on normal human foreskin 
keratinocytes were therefore employed in this study with the aim to determine 
the extent with which cyclin D1 may overcome the M1 and M2 proliferative 
blocks in cells programmed for a definite life span. The results represented in 
chapter 8. reveal p34cy,_1-induced longevity in human foreskin primary 
keratinocytes (see section 8.2.1). Unfortunately in this study an insufficient 
number of human primary keratinocytes were transfected with individual 
expression vector combinations, reducing the probability of obtaining 
immortalisation. The low frequency of HPV-16 E6/E7 immortalisation and/or 
transformation reported in previous studies further supports this argument 
(Vousden eta ! 1988). Furthermore, cells transfected with E5and E7, Cyl-1, E7 
or E7 and Cyl-1 expression systems were able to efficiently bypass M1. Future 
analysis will require transfection of a larger population of cells. In addition, co­
transfection of cyclin D1 expression vectors with cdc2, cdk2, cdk4, cdk5 or 
cdk6 expression vectors into primary keratinocytes may increase or decrease 
the immortalising properties of CCND1.
The transforming competence of viral onco-proteins was shown in 
previous reports to be strongly linked with their ability to associate with host 
tumour suppressors p53 and pRb (Band efa/1991, Hubbert ef a/1992,
Pagano et al 1992a; Tedesco et al 1993, Vousden e ta l 1993). Recently, a 
series of contradictory reports have analysed the ability of p34cycD1 to
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associate with pRb (Ewen et al 1993a, Dowdy et al 1993, Hall et al 1993). Two 
alternative hypotheses (pursued in separate laboratories) differed with respect 
to which protein represented the substrate and which was the effector. One 
proposed mechanism suggested the targeting of active hypophosphorylated 
pRb during G1 by cyclin D1, the over-expression of which would occupy all of 
the available pRb pockets preventing association with other cellular proteins. In 
vitro studies have revealed cyclin D1 induced pRb phosphorylation providing 
an additional means for the tumour suppressor inactivation, however, these 
reactions do not appear to take place in vivo (Matsushime ef a/1992, Hinds et 
al 1992, Kato et al 1993). Loss of pRb was proposed to abolish control of some 
positive proliferative regulators (such as free E2F) and promote cell cycle 
progression (Nevins 1992, Weintraub et al 1992). Alternatively, cyclin D1 itself 
may represent a centrally important promoter of cell cycle progression and 
therefore an object for pRb sequestration. Consequently over-expression of 
cyclin D1 could saturate the binding ability of pRb, allowing free p34cy°D1 to 
promote proliferation and the lack of functional pRb ultimately resulting in a 
similar fate as proposed by the former hypothesis. In view of the observed pRb 
over-expression in the BICR cell lines harbouring CCND1 amplifications 
(described in chapter 4.6), currently the latter explanation would appear more 
likely. This is further supported by the recent findings revealing an increased 
ability of mutated cyclin D1 unable to associate with pRb and overcome the 
inhibitory effects of this tumour suppressor when co-transfected into Saos2 
cells (Hinds et a /1992, Dowdy eta ! 1993). In this example cyclin D1 may have 
rendered itself inaccessible to the sequestering actions of pRb.
Based on the perplexing results obtained in this study following 
transfection of antisense Cyl-1 cDNA expression vectors into primary
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keratinocytes, a new hypothesis can be made regarding the function of cyclin 
D1 in mammalian epithelial cells. The fact that HEK cells into which 3'-5' Cyl-1 
cDNA expression vectors were introduced exhibited a growth advantage forty 
one days from lipofection, suggests that a reduction of endogenous p34°ycD1 
levels may also confer a growth advantage in certain circumstances. The 
diversity of catalytic subunits with which p34cy°D1 jS known to associate would 
be consistent with p34°ycD1 having a number of different functions. As 
substrate specificity and hence stimulatory or inhibitory effects on cellular 
proliferation may be determined exclusively by the kinase subunit, in a 
proliferating cell important decisions involving growth or senescence could be 
determined by the availability and affinity of alternative cdk proteins to 
P34cycD1. The previously suggested inhibitory role of p107/cyclin A/cdk2/E2F 
complexes on cellular proliferation further supports a diverse role for cyclins in 
cell cycle regulation (Devoto et a /1992).
The same type of argument could be used to explain the frequent 
occurrence of CCND1 amplification and over-expression in human SCCs. 
Chromosome 11 q13 is a very dynamic region commonly involved in 
amplification and rearrangements linked to distinct tumour types. Several 
proto-oncogenes are known to map to this area which is large enough to 
encompass many as yet undiscovered genes. Evolutionarily it would be of 
great advantage for a cell to co-amplify genes (the products of which may be 
growth suppressory) with transforming oncogenes, in this way preventing or 
slowing down transformation at the early stages. Following this argument 
CCND1 amplification and subsequent over-expression could be viewed as a 
programmed cellular response to transformation in an attempt to prevent 
uncontrolled growth. The role of cyclin D1 as an exclusively negative regulator
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of cellular proliferation is however hard to imagine, taking into account the 
currently available evidence for its proto-oncogenic properties and the absence 
of observed "normal" or "near-to-normal" cells harbouring increased CCND1 
gene dosage and expression. A more likely picture that is emerging is the 
combined functioning of cyclin D1 as a positive and negative cell cycle 
regulator, which may be determined by the cell type, the availability of catalytic 
partners, regulatory proteins (such as PCNA and potentially p21) and 
substrates. The potential association of pRb and p34cYcD1 need not occur to 
inactivate one or both of these proteins but may be of collaborative nature and 
therefore account for the increase of pRb expression in cells that have 
amplified CCND1. To date cyclin D1 directed inactivation and subsequent 
phosphorylation of pRb has only been revealed in vitro studies reflecting a 
potential although not necessarily real function of the kinase. Nevertheless, the 
majority of published reports provide data that directly contradict any growth 
suppressory functions of cyclin D1, such as the proximity of the CCND1 gene 
to the bci-1 region, the effects caused by constitutive over-expression of 
exogenous cyclin D1 in human diploid fibroblasts and the inability for cells to 
proliferate following a reduction in endogenous p34cy°D1 levels. However, 
these observations may simply reflect the complex role of cyclin D1 and 
directed kinases in regulating the fate of a single cell in dependence of 
environmental factors, cell type, availability of catalytic subunits and state of 
cellular growth.
To date there is no direct evidence for the effects cyclin D1 may have on 
p53. This tumour suppressor protein is known to function during later stages of 
G1 and at the G1/S boundary as a major part of the G1 checkpoint control 
(Lane 1992, Hartwell 1992). However, despite the overlapping time of action
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coupled with p53 phosphorylation on Ser residues, currently the evidence 
linking cyclin D1 and p53 is circumstantial (Lane 1992).
The complex regulatory role of cyclin D1 in cellular proliferation and its 
coupling with alternative kinase subunits is rapidly becoming clear. In the event 
of devising a uniform cure for cancer, cyclin proteins and their associated 
kinases represent an ideal target for inactivation which would bypass the 
complex cytoplasmic signal transduction pathways and effectively prevent 
proliferation of selected cells.
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